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ABSTRACT

Abdominal aortic aneurysm (AAA) disease causes dilation of the aorta that can lead
to aortic rupture and death if not treated early. It is the 14th leading cause of death in the
U.S. and is cited as the 10th leading cause of death in men over age 55, affecting thousands
of patients and their families. To date, AAA patients have minimal access to safe and
efficient imaging modalities for diagnosis as well as pharmacotherapies. AAA is usually
detected and monitored with ultrasonography or contrast-enhanced computed tomography
(C.T.), which doesn’t provide biomechanical information of the AAAs that are essential
for predicting rupture risks. Furthermore, unfortunately, there is no currently known
pharmaceutical treatment to cure the AAAs.
Key pathological processes occurring within AAAs include inflammation, vascular
smooth muscle cell apoptosis, and extracellular matrix (ECM) degradation. The
deterioration of the elastic lamina in the aneurysmal wall is a consistent feature of AAAs
and the fact that the adult elastic lamina does not remodel in aneurysm progression, making
it an ideal target for delivering contrast agents and treatments. In this research, we have
delivered gold nanoparticles (AuNPs), a commonly used C.T. contrast agent, and
pentagalloyl glucose (PGG) loaded nanoparticles to the AAAs in an angiotensin II (AngII)
infusion induced mouse model by conjugating the nanoparticles with antibodies that target
degraded elastin.
Here, owing to their degraded elastin targeting ability, we have observed a positive
correlation between the quantities of the locally accumulated AuNPs in the aneurysmal
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tissue in C.T. scans and the elastin damage levels of the AAAs. Furthermore, the AuNPs
accumulations were found negatively correlated to the mechanical properties of the AAAs,
which makes AuNPs a potential non-invasive surrogate marker of AAA rupture risk.
Moreover, we have shown that targeted delivery of PGG could reverse the aortic dilation,
ameliorate the inflammation, restore the elastin as well as the AAA mechanical properties
of the aneurysmal tissue. Therefore, PGG loaded nanoparticles can be an effective
treatment option for early to middle stage aneurysms to prevent disease progression.
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1. INTRODUCTION

An abdominal aortic aneurysm (AAA) is a cardiovascular disease featured by the
abnormal dilation of the abdominal aorta. Male gender, genetic factors, aging, smoking,
and other cardiovascular diseases such as atherosclerosis, diabetes, hypercholesterolaemia,
and hypertension play as the risk factors of AAA onset [1]. Histologically, AAA is
characterized by chronic transmural inflammation [2], resulting in the breakdown and
elimination of essential proteins in the connective tissue of the aortic wall. Extensive
research about AAAs has revealed that extracellular matrix (ECM) plays a vital role in its
pathophysiology [3]. Mounting evidence has suggested that elastin, one of the critical
components of ECM, drives this progression of this disease by virtue of its degradation.
Among the enzymes that degrade ECM are matrix metalloproteinases (MMPs) and
cathepsins, which can breakdown elastin laminae [4]. If not treated early, the weakening
of the aorta can progressively worsen and led to aortic rupture and death [5]. In order to
reduce the mortality of AAAs, the U.S. Preventive Services Task Force recommends that
men aged 65–75 years who have ever smoked should get an ultrasound screening for
abdominal aortic aneurysms, even if they have no symptoms [6].
The clinical standard for diagnosing AAA is whether the maximum aortic diameter
reached 3cm or aortic dilation reached 1.5-fold [7]. Current imaging methods, such as
ultrasound and computed tomography (CT), are excellent to look at the overall growth of
aneurysms and can provide the geometrical information needed clinically to make the
diagnosis and choose treatment strategies. However, focal aortic wall weakening caused

1

by ECM degradation and remodeling is generally not precisely detected. Such weak spots
exhibit high-stress concentration and can increase the risk of rupture independent of the
AAA size, thereby putting even small AAAs at high risk for rupture. In order to identify
the AAAs that are in higher rupture risks and decrease mortality in AAA patients, it is
desired to develop an imaging modality that could localize vulnerabilities at the aneurysmal
site.
Contrast-enhanced CT, an anatomical imaging technique, has been widely used in
the diagnosis and long-term follow-up due to its ability to provide precise anatomical and
morphological measurements of the AAAs [8, 9]. However, contrast-enhanced CT alone
is unable to provide pathological information of the AAAs, such as the extent of ECM
degradation and identify rupture-prone AAAs accurately. Moreover, a large dose of iodineor gadolinium-based contrast agent is required for performing contrast-enhanced CT, the
toxicity of which places it at a disadvantage compared to other imaging methods such as
magnetic resonance imaging (MRI), nuclear imaging, and optical imaging [9, 10]. Gold
nanoparticles (AuNPs) have been investigated for many years as an ideal radiopaque CT
contrast agent for its excellent X-ray absorbing ability and low toxicity [10]. PEGylated
AuNPs with prolonged blood circulation times were used for imaging of the cardiovascular
system [11]. A targeted delivery of surface-modified AuNPs can reduce the dose of
contrast agent applied, increase the imaging quality, and provide more information of the
AAAs depending on the molecular probe attached to the AuNP surface.
Besides an instructive imaging modality for diagnostic, an efficient treatment
strategy can also achieve mortality benefit. To date, the most effective treatment for AAAs
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is surgical intervention, and no pharmacological treatment is available on the market.
Given the alarming mortality rate of 90% in the case of AAAs [12], and the fact surgical
intervention is not possible in all the cases, it brings us to an imminent need for minimally
invasive treatment options. Many drugs such as statins and doxycycline have been found
to prevent AAA formation and progression in animal models when delivered systemically
[13-15]. However, they were not successfully translated into clinical AAA treatment,
possibly due to that systemic administration does not provide the necessary therapeutic
drug concentration at the site of AAA [16]. A local delivery of the drugs using targeting
nanocarriers could improve their therapeutic efficacy and prevent systemic side effects.
Currently, most of the potential drugs focus on reducing the local inflammation in
the aneurysmal tissue but not reversing already degraded ECM. An ideal therapeutic
intervention would not only prevent further degradation of ECM but also restores the
structural integrity, in turn leading to the restoration of aorta’s mechanical properties. On
multiple occasions, our group has successfully demonstrated the beneficial effects of
pentagalloyl glucose (PGG) in stabilizing and regenerating vascular tissue’s ECM both invitro and in-vivo [17, 18]. Recently Nosoudi et al. have also demonstrated successful
treatment of AAAs induced by a local injury model in rats [19].
In this dissertation research, firstly, we have synthesized and conjugated AuNPs
that possess the ability to target AAAs. It has been shown that the systemic delivery of
surface-modified AuNPs that bind to degraded elastin in an angiotensin II (AngII) mouse
model of AAA provides a unique way to visualize local areas of ECM degradation that are
more prone to rupture. Secondly, we present the successful treatment of AAAs in the same
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mouse model using targeted nanoparticle delivery. We tested our hypothesis that PGG
loaded bovine serum albumin (BSA) nanoparticles can be targeted to damaged elastin in
aneurysmal mouse aorta, thereby not only protecting elastin from MMPs but also
regenerating elastic fibers. Apart from looking at the structural integrity of ECM, we have
studied the ability of the nanoparticles to restore the mechanical properties of the aorta. We
have also delved deeper to investigate if PGG treatment can trigger anti-inflammatory
signals to understand its extended effects on ECM. Overall, our goal was to present targeted
AuNPs delivery as an excellent imaging contrast agent for AAAs and PGG loaded BSA
nanoparticles as an alternative therapeutic approach to reverse AAA clinically.
This dissertation is organized as follows:
§

In Chapter 2, we presented a comprehensive review of the cardiovascular
system and diseases, physiology and histology of abdominal aorta, aortic
elastin content, an introduction to AAAs including pathophysiology and
biomechanics, the methods used for AAA rupture risk assessment, the
animal models used for AAA studies, and the imaging modalities and
treatment for AAAs.

§

In chapter 3, we provided the specific aims designed for this project as well
as a brief description of the approaches we took to achieve these aims.

§

In chapter 4, we described the synthesis and characterization (including size,
surface charge, cytotoxicity, cellular uptake, in-vitro targeting) of elastin
antibody conjugated AuNPs.
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§

In chapter 5, we presented the in-vivo targeting studies of the surfacemodified AuNPs in the AngII mice model and the correlation between the
AuNPs accumulation and the AAA rupture risk.

§

In chapter 6, we presented targeted therapy with nanoparticle loaded with
PGG to protect the vascular elastic lamina and restore the aortic mechanical
properties and showed that it could halt or even reverse the progression of
AAAs in the AngII induced mice model.

§

In chapter 7, we concluded the whole presented research and discussed
future research attempts that needed to be taken to achieve clinical benefits
for AAA patients further.
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2. LITERATURE REVIEW

2.1 The cardiovascular system and cardiovascular diseases
The cardiovascular system, also known as the circulatory system for blood, is one
of the most important organ systems that facilitates blood circulation and mass
transportation [20]. The cardiovascular system consists of two subunits: the heart, which
functions as an anatomical pump that pushes the blood through the whole body, and the
blood vessels, including arteries, veins, and capillaries that are the conduits carrying the
blood [21]. It plays a vital role in maintaining homeostasis by continuously regulating the
blood flowing throughout the system, transporting nutrients, electrolytes, gases, and other
essential materials into the environment where cells reside in as waste products are
removed [22].
Cardiovascular diseases (CVDs) are diseases that involve the heart or blood vessels
(Figure 2-1). The physiological disorders of the heart include arrhythmia, carditis and
cardiomyopathy, heart valve problems, rheumatic heart disease, and congenital heart
disease, and vascular diseases include coronary artery disease, peripheral arterial disease,
stroke, aneurysms, arterial calcification and atherosclerosis, deep vein thrombosis, and
pulmonary embolism. According to the world health organization, it is the leading cause
of death worldwide [23]. CVD accounted for approximately 17.8 million deaths in 2017
globally and this number is expected to grow to more than 22.2 million by 2030, according
to a 2014 study [24]. In the United States alone, CVDs have remained the number one
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cause of death, responsible for as many as 859,125 deaths in 2017. The annual total cost of
CVDs in the US has been estimated at $351.2 billion in 2014 to 15 [25].
2.2 The arteries in the cardiovascular system
An artery, which carries blood from the heart to various organs and tissues of the
body, contains three tunics in the wall. The innermost layer, the tunica intima, is composed
of epithelial and connective tissues that form the continuous endothelial lining of the entire
vascular system. The middle layer, known as the tunica media, is a smooth muscular layer

Figure 2-1. Human cardiovascular system with the associated various cardiovascular
diseases [26].
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supported by connective tissue that is primarily made up of elastic fibers and some collagen
fibers [27]. It is the essential part of the arteries to regulate blood flow and blood pressure.
The tunica externa, also known as the tunica adventitial, is the outermost layer of the
vascular wall composed primarily of connective tissue with fibroblasts, helping to hold the
vessel in a relative position [28].
According to the various sizes, arteries can be categorized into arterioles (with a
diameter below 0.5mm), muscular or distributing arteries (medium-sized), and elastic or
conduit arteries (typically with a diameter larger than 10 mm). Although all types of arteries
are composed of the three tunics, there are some structural differences between different
types of arteries due to their variety of functionalities (Figure 2-2). The arterioles are the
primary resistance vessels that distribute blood flow into capillary beds in the organs,
featured with only one or two layers of the smooth muscle in the tunica media [29]. The
muscular arteries, on the other hand, present a much thicker smooth muscle layer in the
tunica media in corresponding to their leading role in vasoconstriction [30]. The elastic
arteries such as aorta have the thickest tunica media that contains a high percentage of
elastic fibers to withstand the high blood pressure causing by the heart blood ejection [31].
2.3 Physiology and histology of abdominal aorta
The abdominal aorta is a part of the aorta that passes through the abdominal cavity,
beginning at the level of the diaphragm and ending at the common iliac bifurcation [32]. It
supplies all of the abdominal organs such as the liver, stomach, spleen, duodenum with
oxygenated blood to maintain their functionality. As a transitional elastic artery, the
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Figure 2-2. Types of Arteries and Arterioles. Comparison of the walls of an elastic artery,
a muscular artery, and an arteriole is shown. In terms of scale, the diameter of an arteriole
is measured in micrometers compared to millimeters for elastic and muscular arteries [30].
abdominal aorta has a monolayer of endothelium and a scant pad of sub-endothelial fibrous
connective tissue upon an intact internal elastic lamina, a relatively thick media consists of
smooth muscle cells (SMCs) embedded in structural proteins, and an adventitial that
contains a network of vasa vasorum [33, 34]. Since the media normally accounts for up
80% of the abdominal aortic wall, the thickness of the abdominal aortic wall nearly linearly
relates to the number of the medial lamellar units [34]. For an adult human, the normal
abdominal aorta has a media consists of 28 to 30 concentric fibromuscular layers with an
average thickness of 0.8 to 1mm [35].
In large arteries like aorta, the network of vasa vasorum plays an important role in
the delivery of nutrients and oxygen to and the removal of waste products from the aortic
walls. However, it has been demonstrated that the infrarenal abdominal aortic media is
vastly avascular because the vasa vasorum has been shown to only penetrate the media of
vessels with greater than 29 medial lamellar units [34]. Thus, it is likely that the relatively
fewer lamellar units and lower collagen to elastin ratio in the abdominal aortic media
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comparing to the theoretic aorta, and the fact that the survival of SMCs in the abdominal
aortic media mainly depends on trans-intimal diffusion of nutrients make the abdominal
aorta more prone to aneurysmal degeneration [36].
2.4 Elastin in the aortic wall
Elastic fiber is the main component that makes up roughly 50% of the arterial
extracellular matrix (ECM), and provide the necessary load-bearing ability in low-pressure
regions and elasticity for proper cardiovascular function in vertebrate animals [37, 38]. It
has two major components: an elastin core that comprises 90% of the fiber, and a scaffold
of microfibrils, which are composed mostly of fibrillin-1 and -2 [39]. The synthesis of the
elastin fibers can be divided into three stages, known as (a) secretion of the tropoelastin (a
~60 -70 kDa protein) by elastogenic cells, including SMCs, endothelial cells, fibroblasts,
and chondroblasts, into the ECM, (b) coacervation that forms self-aggregated tropoelastin
spherules, and (c) cross-linking that generates the networks of elastic fibers by depositing
the spherules onto microfibrils and forming intramolecular and intermolecular crosslinks
with the participation of lysyl oxidase (LOX) enzymes (Figure 2-3) [40].
ELN is the only tropoelastin gene in humans. Most of the elastin synthesis in human
bodies happens very early in life. As we age, ELN expression decreases dramatically,
resulting in a decrease of elastin product and causing difficulties for elastin damage repair
[41]. The elasticity of the elastin fibers is a result of its massive cross-linking network that
maintains the mechanical stability when elastic fiber undergoes deformation (Figure 2-4).
The reversible elasticity of the aortic elastic fibers plays an important role in maintaining
the
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Figure 2-3. Elastogenesis: from tropoelastin to elastic fibers; Tropoelastin synthesis,
binding with elastin-binding protein (EBP), transport, release of EBP, assembly with
fibulins, binding to microfibrils, LOX-mediated cross-linking, and final formation of an
elastic fiber [42].
Windkessel effect of the cardiovascular system to allow sufficient blood supply in the distal
micro-vasculatures [43].
The amount and organization of the elastic fibers, as well as the collagen fibers in
the aortic ECM, dominate the passive mechanical behavior of the large elastic arteries. The
arteries underwent elastase treatment in animal models were shown to have a significant
increase of the side lengths in both longitudinal and circumferential directions, indicating
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Figure 2-4. Crosslinking of elastin and mechanism of elastin stretch and recoil [44].
the weakening of the arterial wall [45, 46]. Experiments on the aorta from mice lacking
elastin gene (ELN-/-) have demonstrated a reduction in the circumferential material
stiffness at low pressure [47]. Thus, insufficient elastin, improper assembly,
disorganization, fragmentation, and remodeling of the elastic fibers change the passive
mechanical behavior of the elastic arteries.
Aside from the influence it has in aortic mechanical properties, elastin and its
degradation products, resulted from matrix aging and/or cardiovascular diseases, have
signaling effects that can lead to pathological changes to the cardiovascular system. In a
study on rat aorta, Sauvage M. et al. reported the colocalization of transforming growth
factor (TGF) -β1 immunoreactivity and tropoelastin expression in the developing rat aorta
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[48]. The accumulation of elastin has been suspected to change the availability of TGF-b
indirectly by modulating latent TGF-b binding to microfibrils [49]. And soluble
tropoelastin has been demonstrated to regulate the proliferation of VSMCs, as well as to
change the stiffness in an in-vitro cell culture model [50, 51].
Signaling effects of the elastin degradation products, such as elastin‐derived
peptides (EDP), a bioactive product of elastic fiber degradation, and fragmentation that
retain the VGCAPG peptide sequence, mostly depends on their interaction with elastin
receptor complex (ERC) [52, 53]. ECR is a heterotrimeric cellular surface receptor for
elastin composed of a peripheral elastin‐binding protein (EBP, 67 kDa), a protective
protein/cathepsin A (PPCA, 55 kDa) and a membrane‐bound neuraminidase, Neu‐1 (61
kDa) [54]. The EBP subunit presents two functional‐binding sites, including the EDP
binding site that induces signaling pathways, and the galactosugars attaching site, which is
associated with EDP release and dissociation of the complex [42].
The binding between EDP to EBP is capable of activating several intracellular
signaling pathways depending on the cell type (Figure 2-5). EDP can modulate the vascular
tone through its ability to influence the vascular endothelial relaxation and the vascular
smooth muscle cells (VSMCs) contraction [55, 56]. Moreover, the EDP has been implied
to play a crucial role as a chemotaxin in the recruitment of monocytes, neutrophils,
macrophages, and fibroblasts, as well as a regulator of VSMCs migration [57-61]. It has
also been reported that EDP can modulate the macrophage polarization and the
proliferation of fibroblasts and VSMCs [62-64]. The structural and mechanical change in
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Figure 2-5. EDP affect various cell functions through its cognate receptor ERC, playing a
crucial role in the development of cardiovascular diseases such as hypertension,
atherosclerosis, and aneurysm [53].
the large elastic arteries such as aorta can result in a malfunctional circulatory system that
is responsible for many acquired cardiovascular diseases.
Arterial stiffness is one of the structural mechanical properties that depend on the
mechanics of elastic fibers in the arterial wall. The assessment of arterial stiffness is usually
achieved by measuring the pulse wave velocity (PWV), distensibility characterized by
circumferential strain, and Peterson’s elastic modulus [47, 65-67]. Due to the limited
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synthesis timeframe and low turnover rate, the damage of elastin fibers with aging or
disease generally remains unrepaired. Insufficient or destruction of the elastin network
initially leads to decreased stiffness in arteries and is characteristic of the first shift in
mechanical behavior called the initial-softening phase [46, 68]. Meanwhile, the EDPs
induce the local proliferation of VSMCs and fibroblasts and recruit the leukocytes to the
remodeling sites, creating a proinflammatory remodeling environment. The remodeling of
the ECM after the elastin damage, which is characterized as a deposition of non-organized
collagen fibers and proteoglycans, in combination with a change of VSMC plasticity,
stiffen the arterial wall and cause a loss in arterial mechanical properties [69, 70].
2.5 Abdominal aortic aneurysm (AAA)
An abdominal aortic aneurysm (AAA) is an abnormally widened or bulged area of
the abdominal aorta. Depending on the location where the enlargement happens, AAAs
can be divided into four main categories, suprarenal AAAs, pararenal AAAs, juxtarenal
AAAs, and infrarenal AAAs (Figure 2-6). It is characterized by an impaired vessel wall
integrity, which is featured as a progressive disruption and weakening of the ECM, leading
to dilation of the aorta that can be fatal if not treated [35].
A human AAA is diagnosed when the aortic diameter is higher than 3.0cm or more
than 50% larger than the average diameter [5]. AAA is a common disease that has a
prevalence of approximately 4.8% (6.0% for males and 1.6% for females) in the general
population [71]. Including patients who die before reaching the hospital, the mortality rate
due to abdominal aortic aneurysm rupture is 90%, and the number of deaths attributable to
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the AAAs is more than 15,000 per year [72]. It is the 14th leading death cause in the US
and is cited as one of the top 10 causes of death among older men [73].
2.6 Pathophysiology of AAA
Several biological processes and risk factors, including genetic factors, lifestyle-associated
risk factors, and other cardiovascular diseases have been identified to contribute to AAA
pathogenesis. AAA is typically associated with aging and atherosclerosis, with attendant
risk factors such as hypercholesterolemia, hypertension, and diabetes [74]. Smoking is also
a significant risk factor for AAA development. As in a small aneurysm trial, which
randomized 1090 patients with AAA with diameters of 4–5.5 cm between immediate repair
and surveillance, 91.8% of the patients were former or current smokers [75].

Figure 2-6. Crawford’s classification of AAAs [76].
The pathophysiology of AAA has been studied on different levels (Figure 2-7) [5].
On the histological level, AAA onset is associated with chronic adventitial and media
inflammatory cell infiltration, apoptosis of VSMCs, and ECM degradation, primarily
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elastic lamina degradation by proteolytic enzymes such as matrix metalloproteinases
(MMPs) and cathepsins[35, 77, 78]. Many inflammatory cells have been detected in the
aneurysmal tissue, including macrophages, T lymphocytes subset, B lymphocytes,
neutrophils, and mast cells. These cells elevate the inflammation in the aneurysmal tissue
and accelerate the degradation of the ECM by influencing the production of multiple
inflammatory factors and extracellular proteases [5, 79, 80]. Moreover, a recent study
found that the abnormal presence of adipocytes in the aortic adventitial could recruit
macrophages; therefore, increase the MMP-2 and MMP-9 levels and degrade collagen
fibers surrounding them [81]. Aortic VSMCs in the aneurysmal tissue have been shown to
have phenotype changes from a contractile type to synthetic one in consistence with the
cytoskeletal rearrangement, which also preceded elastolysis and gross media remodeling
[74]. Adventitial fibroblasts are presumed to promote structural repair when the damage is
done to the aortic wall. However, the interstitial collagen becomes disorganized and
compromises the mechanical properties of the aortic wall.
On the molecular level, many chemokines, cytokines, proteases, microRNAs
(miRs) and the renin-angiotensin system (RAS) have been implicated in the formation and
progression of AAAs. Some upregulated pro-inflammatory cytokines such as interleukin
(IL)-1b, IL-6, IL-17, IL-23 and tumor necrosis factor (TNF)-a, monocyte chemoattractant
protein (MCP)-1 have been demonstrated to contribute to the recruitment and
differentiation of macrophages at the aneurysmal site [5, 74]. TGF-b, on the other hand, is
a critical down-regulated cytokine that plays a protective role in human AAA pathogenesis
despite its ability to promote thoracic aortic aneurysm (TAA) formation [82].
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Figure 2-7. Pathophysiology of AAA with the table legend that illustrates major cell types,
cytokines, protease, miRs. and RAS involved in AAA pathogenesis [5].
Lysyl oxidase (LOX), an oxidase the activity of which also has been found suppressed in
the AAA, can stabilize the ECM by crosslinking the collagen and elastin and inhibiting
MCP-1 secretion and the subsequent inflammatory responses, and slow down the
progression of the AAA [83].
Some proteases and their inhibitors, including MMP, serine proteases, and cysteine
proteases, have been involved in the AAA formation and progression by causing structural
damage of elastin and collagen in the aortic ECM, which leads to weakening and dilation
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of the abdominal aorta [84]. The complementary role of macrophage-derived MMP-9, and
MMP-2, an MMP that has a unique ability to degrade both elastin and fibrillar collagen,
has been proved critical in the development of AAAs [85]. Cysteine and serine proteases,
on the other hand, can activate neutrophil elastase and some other proteases in AAAs,
which cause further degradation of the ECM and AAA progression [86].
MiRs are a class of short, well-conserved, non-coding RNAs that play their
biological role by influencing the stability and translation of mRNAs [87]. Several miRs
have been identified as crucial regulators during the AAA development recently. A
decrease of miR-29b has been detected in human AAA tissues due to the aortic damage
[86]. However, several studies in mouse models indicated that when the expression of the
miR-29b was further suppressed to levels lower than typical pathological decreases, several
ECM proteins expression was upregulated and the progression of the AAA was slowed
down [88]. The upregulation of murine specific miR-712 and its human/murine homolog
miR-205 has been demonstrated to downregulate two key upstream inhibitors of MMPs,
tissue inhibitor of metalloproteinases (TIMP)3 and reversion-inducing cysteine-rich
protein with kazal motifs (RECK), which leads to ECM degradation and AAA progression
[89]. Moreover, it has been pointed out that the overexpression of miR-181b could
negatively regulate TIMP3 expression and activity [90]. On the contrary, overexpression
of miR-21, a miR that has been identified as a critical mediator for proliferation and
apoptosis of VSMCs, can prevent AAA formation [91].
The relationship between RAS and AAA development has been studied in many
animal studies. The infusion of angiotensin II (AngII) in mice deficient for apolipoprotein
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E (ApoE-/-) or low-density lipoprotein receptor (LDLr-/-) in combine with a high-fat diet
can induce aneurysms and dissections at the suprarenal abdominal aorta [92]. AngII
infusion in mice was shown to associate with the adventitial accumulation of C-C
chemokine receptor type 2 (CCR2)+ macrophages specifically at the sites of aneurysm
formation and the most prominently at the sites of dissection [93]. AngII also stimulates
the angiotensin type 1a (AT1a) receptors to regulate the mitogen-activated protein kinase
(MAPK) signaling cascade and enhance the TGF-b signaling, which eventually leads to
the production of pro-inflammatory factors [74].
2.7 Biomechanics of AAAs
The biomechanics of the aneurysmal aortic wall has been extensively studied to
develop a method to predict the rupture risk of the AAAs. The rupture of the AAAs happens
when the strength of the wall cannot withhold the blood pressure. Thus, studying the effect
of blood pressure on the aortic wall is essential. The aortic wall is a tubular structure that
repeatedly deforms under pulsatile blood pressure, which generates forces that can be
normalized and translated into radical, circumferential, axial, and wall shear stresses
(Figure 2-8) [94].
The formation of the AAAs can significantly change the aortic mechanical
properties due to the degradation of the structural proteins such as elastin and collagen
fibers [95]. Destructive AAA tissue characterization tests such as uniaxial extension test
until failure, biaxial extension tests, and peeling tests were performed for material property
data collection. Anisotropic responses with stiffer behavior have been demonstrated in the
circumferential direction of AAAs in ex-vivo AAA studies [96, 97]. The geometrical
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Figure 2-8. Mechanical loading state of aortic tissue shows circumferential, axial, radial,
and wall shear stresses in the aortic wall.
change of the abdominal aorta and other related pathological changes, including the
formation of an intraluminal thrombus (ILT) and the apoptosis of VSMCs, can result in a
change in the local fluid dynamics [94]. The combination of a weakened aortic wall and
the abnormal fluid dynamics may elevate the mechanical stresses on the aneurysmal aortic
wall and lead to rupture.
2.8 Rupture risk assessment of AAA
The potential risk of an aneurysm rupture is determined by factors such as evolving
geometry, mechanical properties, and hemodynamic loads/perivascular conditions [98].
Nowadays, three major categories of assessment methods have been applied to predict
AAA rupture risk: AAA geometrical analysis, local biomechanics analysis, and biomarker
analysis.
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AAA geometrical analysis
Geometrical information such as maximum aortic diameter has been used as the
standard clinical criteria for assessing the AAA rupture risk and deciding treatment strategy
[99]. Advances in medical imaging, particularly computed tomography angiography
(CTA) and magnetic resonance imaging (MRI), provide exquisite data on overall patientspecific geometries. While using the geometric modeling to predict the rupture risk AAAs,
at least 40 image-based geometric parameters are correlated with AAA rupture and 15 of
the correlates are statistically significant for the predictive model [100]. However, the
recommendation of intervention should not only base on the size of the AAA, as many
small AAAs ruptured while large AAAs remained stable in clinical cases [101].
AAA geometry is complex and, in most cases, cannot be approximated by a thinwalled cylinder. For example, almost all clinically relevant AAAs contain ILTs composed
of fibrin, inflammatory cells, platelets, and red blood cells [99]. The formation of ILT
influences the structural and mechanical properties of the AAA. Thus, to predict the
patient-specific rupture risk more precisely, fine element analysis (FEA) is used to
reconstruct a more accurate 3-dimensional (3D) AAA morphology and to calculate the
biomechanical parameters.
AAA biomechanical analysis
To understand the biomechanical properties of the aneurysms, computational
models have been developed base on the AAA rupture factors (Figure 2-9). These models
can be used to find the mechanical weak point of the aneurysm and predict its rupture
possibility. FEA for AAA usually incorporates risk factors such as AAA geometry, gender,
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Figure 2-9. Process of creation of appropriate 3D reconstruction for stress analysis: A.
Initial surface shaded 3D reconstruction; B. Elimination of anatomic elements not pertinent
to stress analysis; C. Merged 3D reconstruction to obtain outer boundaries of the aortic
wall; D. Initial 3D mesh; E. Refined mesh ready for input into FEA program; and F. Stress
analysis with stress mapped onto the surface of 3D reconstruction with color gradients to
represent stress gradients [102].
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blood pressure, smoking history, and the amount of ILT [103]. Two commonly used
biomechanical dices, peak wall stress (PWS) and peak wall rupture index (PWRI), can be
calculated using FEA to estimate the future AAA rupture risk. As we mentioned
previously, the rupture of AAA happens when the aortic wall stress exceeds the mechanical
strength of the wall. Thus, it is feasible to use PWS, the highest von Mises wall stress
within an AAA, to predict the potential rupture. PWS calculations are based on blood
pressure, aortic wall properties, and the geometry of the 3D AAA model reconstructed
from the CTA images [104]. PWRI is a relatively more sophisticated mechanical parameter
than PWS. While PWS considers only the stress, PWRI is estimated base on the
relationship between the local wall stress and local wall strength, using the following
equation:
𝑃𝑊𝑅𝐼 = max (

𝑊𝑎𝑙𝑙 𝑠𝑡𝑟𝑒𝑠𝑠
)
𝑊𝑎𝑙𝑙 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ

However, the classic FEA is usually performed base on a fixed AAA geometry.
The progression of the AAA with time could greatly change the stress and the strength of
the aneurysmal tissue, thus, make the previous rupture risk evaluation less accurate.
Computational modeling of vascular growth and remodeling (G&R) provides a tool to
model the time evolution of vascular diseases based on the assumption that mechanical
hemostasis exists [102]. On the foundation of the FE analysis for stress, G&R modeling
adapts the growth stimulation to the configuration by introducing the influence of
constituents such as elastin, collagen, and SMCs, to mimic the AAA progression in-vivo
(Figure 2-10) [105]. Zeinali-Davarani, S. et al developed a computational G&R model by
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Figure 2-10. In-vivo configurations for fluid-solid growth simulations, iterative loop, and
information transfer in the coupling between the hemodynamics and G&R simulations
[106].
applying estimated material parameters as well as the distributions of wall thickness and
anisotropy gained from an inverse optimization method to develop the vessel wall model
and then introducing spatial elastin degradation as the stimulation to the model [107].
Sheidaei, A. et al. reported a G&R model based on the effect of wall shear stress to
understand the progression and rupture mechanism of AAAs [106]. These models provided
theoretical frameworks for further developing patient-specific AAA models for clinical
use.
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Both PWR and PWRI have been reported to be higher in symptomatic or ruptured
than in intact AAAs in many independent studies, indicating their potential to be used as
AAA rupture risk assessment tools [103, 108, 109]. Moreover, the development of the
G&R model provided a tool for studying the rupture risk of AAA in a progression
dependent manner. However, the calculations for PWR and PWRI, as well as the
establishment of the G&R models are based on some predefined AAA parameters such as
the aneurysmal wall thickness, due to the limitation in spatial resolution of imaging. The
variety of these parameters between patients can cause inaccuracy of the rupture-predicting
capability of the existing computational models.
AAA biomarkers analysis
In addition to the biomechanical features, some AAA related biomarkers, including
serum EDP concentration, 18F-fluorodeoxyglucose (18F-FDG) uptake, and ILT size can be
used to predict the expansion and rupture of AAAs [110]. As the AAA progress, the
degradation and fragmentation of elastin in the aneurysmal tissue release EDP into the
circulation and can be detected using ELISA method. It has been demonstrated in a fiveyear human small AAA study that serum EDP level is significantly correlated with AAA
expansion in ~90% of the tested cases [111]. The level of the inflammation in the
aneurysmal tissue also varies during the progression of the AAAs. The high metabolic
activity associated with a severe local inflammation precedes a phase of AAA rapid growth
and is then followed by a period of stasis with low metabolic activity [112].
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F-FDG

uptake increase, featuring an increased metabolic activity in the aneurysmal tissue, can be
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detected and quantified using positron emission tomography (PET) and can be used as a
reliable marker for AAA expansion [113-115].
Furthermore, the ILT size is also a promising prognostic growth marker for AAAs.
A thin ILT layer can function as a protection for the aortic wall because it can buffer the
stress and lower the rupture risk for the aneurysm [116]. However, when growing too thick,
the ILT layer can cause the aortic wall to weaken, for example, due to hypoxia. ILT is also
the source of many pro-proteolytic processes that stimulate aortic wall degradation [117].
A clinical study performed by Haller S.J. et al. pointed out that the protective
biomechanical advantage that ILT provided by lowering wall stress seems to be
outweighed by the weakening of the AAA wall, particularly in patients with small ruptured
AAAs [118].
2.9 Animal models for AAA
Animal models of AAA can provide insight into the mechanisms of progression of
the human disease based on the assumption that the biochemical, biomechanical, and
cellular properties in the animals are comparable to those in humans. However, due to the
species-specific variety, there is no perfect animal model for AAAs. Each different
experimental model of AAA only presents partially the pathological features that have been
discovered in human AAAs. AAA animal models have been developed using genetic
manipulation, physical and chemical induction, as well as the combinations of these
technics. Different animal species have been used to create in-vivo AAA models, including
mouse, rat, hamster/guinea pig, rabbit, turkey, dog, sheep, and porcine to study the
mechanisms of AAA.
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Rodent AAA models
Rodents are most wildly used to develop animal models for reasons including the
small size, relative cheapness, great accessibility, and the ability to be genetically
manipulated. Several different techniques, including elastase treatment, calcium chloride
(CaCl2) treatment, AngII infusion, and xenograft transplantation, has successfully induced
the formation of AAAs with different characteristics in rodents.
The elastase model in rodents is performed by intraluminal or periarterial
application of elastase, usually porcine pancreatic elastase (PPE), via a midline abdominal
incision (Figure2-11). Traditionally, to perform intraluminal perfusion of the PPE, the
infrarenal abdominal aorta is dissected from the surrounding connective tissue and isolated
from the circulation by applying atraumatic clamps. PPE is then injected into the isolated
part of the aorta through a catheter. When the perfusion is finished, the catheter and the
clamps are removed to restore the blood flow, and the incision is sutured close. This method
can be challenging to perform due to the small size of the rodent aorta.
A more straightforward elastase treatment that involves an application of a
periadventitial PPE soaked gauze has been developed to introduce elastin damage to the
rodent aorta [119]. Moreover, the combined use of 3-aminopropionitrile fumarate salt
(BAPN) and periadventitial PPE treatment results in an advanced staged AAA that forms
thrombus and can spontaneously rupture [120]. The AAAs developed using the rodent
elastase model have multiple pathological features that are similar to human AAAs
including the infiltration of the macrophages in the adventitial, degradation of media
elastin, apoptosis of VSMCs, and formation of intraluminal thrombus [119, 121].
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Figure 2-11. Intraluminal and periarterial application of elastase on rodent aorta.
Periadventitial administration of calcium chloride at the infrarenal aorta can also
induce AAAs in rodents. The surgical protocol for this model is similar to the periarterial
PPE treatment model, but a gauze soaked with calcium chloride solution is applied instead
of PPE. The expansion of the aorta was mostly reported immediately after the CaCl2
exposure. Increased endothelial permeability and VSMC apoptosis have been documented
in CaCl2 treated vasculature, as well as vascular calcification and the infiltration of
inflammatory cells in the adventitia and media [122]. This model is developed to closely
mimic human AAA pathology in terms of upregulated inflammation, degradation of ECM,
neovascularization, increased oxidative stress, VSMC apoptosis, and heavy aortic
calcification which has been reported in 80% of human AAAs [123]. The main problem
with the CaCl2 AAA model is that there is no evidence of intraluminal thrombus formation
and rupture, as is seen in human AAAs.
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Ang II infusion via a subcutaneously implanted osmotic pump for 28 days, can
induce AAA in wild type C57BL/6 mice or transgenic mice (ApoE-/- or LDLr-/-) (Figure
2-12). Aneurysms in this model are usually observed at the suprarenal abdominal aorta as
well as the ascending aorta, making it a proper model for studying both AAAs and TAAs.
AngII has been known as a peptide hormone that can increase blood pressure by
constricting the blood vessels. Although the infusion of AngII in hyperlipidemic mice can
increase mean arterial pressure, it has been demonstrated that the arterial dilation and AAA
formation in these models was not related to the increased blood pressure [92, 124]. The
upregulation of mRNA expressions of MMP, PPAR-γ, MCP-1, and uPAR in AngII
induced AAAs increases the inflammation in the aortic wall in a blood pressureindependent way [125]. AngII promotes the enlargement of the suprarenal aorta
accompanied by atherosclerosis, medial hypertrophy, accumulation of macrophages in the
external elastic lamina, and thrombosis in ApoE-/- mice, which mimics human AAA
development [126].

Figure 2-12. Development of AngII infused AAA model.
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Transplantation of a decellularized xenograft to replace a part of the healthy rodent
aorta can also induce aneurysms. Usually, a donor aorta, for example, an aorta from guinea
pig, is harvested and decellularized with sodium dodecyl sulfate (SDS) and then transplant
into the rodent via major abdominal surgery. The donor aortic ECM induces a chronic
interspecies immunological response that causes the destruction and dilation of the
xenograft [127]. The infiltration of monocytes and T-lymphocytes has been reported in the
intimal of the transplanted graft [128]. The pre-immunization of rodents with donor aortic
ECM accelerates xenograft destruction and triggers AAA rupture [129]. This model is not
as frequently studied in small animals but can be used to specifically study the roles of the
immune system, aortic ECM, and VSMCs in AAA development.
Non-rodent AAA animal models
The development of new surgical techniques and new devices for AAAs created a
need for animal models that can create AAA with anatomical similarities to humans.
Medical devices, such as stents and grafts, need to be tested before incorporation to the
clinic, and rodent models failed to translate the experimental findings due to their small
size. Thus, increasing efforts have been made to create AAAs in larger species. Chemical
induction is one way that has been wildly used in creating AAAs in large animals such as
rabbits, dogs, and swine. The application of elastase, collagenase, or CaCl2 alone can
induce AAAs in rabbit with a more than 50% dilation [130, 131]. However, for larger
animals like dogs and porcine, a combined treatment (elastase, collagenase, and
angioplasty) must be applied to generate AAAs that are big enough for further study [132].
A large animal model can also be developed using grafts or patches. In the graft model, a
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manufactured graft or a xenograft is interposed into the infrarenal abdominal aorta to
induce aneurysms. And in the patch model, instead of a graft, an elliptical patch or a pouch,
made out of the vein, prothesis vascular graft, and rectus fascia, is applied through a
longitudinal aortotomy [133, 134]. These models which apply biological materials such as
abdominal rectus fascia and veins have rupture characteristics that are similar to humans
[127].
2.10 AAA diagnosis strategies and imaging modalities
When the enlargement of the aorta is greater than 1.5-fold of its normal size, it is
considered an aneurysm [73]. Clinical diagnosis of AAAs is most common by ultrasound
quantification of aortic diameter. It has been wildly used in the screening program for
AAAs in many countries because it is inexpensive, non-invasive, and effective. Men and
women, aged 65 years or older with a smoking or family AAA history, are recommended
to receive onetime ultrasonography of the infrarenal abdominal aorta even if they have no
symptoms [6]. Ultrasound is also used as a monitoring tool for patients with small AAAs
to track AAA progression. Although it has been demonstrated to be a relatively accurate
imaging modality for AAA screening, obese body habitus, bowel gas, and the observer’s
skill set can compromise the ultrasound accuracy [135]. Moreover, the imaging accuracy
of ultrasound decreases as the size of the aorta increases [136].
When ultrasound images are suboptimal, computed tomography (CT) is used as an
alternative imaging method. It is a superior diagnostic modality compared with
ultrasonography because it can provide valuable information with high reproducibility,
including a more accurate AAA morphology as well as the surrounding anatomy, the
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presence of intraluminal thrombus, and calcifications. More advanced CT-based
modalities, such as Helical CT and CTA are wildly used as the imaging modalities for the
pre-operative AAA evaluation because they can generate a 3D road map of nearby vessels
as well for planning surgical repair [137]. Moreover, some findings from the CT imaging
render CTA the ability to provide information for assessing the inflammation level and
rupture risk of the aneurysms. For example, CT-detected delayed enhancement in the aortic
wall represents an increased density of inflammatory cells and neovessels in the aortic
adventitial, and the intraluminal crescent sign represents the bleeding in the intraluminal
thrombus [138]. However, the ionizing radiation and the contrast agents that are used in
CTA can cause adverse effects in cases involving repeated imaging or renal insufficiency.
Magnetic resonance imaging (MRI) is another advanced imaging modality for
AAAs with high sensitivity and reproducibility. MRI can provide high resolution 3D
anatomical imaging of AAAs, as well as the information about aortic calcification,
inflammation, and biomechanics [139, 140]. The advantage of performing magnetic
resonance angiography (MRA), comparing to CTA, is that no ionizing radiation and
contrast agent exposure is required. Instead of gadolinium contrast agent injection, a longer
acquisition time in MRA can also enhance the AAAs [138]. But the use of MRI is limited
because of its relatively high cost, patient-related motion artifact, and patient
claustrophobia during longer scanning times.
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2.11 Contrast agent for computed tomography (CT) scan
The X-ray absorption profile of different materials varies with the density and
atomic number according to the formula that has been used to estimate the X-ray absorption
coefficient under limited conditions:
𝜌𝑍 !
𝜇≈
𝐴𝐸 "
where 𝜌 is the material density, Z is the atomic number, A is the atomic mass and E is the
X-ray energy. Different X-ray absorptions of different materials generate contrast in a CT
scan. Many bodily tissues including bones and lungs are easily recognized in a CT scan
due to their distinct X-ray absorption profile comparing to the soft tissues. However, it
remains challenging to identify the interface between two adjacent soft tissues or between
soft tissue and physiological fluids such as blood [141]. Contrast imaging agents are often
applied to better visualize and differentiate the tissue of interest such as AAA from the
surrounding connective tissue, improve the imaging quality, and increase the CT
sensitivity. Various contrast media with a sufficient in-vivo retention-time has been
developed to fulfill the requirement to highlight the tissue of interest in a CT scan.
Iodine-based contrast agent
Covalently bound iodine has historically been a popular choice for designing CT
contrast agent due to the high atomic number of iodine (Z = 53) (Figure 2-13). The
iodinated contrast agent can be divided into ionic and non-ionic categories. Ionic contrast
agents dissociate into negative and positive ions when dissolved in water while non-ionic
contrast agents do not dissociate and contain polar hydroxide groups that confer them their
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water solubility [142]. Non-ionic contrast agents comparably present more advantages to
be used clinically including lower intrinsic osmolality and lower incidence of adverse
health effects [143]. Over the past few decades, efforts have been made to optimize the
iodinated contrast agent design by manipulating the functional groups present on the
aromatic ring. The purpose of the optimization is to increase the water solubility and biotolerability while decreasing the binding to biological receptors and the toxicity of the
iodinated contrast agent. Moreover, iodine can be encapsulated into nanoparticles to
achieve some additional benefits, including increased blood circulation time, reduced renal
clearance rate, and capillary leakage [144]. It is a better choice to enhance CT imaging for
the cardiovascular system.

Figure 2-13. Different designs of iodinated contrast media [145].
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Lanthanide-based contrast agents
Given their high atomic numbers, Lanthanide-based contrast agents, which are
commonly used in MRI imaging, can also be used as a CT contrast agent for cardiovascular
and pulmonary imaging [146, 147]. Although free lanthanide ions are extremely toxic,
gadolinium (Z = 64), dysprosium (Z = 66), and ytterbium (Z = 70) form highly
thermodynamically stable polyaminocarboxylic acid chelate complexes that make them
clinically safe to be used as contrast agent [148, 149]. Since the lanthanide atoms have
higher atomic numbers than iodine, they can offer higher X-ray attenuation and CT
sensitivity than the equal mole amount of iodine atoms. However, some clinical studies
show that gadolinium imaging media can be a cause of pancreatitis and nephrotoxicity that
results in nephrogenic systemic fibrosis (NSF) and encephalopathy in certain at-risk
patients [150-152]. Lanthanide based contrast agents can be nanoparticulated as well to
increase the stability of the contrast agent, minimize the free lanthanide ion release and
prolong their circulation time in blood [153].
The gold nanoparticles-based contrast agent
Gold nanoparticles (AuNPs) are an ideal radiopaque contrast media because of the
following reasons: (a) gold has high density and high atomic number (Z=79), which renders
it a high X-ray attenuation; (b) AuNPs have been demonstrated to have good
biocompatibility in-vivo; (c) physical, chemical and biological properties of the AuNPs can
be manipulated by the well-established synthesis and modification chemistry [154]. It has
been reported that when the size of the AuNPs falls in a certain range, usually small sizes,
AuNPs have a wild biodistribution and exhibit toxicity [155]. This problem can be solved
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by controlling the size and shape of the AuNPs during synthesis, and by modifying the
surface of the AuNPs with biocompatible molecules such as polyethylene glycol (PEG)
and albumin [156, 157].
Surface coated AuNPs have long blood circulating time and can be used as the
contrast agent for blood pool imaging. Moreover, the surface-modified AuNPs can be used
to image targeted organs. The application of heparin polysaccharides conjugated AuNPs
can produce a highly liver-specific contrast in mice [158]. Lisinopril coated AuNPs can be
used to target the angiotensin-converting enzyme (ACE) overexpression in lung tissue invitro [159]. AuNPs coated with antibodies that can target the pathological biomarkers in
cancer, for example, UM-A9 antibodies and Herceptin, have been studied as specific tumor
targeting contrast agents for CT imaging [160, 161]. Although AuNPs based contrast agent
has been demonstrated to be a great compromise between contrasting properties,
physicochemical properties, and biocompatibility, the high cost of gold has been limiting
its application in clinical CT imaging [154].
Other metallic contrast agents
Other metallic contrast agents such as water-soluble tantalum oxide (Ta2O5) and
bismuth (Z=83) based contrast agents have been studied as inexpensive alternatives for
AuNPs. Ta2O5 nanoparticle is an inexpensive, biocompatible contrast agent that has been
used in tracheobronchial and gastrointestinal imaging [162] The sizes of these particles are
easily controllable and surfaces of Ta2O5 nanoparticles can be modified with zwitterionic
coatings. It possesses better CT attenuation properties than an iodinated agent on a permole basis [141]. Bismuth-based nanoparticles with good X-ray attenuating properties that
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exhibit long vascular half-life have been developed and tested in mice as a potential
contrast agent [163]. However, the clinical application of bismuth-based contrast agents is
confined due to the difficulties in controlling the nanoparticle size and modifying the
surfaces, and the lack of toxicity evaluation. As the synthesis and modification of these
nanomaterials get optimized, they hold promise in the field of cardiovascular, lymphatic
system, and tumor tissue CT imaging.
2.12 AAA Treatment Strategies
Current treatments for AAAs
Currently, AAA patients can be clinically treated with either conservative methods
or surgical interventions depending on the absolute/relative size or the growth rate of the
aneurysm. Conservative management via regularly repeated ultrasonography for smaller
AAAs with diameters vary from 3.0 to 5.4 cm greatly reduced the observed AAA-related
mortality [6]. It is also a common treatment strategy for patients whose assessment of
surgical risk overweighs the benefits. The medical aim for conservative management is to
slow down the growth of AAAs and reduce the rupture risk pharmacologically by treating
AAA related cardiovascular disease such as hypertension [164]. In the meantime, patients
are recommended to quit the AAA promoting lifestyles such as smoking and unhealthy
diets. By limiting the risk factors associated with AAA progression, patients with
nonprogressive small aneurysms can get a better benefit from a conservative approach than
a surgical treatment that usually has high risks of complications.
However, for patients with (a) AAAs that reach a diameter threshold of 5.5 cm, (b) smaller
AAAs of which the diameters grow 1.0 cm per year, or (c) ruptured AAAs, a surgical repair
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is usually recommended to diminish the risk of fatal rupture [165]. The two most common
and effective interventions for AAAs are traditional open surgery (OR) and abdominal
endovascular aneurysm repair (EVAR). OR fix the AAA with a major operation by
excluding the aneurysm with a synthetic tube or bifurcated graft while EVAR only requires
a small groin incision that allows the placement of a stent-graft in the aneurysm (Figure 214) [166]. Although surgical repair can effectively reduce the overall AAA mortality,
perioperative mortality remains high because of the risk of operation process including
long surgical time and a large surgical incision during an OR surgery, and post-operation
complications such as infection, ischemia, thromboembolism, pulmonary insufficiency,
and myocadiac dysfunction for both OR and EVAR treatment [167].

Figure 2-14. Open repair and endovascular repair of an infrarenal AAA [166].
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Potential pharmacotherapy for AAAs
A lot of recent studies focused on developing pharmacotherapy for AAA to stop the
expansion of AAAs at an early stage or reduce post-operation complications, so the patients
can avoid surgical risks. Most of the prospective pharmacotherapies aim to reduce the local
inflammatory response in the aneurysmal tissue and stabilize and regenerate the damaged
aortic wall. One of the main targets for the AAA pharmacotherapies is the class of MMPs.
MMPs are a group of calcium-dependent zinc-containing endopeptidases that play an
important role in ECM degradation and tissue remodeling [168]. There are 23 known
human MMPs currently (Table 2-1), among which upregulated activities of MMP-2 and
MMP-9 in the aneurysmal tissue have been wildly studied in the pathogenesis of AAAs.
MMP inhibitors, including doxycycline and batimastat (BB-94) (Figure 2-15), are
the most extensively tested pharmacotherapy for AAA treatment in both animal models
and clinical trials. The administration of MMP inhibitors can reduce the production and the
activity of MMPs, thus, prevent the destruction of elastic lamellae without decreasing
inflammatory cell infiltration [169]. Doxycycline is a synthetic antibiotic derived from
tetracycline that has been clinically used to treat many different types of infections. It also
has some non-antibiotic properties, including inhiation of inflammation, proteolysis,
angiogenesis, and apoptosis [15]. Doxycycline inhibits MMPs via diminishing the
activation of pro-MMPs, accelerating the MMP degradation, and loss of enzymatic activity
[170].
The inhibition of MMP activity can be also achieved by altering the enzyme
structure by chelating the zinc (II) ion of the active site, binding to the backbone of the
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Table 2-1. Human matrix metalloproteinase
No.

Class

MMP No.

Trivial name

1

Collagenases

MMP-1

Interstitial collagenase

2

MMP-8

Neutrophil collagenase

3

MMP-13

Collagenase 3

MMP-2

72 kDa gelatinase A

MMP-9

92 kDa gelatinase B

MMP-3

stromelysin-1

7

MMP-10

stromelysin-2

8

MMP-11

stromelysin-3

MMP-7

Matrilysin 1

MMP-26

Matrilysin 2

4

Gelatinases

5
6

9

Stromelysins

Matrilysins

10
11

MT-MMPs

MMP-14

MT-1 MMP

12

(Transmembrane)

MMP-15

MT-2 MMP

13

MMP-16

MT-3 MMP

14

MMP-24

MT-5 MMP

MMP-17

MT-4 MMP

MMP-25

MT-6 MMP

MMP-12

Macrophage elastase

18

MMP-19

RASI-1

19

MMP-20

Enamelysin

20

MMP-21

-

21

MMP-23

CA-MMP

22

MMP-27

-

23

MMP-28

Epilysin

15

(GPI anchored)

16
17

Other enzymes
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enzyme, or interacting with subsites of the enzyme [171]. BB-94 is one of the board
spectrum MMP inhibitors that has a hydroxamate group which can bind to the active zinc
in MMPs [172]. Treatment with a low dose of BB-49 with an aneurysm targeting
nanoparticle system has been reported to suppress MMP activity and AAA progression in
a CaCl2 induced rat AAA model [169].

Figure 2-15. Structure of doxycycline and batimastat.
Several drugs, such as pyrrolidine dithiocarbamate (PDTC) and statins, were
studied for their ability to reduce the inflammatory response in aneurysmal tissue by
interacting with pro-inflammatory signaling pathways. Nuclear factor-kappa B (NF-κB) is
a transcription factor implicated in the processes of inflammatory responses and oxidative
stress. The activation of NF-κB signaling pathway can result in mRNA expressions of the
genes for numerous cytokines, growth factors, and adhesion molecules [173]. NF-κB
activation is a major early event in the pathogenesis of inflammation-related vascular
diseases, making the blockade of endothelial NF-κB signaling a promising strategy for
preventing vascular inflammation and dysfunction, especially aneurysm formation [174].
PDTC, an antioxidant, and inhibitor for NF-κB signaling pathway, has been reported to
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successfully relieve cancer cachexia and attenuate lipopolysaccharide (LPS) induced injury
[175-178]. PDTC can induce the expression of the regulator of calcineurin activity 1
(RCAN1), thus, prevent the activation of NF-κB signaling pathway (Figure 2-16) [179].
Considering the important role NF-κB plays in the AAA pathogenesis, PDTC has also been
tested in animal AAA models, and has effectively inhibited AAA progression by
modulating the expression of MMPs and proinflammatory cytokines [180-182].

Figure 2-16. PDTC inhibits NF-κB signaling via inducing RCAN1 expression [179].
Statins, the inhibitors of 3-3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase, are a class of well-established drugs for lowering the cholesterol level in
vascular diseases [183-185]. It has been shown that statins can reduce the secretion of proinflammatory proteins such as MMPs and MCPs in ex-vivo studies with cultured human
AAAs by preferentially inhibit the Rac1/ NF-κB signaling pathway [186, 187]. Further
studies on simvastatin and pravastatin (Figure 2-17), two kinds of statins that had the fewest
side effects in this class of medications, have demonstrated their ability to increase TIMP1 production in rodent models [13, 14]. Statin treatment not only attenuates the AAA
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progression in animal models but also in clinical studies. In a study of 130 patients with
AAAs not treated surgically, the group of patients who were received statins treatment
showed significantly smaller AAA sizes and lowered mortality comparing to the group of
patients not treated with statins [188].

Figure 2-17. Structures of simvastatin and pravastatin.
The development of AAA is associated with increased oxidative stress in the aortic
wall. Overproduction of reactive oxygen species (ROS) as a result of the change in aortic
mechanical stress and expression of cytokines can subsequently induce vascular
inflammation, increased MMP activity, SMCs apoptosis, and change in collagen properties
[189]. α-tocopherol, known as vitamin E, is a dietary antioxidant that has been
demonstrated to reduce macrophage infiltration, osteopontin (OPN) expression and ROS
activity in an AngII induced ApoE-/- mouse AAA model [190]. The size and weight of
these AAAs were both decreased, indicating that vitamin E has the potential to slow down
AAA progression. β-carotene is another antioxidant that has been reported to attenuate the
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AAA formation. β-carotene may activate RAR/RXR pathway and dimerize with
peroxisome proliferator-activated receptors (PPARs) to repress the target genes, regulate
inflammatory reactions, alleviate macrophage recruitment and resolve atheromatous
plaques in the ApoE-/- mice model [125].

Figure 2-18. Structures of α-tocopherol and β-carotene.
Given the fact that RAS participates in several pro-AAA mechanisms, ACE
inhibitors, and angiotensin receptor blockers (ARB) have been studied as pharmacological
treatments for AAAs [191]. It has been well established that the clinical application of ACE
inhibitors and ARBs can regulate the blood pressure in patients with hypertension [192].
The decrease in blood pressure lowers the aortic wall stress, thus decrease the rupture risk
of AAAs. Moreover, ACE inhibitors and ARBs have anti-inflammatory effects on the
aneurysm wall by suppressing the NF- κB pathway and TGF-b/SMAD signaling [193].
ACE inhibitors such as captopril, lisinopril, and enalapril prevented the development of
AAA and attenuated the degradation of media elastin in an elastase infusion model [194].
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ARBs such as telmisartan and valsartan limit the progression of AAAs by inhibiting the
angiotensin II type I receptor (AT1R) cascade [195-197].
Table 2-2. Potential pharmacotherapy for abdominal aortic aneurysms
Drugs

Known mechanisms

Effects

Doxycycline

Pro-MMPs activation ↓

MMP-9 ↓, MMP-2 ↓, preserved elastin

BB-94

Zinc (II) ion chelation

MMP-9 ↓, MMP-2 ↓, preserved elastin

NF-κB pathway ↓,

Cellular infiltration ↓, MMP-9 ↓, IL-1b ↓,

Notch pathway ↓

IL-6 ↓, preserved elastin

PDTC
Macrophage infiltration ↓, MMP-9 ↓, MCP-1
statins
↓, MCP-2 ↓, epithelial neutrophil-activating
(simvastatin and

Rac1/NF-κB pathway ↓
peptide (CXCL5) ↓, TIMP-1 ↑, preserved

atorvastatin)
elastin
α-tocopherol

Oxidative stress ↓

Macrophage infiltration ↓, ROS ↓, OPN ↓

Oxidative stress ↓,

Macrophage infiltration ↓, ROS ↓,

RAR/RXR pathway ↑

Atheromatous plaques ↓

β-carotene
AT1R ↓, AT2R ↓, NFACE inhibitors

Blood pressure ↓, MMP-9 ↓, preserved

κB pathway ↓, TGF-

elastin

b/SMAD ↓
AT1R ↓, ERK ↓, NF-κB

Blood pressure ↓, MMP-9 ↓, Bcl-2/Bax ↑,

pathway ↓

preserved elastin

ARBs
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All the drugs that can be used as a pharmacotherapy for AAA mentioned above are
summarized in Table 2-2.
Polyphenols are a large and varied family of natural compounds that consist of a
hydrophobic core surrounded by phenolic (-OH) groups on the exterior. Pentagalloyl
glucose (β-1,2,3,4,6-Pentagalloyl-O-D-Glucopyranose, PGG) is one of the tannic acid
derivatives that contain five identical gallic acid ester linkages involving the aliphatic
hydroxyl groups in the sugar core (Figure 2-19) [198]. It has gained a lot of scientific
attention recently because of its potential use as an antimicrobial, anti-inflammatory,
anticarcinogenic, antidiabetic, and antioxidant agent [199].
Studies indicated that PGG could be used as an ECM stabilizer due to its capability
to bind to structural fibers in the ECM and, in doing so, render them resistant to enzymatic
degradation. Periarterial treatment with PGG preserved elastin fiber integrity and hindered
aneurysmal dilatation of the abdominal aorta in clinically relevant calcium chloride and
elastase-induced animal injury model of AAA [200, 201]. More interestingly, enhancement
of ECM biosynthetic enzymes such as LOX can not only stabilize the ECM but also
reduced inflammatory responses, including MCP-1 secretion, macrophage infiltration, and
c-Jun N-terminal kinase (JNK) pathway activation, thereby preventing AAA progression
in mice [83].
Most of the pharmacotherapies mentioned above were tested in animal models. To
translate the research findings into clinical practice, further studies need to focus on how
these drugs interact with human AAA in-vivo. In the established human AAA treatment
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clinical trials, drugs were usually administrated systemically. Although systemic
pharmacologic treatments have shown effectiveness in animal models, they did not bring
many benefits to the AAA patients due to either low local drug concentration or severe

Figure 2-19. Gallic acid and PGG structure [202].
systemic side-effects. For instance, systemic delivery can cause off-target inhibition of the
MMP activities that are essential for normal homeostasis [203]. Since AAA is
predominately localized to a limited area on the aorta, targeted delivery of pharmacologic
agents is a tempting approach to increase therapeutic efficacy and reduce systemic side
effects. Local drug delivery can be achieved by establishing a nanoparticle system that
targets pathological biomarkers located in the aneurysmal tissue or combining the drugs
with medical devices such as grafts or endovascular stents via surface coating.
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2.13 Targeting nanoparticles (NP) systems
Nanotechnology is a powerful tool that has been wildly used in developing and
optimizing novel diagnostic strategies and pharmacotherapies in many fields. The
physiological and chemical properties of the materials change drastically in nanoscale. It
provides a possibility to make the synthesized materials less toxic and more biocompatible
for in-vivo use by making them into size-controlled and surface-modified NPs. NPs are
relatively stable in biological systems, characterized by a long blood half-life and their
ability to evade elimination by the reticuloendothelial system [204]. The surface
modification also can render NPs certain unique features that enable them to target specific
tissues or organs to maximize the beneficial effects of the loaded chemicals by improving
local availability and lower off-target complications.
Many types of nanosystems, including dendrimers, quantum dots, micelles,
liposomes, polymeric nanoparticles, carbon nanotubes, albumin, and metallic nanoparticles
such as gold and iron oxide, have been studied in a range of diseases. The nanosystem is
usually selected base on the applications. For example, self-assembling peptide amphiphile
nanofibers are being investigated as treatments to modify stem cell proliferation and
differentiation in regenerative medicine [205]. Gold nanoparticles, magnetic iron oxide
nanoparticles, and quantum dots can be used directly for targeted bioimaging [206-208].
Moreover, drugs can be loaded to the surface of these nanosystems via surface
modifications to achieve both diagnostic and treatment capabilities at the same time [209211]. Dendrimers, polymeric, liposomal, and albumin nanoparticles have been extensively
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studied as in-vivo drug delivery nanocarriers because of their high biocompatibility,
biodegradability, and high dug payload [212-214].
To date, the targeting of AAAs for therapeutic and imaging purposes remains
significantly challenging because of the limited number of viable targets and a relatively

Figure 2-20. Schematic diagram of nanocarriers, potential targets, and potential
applications in medicine [215].
low hemodynamic residence time in the diseased aorta. As NPs have to be administered
intravenously into circulation to target vascular disease, an immune response, known as
opsonization, to the blood proteins that are absorbed onto the particle surface will occur
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[216]. Opsonization will result in the particles being quickly eliminated from circulation
by the mononuclear phagocyte system (MPS), and the desired imaging and therapeutic
effect would not be achieved [217]. Yet, despite the difficulties in designing targeting
systems for vascular diseases, some surface-modified nanosystems have been developed
to successfully target AAAs.
Metallic nanoparticles
Ultra-small SPIO (USPIO) nanoparticles are a novel category of MRI contrast
agents that play a crucial role in the imaging of AAAs. USPIO nanoparticles include
ferumoxtran-10 and ferumoxytol with a diameter of <50 nm. They can be used as a blood
pool contrast agent but also can be taken up by tissue-resident macrophages and can be
used to identify cellular inflammation within tissues [218]. In several rodent animal
models, marked accumulation of USPIO-labeled macrophages was found within the
aneurysmal aorta that could be identified by MRI and was confirmed by
immunohistochemistry [219-221]. Preliminary evidence of USPIO uptake in human
abdominal aortic aneurysms (AAA) has been described by Sadat U. et al in a 14 patient
study [222]. Thus, USPIO enhanced MRI can be potentially effective in the quantification
of the AAA associated inflammatory processes.
Cross-linked iron oxide nanoparticles (CLIO) also have been reported to possess
the ability to target the monocytes/ macrophages in the aneurysmal tissue. A recent study
performed in ApoE-/- mice indicated that dextran-coated iron oxide nanoparticles could be
labeled with fluorine-18 (18F) and could provide a specific signal intensity enhancement in
the aneurysmal wall in PET -CT scans [223]. In this reported AAA targeting NP system,
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CLIO was avidly internalized by phagocytic cells in the aneurysmal tissue to achieve
targeting and 18F functioned as the PET scan tracer to visualize the inflammatory level of
the AAAs.
Polymeric nanoparticles
Biodegradable polymeric NPs have shown significant therapeutic potential for
controlled drug delivery. Nanoparticles made of polymers, such as poly (lactic acid) (PLA),
poly-lactic-co-glycolic acid (PLGA), polyethylene glycol (PEG), and their copolymers,
present themselves as lucrative options for drug delivery owing to the possibility to tailor
their physical, surface, and degradation characteristics. Drugs that are enclosed within the
polymeric NPs would be protected from potential degradation by enzymes or hydrolysis,
and the encapsulation would allow for developing more flexible and patient-friendly
delivery techniques [224]. Most of the drug-loaded polymeric NPs can be obtained using
an emulsification-solvent evaporation technique [225, 226].
PLA is biocompatible, biodegradable by hydrolysis and enzymatic activity. It has
low immunogenicity, as well as a broad range of mechanical and physical properties that
can be engineered appropriately to suit different applications [227]. The matrix of PLANP allows the control of drug release kinetics, offering PLA-NP based drug carriers the
benefit of sustainable therapeutic drug release over prolonged periods [228]. The United
States Food and Drug Administration (FDA) has approved the use of PLA-NPs in humans,
which makes PLA-NPs suitable for expedited clinical translation. Previous studies from
our lab have demonstrated the ability of the antibody conjugated PLA-NPs to target
aneurysmal tissue and slowly release therapeutic drugs [169, 229].
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PLGA is a co-polymer with physicochemical characteristics that vary with the
lactic to glycolic ratio. Its application in humans has also been approved by the FDA [230].
Surface modified PLGA NPs have been used for AAA therapeutic and imaging purposes.
Surface functionalization of PLGA NPs with a cationic amphiphile, such as
didodecyldimethylammonium bromide (DMAB), endows the NPs with the ability to bind
fibrin clots [231]. When loaded with fibrinolytic drugs, the NPs have been shown to slowly
cause clot lysis and attenuate the proteolytic loss of vascular elastic matrix. Moreover,
hyaluronan oligomers loaded PLGA NPs have been reported to have a controlled and
sustained drug delivery profile and elastogenic induction property when added into
cultured aneurysmal rat aortic SMCs [232]. PLGA NPs have also been used to encapsulate
contrast agents such as iron oxide and gadolinium, and modified to target thrombosis to
enhance the AAA MRI signal intensity [233, 234].
Albumin based nanoparticles
Albumin, a major transport protein component in blood plasma, has been
commonly used for drug delivery because it is known to be non-toxic, non-immunogenic,
biocompatible, and biodegradable. Albumin in its monomeric formula and albumin-based
nanoparticles have emerged as attractive drug carriers, owing to its promising intrinsic
binding capability of a significant amount of drug molecules [235]. According to the
sources, albumin can be divided into three major types: ovalbumin (OVA) from egg white,
bovine serum albumin (BSA), and human serum albumin (HSA). BSA is a type of albumin
that is wildly accepted in the pharmaceutical industry because of its medical importance,
low cost, and ease of purification. HSA could be used to substitute BSA in in-vivo
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applications to avoid a possible immunologic response [236]. Registered HSA-based
particles such as Albunex™ and Abraxane™ presented high in-vivo tolerance and great
drug delivery profile in clinical studies [237, 238].
NPs that are made out of albumin have been studied for targeting several vascular
diseases. Apatinib-loaded HSA NPs have been used to inhibit vascular endothelial growth
factor (VEGF) induced retinal vascular leakage both in vitro and in vivo in a study
performed by Jeong J. H. et al. [239]. Piceatannol-loaded BSA NPs have been studied to
prevent vascular inflammation by blocking β2 integrin signaling in leukocytes and
detaching the adherent neutrophils on vascular endothelial cells [240]. Ji, J. et al have
reported a method to crosslink albumin NPs crosslinked into albumin ultrasound
microbubbles. A highly expressive tissue-type plasminogen activator gene (t-PA) plasmid
was packaged inside to prevent the formation of thrombosis in a dog model of coronary
bypass [241]. More importantly, according to the previous research from our lab, an
antibody conjugated BSA-NPs drug delivery system loaded with PGG has been shown to
be capable of targeting AAA in a CaCl2 induced rat model and an elastase-induced mouse
model [169, 201]. And ethylenediaminetetraacetic acid (EDTA)-loaded BSA NPs
conjugated with the same antibodies have been reported to successfully target chronic
kidney disease-induced arterial calcification in a rat model and achieve therapeutic
purposes [242]
Albumin nanoparticles can be prepared using techniques including coacervation,
emulsification, thermal gelation, and nanospray drying. Different techniques result in
albumin NPs with different sizes. The coacervation method can be used to produce NPs
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with mean diameters between 150 and 280nm [243]. In the process of simple coacervation,
albumin is phase-separated by adding a desolvating agent such as ethanol to diminish the
solubility of albumin in the aqueous phase. In order to obtain stable albumin nanoparticles,
crosslinker such as glutaraldehyde, polyethyleneimine (PEI), methyl polyethylene glycol
modified oxidized dextran (Dextranox-MPEG), formaldehyde, and 1-ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC) is then used as a to harden the coacervates
[244, 245].
Biomarkers for AAA targeting
Targeting of NPs can be achieved either passively or actively. Passive targeting
mainly relies on inflammation/hypoxia-induced increase of vascular endothelium
permeability. It is the concept that was commonly used for targeting tumors because of
their enhanced permeability and retention (EPR) effect [246, 247]. The leaky vessels and
the absence of normal lymphatic drainage in tumors contribute to the local accumulation
of macromolecules larger than 40kDa and NPs [248]. The circulation time of the NPs in
the blood pool plays an important role in passive targeting. The prolongation of the
circulation time can be achieved by NPs surface coating, for example, PEGylation [249].
Active targeting, on the other hand, depends on molecular recognition such as
ligand/receptor and antigen/antibody interactions. Surface modification with molecules
that target disease-related biomarkers is essential for NPs active targeting. Comparing to
free drug delivery or passive targeting, active targeting can significantly increase the
quantity of drug delivered to the tissue of interest [250, 251]. Moreover, the active targeting
of AAAs can be achieved by a combination usage of NPs and external medical device.
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Magnetic NPs can be guided to the location of the AAA under the influence of an applied
external magnetic field. Superparamagnetic iron oxide (SPIO) nanoparticles, along with
doxycycline were encapsulated in poly(lactic-co-glycolic acid) (PLGA) NPs and were
successfully delivered to the aneurysmal tissue owing to the magnetic properties of SPIO
[252].
The physiological abnormalities in aneurysmal tissues can generate local
biomarkers for AAA targeting imaging and drug delivery. Overproduced ROS in the AAA
wall provides targeting possibility for NPs made out of ROS responsive materials. An
oxidation-responsive β-cyclodextrin (OxbCD) material based nanocarriers have been
reported to successfully release loaded rapamycin upon triggering by a high level of ROS
in a CaCl2 induced rat AAA model [253]. The inflammatory response can also produce
biomarkers for targeting, such as macrophage infiltration and upregulation of inflammatory
molecules. The macrophage infiltration has been labeled by USPIO and was enhanced in
MRI imaging for inflammation assessment in an ApoE -/- mice AAA study carried out by
Turner, G.H. et al. [220]. The αvβ3 integrin, a cell surface glycoprotein receptor, has been
shown to be upregulated in neovessel endothelial cells and atherosclerotic macrophages
and has been used as a AAA target [254]. By using Arg-Gly-Asp (RGD), an extensively
studied short amino acid sequence binder of the αvβ3 integrin, both macrophages and
angiogenesis within AAA lesions in ApoE -/- mice can be targeted [255]. Cathepsin K, a
lysosomal protease that is highly overexpressed within AAA tissue, was targeted with
antibody conjugated cationic amphiphile (DMAB)-modified submicron particles [256].
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The pathological structural changes in the aneurysmal tissue result from ECM
degradation can be also used as targets for localized delivery. The microstructural defects
in the aneurysmal wall have been successfully targeted in an elastase-induced rat AAA
model using rapamycin loaded poly (γ-benzyl L-glutamate) (PBLG) NPs [257]. Degraded
elastin fibers have been targeted using elastin antibody-conjugated PLA NPs loaded with
BB-94 in a CaCl2 induced rat AAA model [169]. The remodeling of the ECM causes
abnormal deposition of collagen in the aneurysmal wall, which can also be used as a target.
CNA-35 functionalized paramagnetic/fluorescent micellar nanoparticles target type I
collagen in the AAA and result in a significantly higher magnetic resonance signal
enhancement in the aneurysmal wall that can be used to predict the rupture risk [258]. The
formation of AAAs and ILTs is associated with endothelial dysfunction and injury as
animal models of endothelial dysfunction and endothelial nitric oxide synthase (eNOS)
uncoupling had a very high rate of AAA formation [259]. The damaged endothelial cells
on the surface of the AAA wall can be targeted with microbubbles conjugated with
molecules that have affinities to specific endothelial determinants such as P-selectin [260].

57

3. PROJECT RATIONALE AND SPECIFIC AIMS

As described in the previous chapter, AAA patients can be currently treated with either
conservative methods or surgical interventions depending on the extent of disease
progression. Up to 90% of detected AAAs are small enough that they do not require
surgery. However, for patients who do not meet the surgical criteria, their AAAs can still
rupture unpredictably. Patients diagnosed with smaller AAAs are under a life-threatening
situation since about 13% of AAAs cause death in patients before they are recommended
for surgery [96]. This could be a result of the limitations of current imaging modality and
the lack of pharmacotherapies. On the one hand, current imaging methods are excellent to
look at the overall growth of aneurysms, while focal aortic wall weakening is generally not
precisely detected. Such weak spots are usually the repercussions of severe elastin
degradation in the aneurysmal tissue and can increase the risk of rupture. On the other hand,
the small AAAs or AAAs that cannot be surgically replaced are also not treated effectively
because there are no current pharmacological treatments to prevent AAA expansion
approved by the FDA.
An imaging modality that can provide progression information other than diameter
change of the AAAs is necessary to identify the patients with higher rupture risks, even if
the sizes of their aneurysms were still small. To date, there is no satisfying imaging method
that could be used to predict the rupture risk of AAAs. Current clinical diagnostic imaging
modalities such as abdominal ultrasound imaging or contrast-enhanced CT provides mostly
geometrical information of the AAAs but little insight on these factors that precede rupture
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in AAAs. Moreover, in order to visualize the vascular system, a large dose of contrast agent
is required for performing contrast-enhanced CT, the toxicity of which may raise concerns
among the patients and place it at a disadvantage [141, 261]. Thus, it is desired to develop
a more biocompatible and efficient contrast agent for CT imaging that can reveal the
mechanical properties of the AAAs.
AAA treatment strategies are usually chosen based on the criteria that the treatment
should bring more benefits than risks to the patient. With a well-established imaging
modality that provides information about AAA rupture risks, clinical decisions will no
longer be made simply contingent on the AAA sizes. For the patients with small AAAs
who are left to wait until their AAA grows large enough to require surgery, or the patients
whose peri and post-operatory risks are too high to receive surgical intervention,
pharmacological management of aneurysms would be an attractive option. During the last
decade, several pharmacological therapies to stop ECM degradation showed promising
results in animal studies, as mentioned in the previous chapter. However, the high required
dose and related off-target systemic side effects of these drugs limited the translating of
these drugs into clinical application.
Among all the drugs that have been studied to reduce the inflammatory response,
halt ECM degradation and suppress the ARS activities, PGG is highly promising for
clinical use because of its relatively low cytotoxicity and ability to bind to stabilize the
ECM to prevent AAA progression and improve the mechanical properties of the damaged
aortic wall [262]. Although PGG is usually considered safe or even beneficial at low levels,
few studies report on the acute toxicity of the use of a high dose of PGG in animals such
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as a precipitous and lethal drop of blood pressure and a significant reduction in blood urea
nitrogen level [263]. It is important to lower the required PGG dose for treating AAAs in
vivo to achieve long-term treatment safety. A local drug delivery system with a controlled
drug releasing profile can greatly increase the efficiency of the drug. Surface modified
nanocarriers are great candidates for developing a target-oriented and controlled delivery
system for precise medicines owing to their customizable characteristics. It can achieve the
same therapeutic effect as systemic drug delivery while administrating drugs at a much
lower total dosage.
The innovation strategy of this research is to develop a targeted CT imaging
contrast agent using surface modified AuNPs, as well as a therapeutic local drug delivery
system that delivers PGG to the degraded matrix in the aneurysmal tissue. We hypothesize
that elastic lamina degradation can be measured by site-specific targeting of AuNPs to the
degraded elastic laminae and that the spatial distribution of AuNP binding will correlate
with wall weakness. Thus, these AuNPs could prove useful as a non-invasive surrogate
marker of AAA rupture potential. We further hypothesize that the targeted delivery of
pharmacological agents will prevent expansion and the ultimate rupture of AAA. The
potential of targeting PGG loaded albumin NPs to be used as a novel local pharmacological
treatment to stop and reverse the progression of AAAs by preserving and regenerating
elastin in the aneurysmal aorta without severe systemic side effects would be studied in
this research.
Specific aim 1: To synthesize and characterize AuNPs that can target degraded elastin
and create distinguishable CT contrast in the vascular wall.
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Sub aim 1: To synthesize, characterize and functionalize AuNPs.
Approach: We will firstly synthesize citrate-capped AuNPs with a size of ~150nm
using a kinetically controlled seeded growth method [264]. Then after we replace the citrate
cap on the surface of the AuNPs with PEG, the AuNPs will be conjugated with custom
made elastin antibodies that can target the degraded elastin. The size and zeta-potential of
both bare and antibody-conjugated AuNPs (EL-AuNPs) will be measured for
characterization.
Sub aim 2: To investigate the toxicity and in-vitro targeting of EL-AuNPs.
Approach: We will use human smooth muscle cells (hSMCs) to evaluate the
cytotoxicity of the EL-AuNPs. EL-AuNP uptake will be evaluated in both hSMCs and
mouse macrophages. We will optimize the targeting performance of EL-AuNPs by trying
out different combinations of PEG to AuNP ratios and incubating conditions. PPE treated
porcine carotids will be used to study the in-vitro targeting and imaging capability of ELAuNPs.
Specific aim 2: To investigate whether EL-AuNPs can be targeted to AAAs in-vivo
and to build a correlation between the micro-CT signal intensity of the targeted ELAuNPs and the mechanical properties of the aneurysm in a clinically relevant AAA
animal model.
Sub aim 1: To build an ex-vivo correlation between the micro-CT signal intensity
of targeted EL-AuNPs and mechanical properties of the aneurysmal tissue.
Approach: We will use the AngII infused mice model of AAA for these studies.
We will inject EL-AuNPs intravenously to target the AAA in-vivo. Then the entire mouse
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aorta will be explanted and imaged using micro-CT. We will quantify the micro-CT signal
intensities of EL-AuNPs accumulated within the aneurysms from the ex-vivo scans and
correlate them with the corresponding burst pressures. We will perform histological
analysis on the targeted aneurysms to reveal the targeting site of the EL-AuNPs.
Sub aim 2: To visualize AAAs in-vivo with micro-CT using EL-AuNPs as a
contrast agent and build a correlation between the targeted micro-CT signal intensity and
mechanical properties of the aneurysmal tissue.
Approach: We will still use the AngII infused mice model of AAA for these studies.
We will first, inject EL-AuNPs intravenously to visualize the AAAs distinctively in-vivo
with micro-CT. Secondly, we will quantify the in-vivo micro-CT signal intensity of ELAuNPs accumulated in the suprarenal aortic region since it is where the aneurysm usually
develops in this animal model. And we will correlate the obtained signal intensity with the
corresponding aortic burst pressure which represents AAA rupture risk, to investigate the
potential of EL-AuNPs in predicting the progression of AAAs. We will perform
histological analysis on the targeted aneurysms to reveal the targeting site of the ELAuNPs.
Specific aim 3: To investigate whether PGG loaded albumin NPs that are conjugated
with antibodies can be targeted to AAAs in an AngII model and whether they stop
the disease progression and restore the healthy function of the aortic wall by repairing
elastin matrix.
Approach: PGG loaded NPs will be synthesized and conjugated to anti-elastin
antibodies. In AngII infused mice, we will investigate whether systemic injection with
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PGG loaded NPs can target and reverse already developed AAA by monitoring the
diameter changes of the aneurysms with an ultrasound system. We will also study the
change in biomechanical properties of the aneurysmal tissue, such as biaxial mechanical
properties, circumferential strain, and PWV. We will study the effect PGG has on the
systemic and local status of inflammation, the local genetic expression, and the structure
of ECM in the aneurysmal tissue.
Each specific aim research is described in separate chapters below.
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4. SPECIFIC AIM 1: TO SYNTHESIZE AND CHARACTERIZE AuNPS THAT CAN
TARGET DEGRADED ELASTIN AND CREATE DISTINGUISHABLE CT
CONTRAST IN THE VASCULAR WALL
4.1 Introduction
Gold in nanoscale has been studied as an ideal radiopaque CT contrast agent for its
high density, high atomic number, high X-ray absorption coefficient, and low toxicity
[141]. The shape and size of the nanosized gold can be easily controlled during the
synthesis. And the availability of different kinds of surface modification methods for AuNP
renders it the potential to be a safe and effective contrast agent that can be applied both
systemically and locally. PEGylated AuNPs with prolonged blood circulation times have
the potential to be used to create contrast for the imaging of the cardiovascular system with
aneurysms [265]. Moreover, surface modified AuNPs with a size of about 15nm have been
targeted delivered to enhance the contrast of tumors, lymph nodes, and micro-calcifications
in-vivo [266-268].
However, AuNPs with small sizes are not suitable for targeting vascular wall
because of a large amount of unspecific cellular uptake and clearance by the host immune
system. Moreover, a few studies have shown in-vivo toxicity of small AuNPs including
acute inflammation and apoptosis in the liver, loss of structural integrity in the lungs, and
diffusion of white pulp in the spleen, accompanied by gene expression changes [269-271].
AuNPs with a particle size of ~150nm show better biocompatibility and increased
circulation time owing to their ability to escape the endothelium uptake and phagocytosis
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by macrophages, thus, have a better potential to be used as a AAA targeting contrast agent
for CT scan.
AuNPs are usually synthesized by a standard single phased water-based reduction
of a gold salt with citrate as the initiator as described by Turkevich, J. et al and refined by
Frens, G. [272, 273]. Briefly, HAuCl4 solution was brought to boil and then the sodium
citrate solution was added. An immediate color change of the solution was observed
indicating the nucleation and formation of monodispersed spherical particles. The mixture
was then kept boiling till the reduction of gold chloride was complete. However, this
method was usually used to produce AuNPs with a size smaller than 100nm. In order to
get monodisperse citrate-stabilized AuNPs with sizes larger than 150nm and uniform
quasi-spherical shapes that are preferable in AAA targeted imaging, we adapted an
improved seed growing AuNP synthesizing method reported by Bastus, N. G. et al for this
research [264].
Surface modification for AuNPs also plays an essential role in AAA targeting. Invivo targeting of AuNPs is achieved through either passive or active targeting. Passive
targeting depends on the homing of the vectors in unhealthy tissues due to extravasation
through the leaky blood vessel, while active targeting presents ligands on the AuNP surface
for specific recognition [274]. In this study, the elastin antibodies that only bind to
degraded elastin will be conjugated to the AuNP surface to actively targeting degraded
elastin fibers presented in aneurysmal aortic walls. The quality of the conjugation will
affect the number of antibodies attached to the AuNPs surface, thus, influence the targeting
efficiency of EL-AuNPs. The accumulated EL-AuNPs at the aneurysmal site will
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eventually be visualized in the CT scan by generating contrast against surrounding soft
tissues. When the targeting efficiency is high, the dose of systemically administrated ELAuNPs to generate enough contrast in AAAs would be lower. Thus, the conjugation
process should be optimized to reduce the required EL-AuNPs dose while still allow the
production of acquiring high-quality CT images that provide accurate information about
the rupture risks of AAAs.
4.2 Materials and Methods
Synthesis of ~150nm AuNPs
Citrate-stabilized AuNPs with a size of ~150nm were synthesized using a
kinetically controlled seeded growth method (Figure 4-1) [264]. Briefly, the reduction of a
gold hydrochloride solution was initiated by injecting 1 mL of 25mM HAuCl4• 3H2O
(Sigma Aldrich, St. Louis, MO) into 150 mL of 2.2 mM sodium citrate (Sigma Aldrich, St.
Louis, MO) in a three-necked round-bottomed flask at boiling temperature for 10 min
under vigorous stirring to form Au seeds with a diameter of ~10nm. Immediately after the
synthesis of the Au seeds, the reaction was cooled to 90 °C in the same reaction vessel to
avoid the secondary nucleation.
Then, 1 mL of 25 mM HAuCl4 solution was injected into the reaction vessel and
allowed to react for 30 mins. This process was repeated twice before the sample was diluted
by extracting 55 mL of sample and adding 55 mL of 2.2mM sodium citrate. This diluted
solution was then used as a seed solution, and the growing process was repeated. In order
to control the growing speed and maintain the homogeneous growth of the AuNPs, the gold
precursor to seed particle concentration was carefully controlled. The sizes of the AuNPs
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were monitored after each growth step and the growth step was repeated until the AuNPs
reaches the desired size. AuNPs solution was allowed to cool down and stored at 4°C for
further usage. The sizes of three different batches of AuNPs were measured to evaluate the
reproductivity of this method.
Preparation of EL-AuNPs under different conjugation conditions
The citrate-capped AuNPs were then conjugated with degraded elastin targeted
antibodies using a three-step method (Fig 4-2). Three different batches of EL-AuNPs were
produced under different conjugating conditions (Table 4-1). For the first batch of ELAuNPs, a heterobifunctional thiol-PEG-acid (SH-PEG-COOH, 2000MW, Nanocs, NY)
was firstly added to the AuNPs at a weight ratio of 1:4 (PEG: AuNPs) to replace the citrate
cap of the AuNPs. The SH-PEG-COOH can not only stabilize the AuNPs but also provided
carboxylic groups for further modifying reaction. The PEGylation process was finished at
25ºC for 4 hours. Secondly, a commonly used EDC (N-(3-Dimethylaminopropyl)-N-ethyl
carbodiimide)/NHS (N-hydroxysulfosuccinimide) chemistry was applied to provide
binding sites for antibodies on PEGylated AuNPs. EDC (Oakwood Chemical, Estill, SC)
and NHS (Sigma Aldrich, St. Louis, MO) were added to the PEGylated AuNPs at a weight
ratio of 1:2:1 (EDC: NHS: PEG) and incubated at 25ºC for 2 hours. Finally, the anti-elastin
antibody (custom-made at Clemson University) was incubated with the surface modified
AuNPs overnight to achieve the final conjugation.
For the second batch of EL-AuNPs, SH-PEG-COOH was added to the AuNPs at a
weight ratio of 5:2 (PEG: AuNPs) and incubated at 25ºC for 8 hours. Then, EDC and NHS
were added to the PEGylated AuNPs at a weight ratio of 1:2:1 (EDC: NHS: PEG) at 25ºC
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Figure 4-1. A schematic overview of the synthesis of AuNPs.
for 4 hours before antibodies were added and incubated overnight at 4ºC. And for the third
batch of EL-AuNPs, AuNPs were incubated with the SH-PEG-COOH at a weight ratio of
4:1 (PEG: AuNPs) at 4ºC for 48 hours. Then, EDC and NHS were added to the PEGylated
AuNPs at a weight ratio of 1:2:1 (EDC: NHS: PEG) and incubated at 25ºC for 6 hours
before conjugating to the antibodies overnight at 4ºC.
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Figure 4-2. A schematic overview of the conjugation of elastin antibody to AuNPs.
Table 4-1. Different conjugation conditions for AuNPs

PEG: AuNP

PEGylation

EDC/NHS
incubation

Batch 1

1:4

4 hours, 25°C

2 hours, 25°C

Batch 2

5:2

8 hours, 25°C

4 hours, 25°C

Batch 3

4:1

48 hours, 4°C

6 hours, 25°C

Characterization of AuNPs and EL-AuNPs
The hydrodynamic sizes of the AuNPs were measured after each diluting step and
were also measured before and after the conjugation using a dynamic light scattering (DLS)
system (Zetasizer Nano ZS, Malvern, Westborough, MA). Briefly, 40µL of each sample
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was diluted in 1mL DI water and was then measured in disposable acrylic cuvettes under
room temperature. Three measurements with at least twelve runs per measurement were
performed for each sample with an absorption (k) of 3.32 and a refractive index (n) of 0.02.
The zeta-potentials of AuNPs before and after the conjugation were measured using the
same DLS system. Briefly, 40µL of each sample was diluted in 1mL DI water and was
injected into the disposable folded capillary cells. Zeta potentials were measured under
room temperature and three measurements with 100 runs per measurement were performed
for each sample using the Smoluchowski model with an F(ĸa) value of 1.50.
To determine the concentration of the prepared AuNPs and EL-AuNPs, 1mL of
each sample was firstly digested with 1mL of aqua regia in glass test tubes under room
temperature for 1 hour. Then, the digested samples were dried under constant nitrogen flow
until all the liquid was vaporized. The remaining solids were re-dissolved in 6mL of 0.1M
hydrochloride acid and were sent to Agricultural Service Laboratory, Clemson University,
for gold element quantification.
Cytotoxicity of EL-AuNPs
A standard live/dead assay was performed to evaluate the cytotoxicity of ELAuNPs in hSMCs. Cells were seeded at a density of 10,000 cells/well in a 24-well tissue
culture plate and incubated at 37ºC, 5% CO2 overnight. 10µL of EL-AuNPs (to achieve a
final concentration of 1.0, 2.0, and 5.0mg/mL) were then added into the seeded cells in
triplicates and were incubated at 37ºC, 5% CO2 for 1 hour. Then the cells were stained with
Live/Dead cell staining kit II (PromoCell, Heidelberg, Germany) for 40 mins at room
temperature and then imaged with a fluorescent microscope (Keyence, Itasca, IL). Live
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cells were stained with the polyanionic dye calcein that produced an intense uniform green
fluorescence with excitation of 495 nm and emission of 515 nm while dead cells were
stained with EthD-III that produced a bright red fluorescence which was observed with
excitation of 530 nm and emission of 635 nm.
The lactate dehydrogenase (LDH) assay (Thermo Scientific, Rockford, IL) is used
to evaluate the cytotoxicity of EL-AuNPs in hSMCs in a quantified manner. Briefly, after
determining the optimum cell number for LDH cytotoxicity assay, 10,000 cells/well were
seeded in 100µL of media in a 96-well tissue culture plate, and the plate was incubated at
37ºC, 5% CO2 overnight for the cells to attach. 10µL of EL-AuNPs (to achieve a final
concentration of 1.0, 2.0 and 5.0mg/mL) were then added into the seeded cells in triplicates
and were incubated at 37ºC, 5% CO2 for 45 mins alone with a complete medium control
without cells, and triplicates of both spontaneous LDH activity controls and maximum
LDH activity controls. 50µL of each sample medium was transferred to another flat bottom
96 well-plate followed by adding 50µL of the reaction mixture to each sample well and
incubating at room temperature for 30 mins protected from light. The reaction was stopped
by applying 50µL of stop solution to each sample well and the absorbance of each sample
at 490nm and 680nm was measured using a spectrophotometer (Epoch, BioTek, Winooski,
VT). %Cytotoxicity was then calculated using the following two equations:
𝐿𝐷𝐻 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = (𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑎𝑡 490𝑛𝑚) − (𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑎𝑡 680𝑛𝑚) (1)
%𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 =

𝑇𝑟𝑒𝑎𝑡𝑒𝑑 𝐿𝐷𝐻 𝑎𝑐𝑡𝑖𝑐𝑖𝑡𝑦 − 𝑆𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝐿𝐷𝐻 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦
× 100 (2)
𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝐿𝐷𝐻 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 − 𝑆𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝐿𝐷𝐻 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦
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Cellular uptake of EL-AuNPs
Mouse macrophages were used as the cell line for in-vitro cellular uptake
evaluation. Mouse macrophages were seeded in a 12-well plate with a density of 40,000
cells/well. Cells were then cultured in RPMI-1640 growth media that contains 10% fetal
bovine serum at 37 °C with 5% CO2 overnight for complete attachment. Macrophages were
treated with 2mg/mL of EL-AuNPs for different periods (4 and 24 hours) in triplicates,
after which the supernatant was removed, and cells were washed 3 times with PBS.
Macrophages were gently scraped off the plate using cell scrapers, resuspended in 1mL of
PBS, and collected by centrifugation at 1000 g for 4 minutes. Collected macrophages were
further washed 3 more times with PBS and were lysed in an acid solution (2% HCl + 2%
HNO3) for 5 days for the quantification of gold by inductively coupled plasma mass
spectrometry (ICP-MS).
The hSMCs were used for further in-vitro cellular uptake evaluation. hSMCs were
plated at a density of 200,000 cells/well in a 12-well plate and cultured in complete growth
media at 37 °C with 5% CO2 overnight for complete attachment. hSMCs were treated with
2mg/mL of EL-AuNPs in triplicates for 4 and 24 hours, respectively. Trypsin/EDTA was
used to release the hSMCs from the plate and the cell suspensions were centrifuged at 1000
g for 5 min. hSMCs were collected and washed for 3 more times with PBS then treated
with an acid solution (2% HCl + 2% HNO3) for 5 days to prepare lysates for the
quantification of gold by ICP-MS.
In-vitro targeting of EL-AuNPs
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The targeting and imaging property of EL-AuNPs were tested using an in-vitro
elastase treated porcine carotid model. Porcine carotids were bent into a U-shape and the
middle part of each porcine carotid was immersed in 1mL of 20U/mL PPE (Tris buffered,
pH= 7.8) for 90mins to induce limited elastin damage (Fig 4-3). After the PPE treatment,
entire segments were immersed at 4 ºC overnight in three batches of 2mL of 3mg/mL ELAuNPs that were conjugated differently. Samples were washed in phosphate-buffered
saline (PBS) three times for 5 mins per time to remove the non-specifically bound ELAuNPs and were scanned with micro-CT (0.2mm Al filter, 90kV, 250mA, 300ms) (Bruker,
Billerica, MA) in corn oil. Reconstructions were carried out using the Skyscan NRecon
software based on the Feldkamp algorithm. The distribution of the EL-AuNPs within the
whole porcine carotids were visualized by building a 3D model using the maximum
intensity projection (MIP) mode in the CT-Vox software.

Figure 4-3. Schematic representation of the in-vitro PPE treatment of the middle part of
porcine carotids that were used to test the targeting properties of EL-AuNPs.
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Moreover, a quantitative in-vitro study has been performed on rat aortas to decide
if there was a correlation between the EL-AuNPs accumulated in the tissue and the elastin
damage level. The rat aorta segments with different elastin degradation levels were
obtained by immersing the rat aorta segments in PPE for a different amount of time.
Briefly, the rat abdominal aorta was firstly separated into suprarenal and infrarenal
segments to minimize the influence of the intrinsic aortic elastin content difference. Then,
the segments were immersed in 2 mL of 5U/mL PPE (Tris buffered, pH= 7.8) for 30, 60,
and 90mins respectively to induce different levels of elastin damage. After PPE treatment,
the segments were washed in PBS and immersed in 2 mL of 2mg/mL optimized EL-AuNPs
overnight at 4 ºC under slow rocking. Samples were washed PBS three times for 5 mins
per time to remove the non-specifically bound EL-AuNPs and were scanned with microCT (40kV, 600mAs, 300ms, no filter). The EL-AuNPs were separated from the aortic
tissue and quantified using CT-An software and normalized to the volume of the sample.
And 3D models of the aortic segments and the EL-AuNPs attached to the tissue were built
using the same software and the models were visualized using the CT-Vol software.
Histological analysis
After being washed in deionized (DI) water, porcine carotid, and rat aorta segments
from the treated middle and two untreated ends were embedded in optimal cutting
temperature (OCT) compound (Sakura Finetek, Torrance, CA) and froze in -80ºC to form
blocks. The blocks were then sectioned per standard procedures. Five-micrometer sections
were mounted on positively charged glass slides. And slides were placed in 100% precooled acetone (Fisher Science Education, Nazerath, PA) for 10 minutes to fix the sections.
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Subsequently, the slides were rinsed with tap water for 5 minutes to remove the OCT
compound and stained with Verhoeff-van Gieson (VVG) for elastic fibers.
Desmosine quantification
Desmosine is a component of elastin that cross links with its isomer, isodesmosine,
giving elasticity to the tissue [275]. Desmosine in the PPE treated aortic tissue was
measured to be a marker for healthy elastin preserved in the tissue, representing the elastin
damage level. Firstly, a small piece of tissue was cut off from each aortic sample and was
lyophilized and the dry weights of which were weighed and recorded. The small aortic
pieces were then homogenized to release the desmosine. The desmosine was measured
using a mouse desmosine enzyme-linked immunosorbent assay (ELISA) kit
(MyBiosource, San Diego, CA) and normalized using the dry weight of each tissue piece.
Statistical analysis
All in vitro experiments including cell culture studies and tissue studies were done
in triplicates. The data are reported as the mean ± standard deviation. Data from different
groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s
HSD as a post-hoc test. Results were reported at three different significant levels: *** p≤
0.01, ** p≤0.05, and * p≤0.1.
4.3 Results
Characterization of AuNPs and EL-AuNPs
The sizes of the AuNPs increased gradually after each growth step and after 18
growth steps, the dynamic diameter of the AuNPs reached ~150 nm (Figure 4-4A and Table
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4-1). The Z-average hydrodynamic size of the obtained AuNPs after 18 growth steps was
146 nm with a polydispersity index (PdI) of 0.060. According to the size distribution by
volume, the peak of the diameters appeared at 169 nm with a standard deviation of 48 nm.
These results indicated that we successfully synthesized monodispersed AuNPs most of
which had a size of around 150 nm. The final Z-average sizes of the other two different
batches of AuNPs were 143 nm (PdI: 0.050) and 154 nm (PdI:0.047)
Table 4-2. The Z-average diameters and volume distribution of AuNPs from each growth
Growth
step

Z-Average
diameter (nm)

Volume distribution
peak (nm)

St Dev
(nm)

1

24

13

5

2

26

16

6

3

26

19

7

4

28

23

7

5

31

26

9

6

34

30

10

7

36

32

11

8

41

39

12

9

44

43

14

10

51

48

16

11

60

54

22

12

62

58

24

13

73

63

30

14

99

93

52

15

100

97

50

16

113

127

39

17

131

150

49

18

146

169

48
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respectively, with volume distributions of 168 ± 51 nm and 177 ± 47 nm respectively. The
batch to batch variation of the AuNP size distribution was very small.

Figure 4-4. Size distribution by intensity measured using the DLS system. (A) Sizes of
AuNPs from growth step 13 to 18. (B) Sizes of three different batches of AuNPs.

Figure 4-5. Size and zeta-potential characterization of AuNPs and EL-AuNPs. (A) Size
distribution of AuNPs before and after conjugation; (B) Zeta-potential distribution of
AuNPs before and after conjugation.
After the conjugation step, the intensity weighed hydrodynamic diameter of the
AuNPs increased from 145 ± 46 nm to 157 ± 44 nm, and the volume weighed
hydrodynamic diameter of the AuNPs increased from 156 ± 57 nm to 173 ± 53 nm,
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indicating the formation of a PEG-EDC-NHS-Antibody shell surrounding the AuNPs in
place of the original citrate cap (Figure 4-5A). The average zeta-potential of the AuNPs
also increased from -17.6 ±9.4 mV to -10.4 ±4.2 mV after the conjugation, which also
confirmed that the completion of the surface modification (Figure 4-5B).
Cytotoxicity of EL-AuNPs in hSMCs
The cytotoxicity of EL-AuNPs was tested at a concentration of 1, 2, and 5mg/mL.
EL-AuNPs tested at all three concentrations were not found toxic to hSMCs in cell cultures
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Figure 4-6. Live/dead assay for deciding cytotoxicity of EL-AuNPs with concentration of
1mg/mL, 2mg/mL and 5mg/mL.
according to both live/dead assay and LDH assay. Live/dead assay of hSMCs showed no
abnormalities in morphology and a limited number of dead cells (Figure 4-6). The live and
dead cells were identified and counted for each group from the images and the percentages
of the dead cells were calculated. The cell viabilities for all three treated groups were
similar to the control group (Table 4-3).
Table 4-3. Live/dead cell count and the percentage of dead cells
Total count

Live count

Dead count

Dead (%)

CTRL

45

36

9

20.0%

1mg/mL

53

44

9

17.0%

2mg/mL

100

81

19

19.0%

5mg/mL

51

40

11

21.6%

According to the LDH cytotoxicity assay, the average LDH activity of the
spontaneous control is 0.232 and the average LDH activity of maximum control is 2.766.
The average LDH activities for 1, 2 and 5mg/mL group are 0.229, 0.230, and 0.229,
respectively. The LDH activities in EL-AuNPs treated group is not significantly different
from the spontaneous control group and none of the calculated average percentages of
cytotoxicity of the three treated groups were positive (Figure 4-7). It provided further
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evidence to indicate that the treatment with EL-AuNPs at a concentration of 1, 2, and
5mg/mL shown no cytotoxicity to cultured hSMCs.

Figure 4-7. Cytotoxicity (%) calculated from LDH assay, the cytotoxicity percentage of
individual sample was represented with a circle and the average result was represented with
a bar.
Cellular uptake of EL-AuNPs
For mouse macrophages, the mass of the intracellular gold after incubation for four
and twenty-four hours with the AuNPs were both below the detection limit of ICP-MS. For
hSMCs, the average mass of the AuNPs taken by the cells after incubation for 4 h was
13.17µg. The percentage uptake from the total added gold was 0.687%. After incubation
for 24 h, the average mass of gold in the cells incubated with AuNPs was 16.69µg and the
percentage uptake from the total added gold was 0.834%. Thus, AuNPs as prepared for in-
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vivo studies showed no significant uptake by hSMCs and mouse macrophages in cell
cultures due to their size and negative surface charge.
In-vitro targeting study for optimizing the conjugation condition
After PPE treatment of the porcine carotids, the elastin fibers in the middle segment
of the porcine carotids were fragmented and degraded while the elastin fibers in the two
ends remain intact, as shown in the VVG staining (Figure 4-8). It suggested that we
successfully established a partially damaged in-vitro elastase model for studying the ability
of the EL-AuNPs to target the degraded elastin in the vascular wall.

Figure 4-8. VVG stain for untreated and elastase treated porcine carotid sections.
In the 3D models that were reconstructed from the micro-CT scans, the EL-AuNPs
showed a much higher contrast than the soft tissue because of its higher x-ray adsorption
rate (Figure 4-9). EL-AuNPs accumulated exclusively at the PPE treated section while
sparing the untreated healthy two ends of the carotids, indicating the targeting ability of
the EL-AuNPs to degraded elastin. Also, different combinations of conjugation conditions
resulted in different targeting efficiency of EL-AuNPs. For the porcine carotids treated
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with batch one EL-AuNPs, the CT scan had not shown the accumulation of EL-AuNPs in
the damaged tissue. Batch two EL-AuNPs showed some targeting signal at the damaged
site in the CT scans, but the signal was still very weak. The third batch of EL-AuNPs
provided strong and specific signals in the reconstructed micro-CT model in the PPE
treated porcine carotid tissue. The third conjugation condition which showed the highest
signal intensity of the EL-AuNPs at the damaged section was used for further studies.

Figure 4-9. Signals for differently conjugated EL-AuNPs in the reconstructed porcine
carotid MIP models. B1, B2, and B3 were the porcine carotids that were targeted with ELAuNPs conjugated under the first, second, and third conditions mentioned in Table 4-1
respectively.
After PPE treatment of the rat aortic segments for 30, 60, and 90 mins respectively,
different levels of elastin fiber fragmentation and degradation were observed in VVG
staining (Figure 4-10). In the control group, the elastin fibers in the aortic wall were intact
and well-aligned. As the PPE treatment time increased, the elastin laminae became more
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disorganized and fragmented. The quantification of desmosine in the PPE treated tissues
further confirmed different damage levels of the elastin content. All three treated groups

Figure 4-10. VVG staining of healthy control and rat aortic tissue after 30, 60, and 90
minutes of PPE treatment. The aortic lumen was indicated with *.

Figure 4-11. Quantification of desmosine extracted from damaged aortic tissue using
ELISA assay, ***p<0.01, **p<0.05, *p<0.1.
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had significantly lower desmosine concentration comparing to the control group.
Moreover, the quantities of desmosine in the tissues decreased as the PPE treatment time
increased (Figure 4-11). These results suggested that a longer PPE treatment time can
induce a more severe elastin degradation in the rat aortic tissue. It provided us a model for
studying the correlation between the quantity of targeted EL-AuNPs and the aortic elastin
damage level in-vitro.
3D reconstructed Micro-CT model showed the distribution of the EL-AuNPs within

Figure 4-12. 3D models of the aortic tissue samples and the accumulated EL-AuNPs
(highlighted in yellow) reconstructed from micro CT imaging.
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the rat aortic tissues (Figure 4-12). The signal from EL-AuNPs was differentiated from the
aortic tissue and highlighted yellow. More EL-AuNPs were found accumulating in the 90minute PPE treated group comparing to the 30- and 60-minute group. And the 30- minute
group showed the least EL-AuNP attachment to the tissue. Moreover, for quantitative
analysis, the amount of the EL-AuNP signal was calculated and normalized to the total
volume of the tissue. A negative correlation between the EL-AuNP to tissue ratio and the
concentration of desmosine in the tissue has been built (Figure 4-13). As the desmosine
level in the tissue decreased and the signal percentage of EL-AuNPs increased. Since a
lower tissue desmosine concentration indicated more elastin degradation, the accumulation
of the EL-AuNPs within the tissue could positively correlate to the degree of tissue elastin
damage.

Figure 4-13. The correlation of the EL-AuNPs to tissue ratio with tissue desmosine
concentration.
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4.4 Discussion
Colloidal gold is wildly used in nanotechnology research as model particles. They
can be synthesized in different shapes, such as spheres, rods, and stars, with various size
ranges. And AuNPs with different shapes and sizes have different pharmacokinetic and
biodistribution parameters [276]. In order to increase the efficacy of using AuNPs for
biomedical purposes, the combination of shape and size has to be chosen carefully
according to specific applications. For drug-delivery or imaging applications, spherical
AuNPs suit the best since they can be easily synthesized with high monodispersity using
highly labile stabilizing ligands that allow for facile, efficient, and high-density ligand
exchange [277].
Besides, the size has been demonstrated to influence the blood half-time and the
biodistribution of the AuNP, two parameters that play important roles in achieving desired
biomedical effects when injected intravenously. A study of the size-dependent
biodistribution of the AuNPs in rats performed by De Jong, W.H. et al. has demonstrated
that small AuNPs had more widespread organ distribution while larger particles were only
detected in blood, liver, and spleen [278]. In this study, in order to target AAAs, we
synthesized spherical AuNPs with a hydrodynamic size of ~150 nm. The spherical shape
was beneficial for attaching antibodies to the surface of AuNPs to achieve targeting. And
the relatively large size could prevent the AuNPs from staying in organs like the brain and
lungs while still allow them to circulate for enough time to ensure vascular targeting.
The cytotoxicity of the AuNPs was also reported to be size and shape dependent.
Generally, the cytotoxicity of the AuNPs decrease as the size increase. Pan, Y. et al. have
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demonstrated that AuNPs 1–2 nm in size have a much higher cytotoxicity and wilder
distribution comparing to larger 15-nm gold colloids [279]. Mateo, D. et al. have reported
that stronger cytotoxic effects were observed in 30 nm AuNPs treated human dermal
fibroblasts than those obtained with the 50 and 90 nm NPs-treated cells [280]. Meanwhile,
different shapes of AuNPs have different cytotoxic profiles. Lee, Y.J. et al. have reported
that among chitosan capped nanorods, stars and spheres, nanorods showed the highest
toxicity against AGS, HeLa, HepG2, and HT29, followed by nanostars and finally by
nanospheres [281]. Furthermore, surface modification has been proved to help reduce the
AuNPs cytotoxicity. Niidome, T. et al. suggested that surface modification of gold
nanorods with PEG could reduce their in-vitro toxicity [282].
For our EL-AuNPs with a size of ~170 nm, Live/dead assay showed no difference
in cell viabilities between EL-AuNPs treated group and untreated control. LDH leakage
due to cell membrane damage was measured as another indicator of EL-AuNP-induced
cytotoxicity. Cells that were treated with EL-AuNPs showed no higher LDH leakage in the
short term comparing to the untreated control. These results suggested the low cytotoxicity
of EL-AuNPs on hSMCs in-vitro. The good biocompatibility of the EL-AuNPs could be a
result of the combination of their spherical shape, relatively large particle size, and
PEG/antibodies coated surface. Thus, it is considered safe to use the AuNPs at the
concentration designed for in-vivo studies.
Surface functionalized AuNPs have been regarded as an ideal contrast agent for
diagnostic purposes because of their great imaging properties and biocompatibility. Not
only their surface can be modified with PEG to achieve prolonged circulation time for
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blood pool imaging, but also, the conjugation with molecules that target specifically to
pathological biomarkers renders AuNPs the ability to selectively and effectively enhance
the contrast of the tissue of interest. Passive targeting, active targeting, or a combination of
both strategies can be used to achieve aneurysm-specific particle accumulation for
imaging. For example, Kim, D. et al. reported that they have gained more than 4-fold
greater CT intensity when imaging prostate cancer by using AuNPs that has been surface
functionalized with a prostate-specific membrane antigen (PSMA) RNA aptamer that
actively targeted prostate cancer cells that express the PSMA protein [283].
The amount of contrast that could be generated in CT scans depends on the
mass/concentration of the contrast agent accumulated in the desired tissue. For blood pool
imaging, a large dose of contrast agent is usually applied to visualize the vasculatures,
which could result in side effects such as hepatoxicity and nephrotoxicity [284]. Thus,
targeting efficiency of the EL-AuNPs could drastically influence the imaging quality and
should be optimized to reduce the systemic dosage required. For a given size of
nanoparticles, how NP surface modification was achieved would influence their surface
charge and the number of conjugated surface antibodies. Thus, it would result in variable
clearance rate in-vivo and different chances for the antibodies to interact with the desired
ligands. In our study, we conjugated EL-AuNPs using different combinations of PEG to
AuNPs ratio, PEGylation duration and temperature, and the incubation time for the
EDC/NHS reaction. Moreover, the combination that showed a higher contrast at the
elastase damaged area in an in-vitro porcine carotid model was considered to have a better
targeting efficiency. The combination that has presented the highest targeted signal in the
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CT scan has been chosen as the protocol to prepare the EL-AuNPs that were used in
targeting studies.
However, surface coatings can change the charge of the nanoparticle and alter
protein adsorption and cellular uptake during circulation [285]. Nanoparticles that are
positively charged have higher rates of phagocytosis and shorter blood circulation half-life
than neutral and negatively charged particles [286]. We successfully conjugated the AuNPs
to be negatively charged according to the results of the zeta-potential measurement. It
would help the NPs avoid being phagocytosed by macrophages and also uptake by any
other cells like SMCs and make them applicable for effective vascular targeting. According
to the cellular uptake study performed in hSMCs and mouse macrophages, an infinitesimal
amount of the AuNPs was detected that entered the cells. The fact that most of the AuNPs
stayed outside of both SMCs and macrophages rendered them the ability to achieve
targeting to the aortic lesions. Moreover, our AuNPs were surface modified with antibodies
that could specifically bind to the degraded elastin. It has been shown in our in-vitro study
that these EL-AuNPs s could target to the tissues that presented elastin damage and
specifically increased the local contrast in CT-scans. Since the degradation of elastin
laminae is one of the key pathological features of AAAs, it is possible to use EL-AuNPs to
target AAAs in-vivo for imaging purposes.
Based on the elastin targeting property of the EL-AuNPs, we investigated the
correlation between the EL-AuNPs accumulation and the elastin damage using an in-vitro
elastase model. Different elastin damage level could be induced by treating the aortic tissue
for a different amount of time and the degradation of the elastin in this model were not
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reversible. Since elastin is an important mechanical component in the aortic wall that
provides strength and elasticity to endure the stress given by the blood flow [287], the
decrease in elastin content could result in a weaker aortic wall with a higher rupture risk.
Moreover, as more elastin in the aortic wall degraded, it provided more binding sites for
the elastin antibodies anchored on the surface of the EL-AuNPs. We have observed a
positive correlation between the gold to tissue volume ratio and the duration of elastase
treatment, which indicated that more EL-AuNPs have accumulated in the samples with
more degraded elastin. This observation suggested that our EL-AuNPs had the potential to
be used as an indicator of elastin damage and a novel tool for evaluating the rupture risk of
the AAAs.
4.5 Conclusion
In this aim, we successfully produced degraded elastin antibodies conjugated
AuNPs that had an average size of ~170 nm and were negatively charged. We have shown
that these NPs are biocompatible with minimal cytotoxicity to SMCs and low cellular
uptake by both SMCs and macrophages. After being tested in an elastase treated porcine
carotid model, the EL-AuNPs presented the ability to actively target the tissue with elastin
damage and can increase the contrast of the targeted area in CT scans. Moreover, the
accumulated gold to tissue ratio decided by the CT analysis was positively correlated to
the damage level of the elastase treated tissue. Thus, the EL-AuNPs could be used as a safe
and efficient targeting CT contrast reagent for vascular diseases with the potential to reveal
the local elastin damage.

90

5. SPECIFIC AIM 2: TO INVESTIGATE WHETHER EL-AuNPS CAN BE
TARGETED TO AAAS IN-VIVO AND BUILD A CORRELATION BETWEEN THE
MICRO-CT SIGNAL INTENSITY OF EL-AuNPS AND MECHANICAL
PROOERTIES OF THE ANEURYSM IN AN ANGII INFUSION INDUCED MOUSE
MODEL
5.1 Introduction
Ultrasonography is the gold standard tool for AAA screening and diagnostic due to
its simplicity, safety, validity, cost-effectiveness, reproducibility, and public acceptance
[288]. It can provide relatively precise AAA geometrical information such as the diameter
and the growth rate of the aneurysm, which are commonly used as clinical interventional
criteria. However, the potential risk of an aneurysm rupture is determined by its mechanical
condition more than just AAA geometry. The intrinsic biomechanical properties and the
environmental stress conditions of the aneurysm change all the time during the disease
progression and decide the rupture risk of the AAAs.
Although large AAAs are statistically more prone to rupture, small AAAs can fail
prior to meeting the surgical criteria. Patients with smaller AAAs can still be under a lifethreatening situation since about 13% of AAAs cause death in patients before they are
recommended for surgery [96]. Thus, geometrical information alone is insufficient as a
universal predictor for AAA failure. Identification of localized vulnerabilities (i.e., weak
points within the wall) would provide crucial diagnostic information to aid clinical
strategies and decrease mortality in patients suffering from AAAs. A targeted nanoparticle
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system can be ideal to serve the purpose of providing pathological information for AAAs
when being used as an imaging contrast agent.
As described previously, key pathological processes occurring within AAAs such
as increased ROS activity, inflammation, VSMCs apoptosis, and ECM remodeling have
emerged as potential targets for nanoparticle-based diagnostics. Imaging agents and drugs
have been successfully delivered to the AAAs by applying surface modified NPs that target
these biomarkers as carriers. However, levels of inflammation and collagen remodeling
that happen in the AAA vary with time and patients, and therefore cannot be used as a
reliable surrogate for chronic aneurysmal rupture risk assessment. On the other hand, since
there is rarely elastin synthesis in adults, the elastic lamina in the aortic wall does not
remodel substantially within the timeline of aortic disease progression. The degradation of
the aneurysmal wall is a consistent feature of AAAs making it an ideal target for delivering
NPs.
Animal models are well established for studying AAAs in-vivo. Considering the
complicated in-vivo environment, it is important to test imaging agents and treatments with
AAAs that were developed in animal models to provide some insights about how they
might interact with human bodies. Many models of AAAs have been developed that use a
diverse array of methods for producing the disease, including but not limited to genetic
manipulation and chemical induction [289]. The genetic approaches are spontaneous and
engineered mutations and the chemical approaches include the intraluminal infusion of
elastase, peri-aortic incubations of calcium chloride, and subcutaneous implantation of
AngII osmotic pump.
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Even though these models recapitulate some facets of the human disease including
medial degeneration, inflammation, thrombus formation, and rupture, each animal model
can only mimic some pathogenesis of the real disease. The AngII infusion induced AAA
model in the LDLr −/− mice is ideal to be used in the studies that aim to understand the
AAA mechanical properties because of the formation of the ILTs in this model. Moreover,
the formation of AAAs in the systemic AngII infusion induced model resembles human
disease in the setting of mild hypertension with an enhanced incidence in the presence of
hyperlipidemia [290].
5.2 Materials and methods
The animal study of EL-AuNPs was performed in an established AngII infusion
induced mouse AAA model. The EL-AuNPs that were accumulated in the AAA sack via
active targeting were visualized using both ex-vivo and in-vivo micro CT imaging (Figure
5-1). Briefly, the animal study can be divided into three parts: development of AAAs invivo, micro CT imaging, and tissue analysis. The AAAs were firstly induced in mice by
the application of high cholesterol diet and AngII from subcutaneously implanted osmotic
pumps. And the pumps were explanted from the mice before imaging to eliminate the high
imaging noise given by the metal core of the pump. EL-AuNPs were injected intravenously
to achieve targeting and create contrast. In the imaging step, the aortas were explanted and
cleaned after the euthanasia for ex-vivo imaging study and were imaged with the micro-CT
when immersed in corn oil to prevent it from drying out, while a live abdominal micro CT
scan was performed before euthanasia and organ harvesting for the in-vivo imaging study.
The harvested aortas were then analyzed mechanically and histologically.
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Figure 5-1. Schematic representation of the study design.
Preparation of EL-AuNPs
For the ex-vivo imaging study, citrate capped AuNPs were purchased from
Meliorum Technologies (Rochester, NY) with an average size of 150.0 ± 25.0 nm. And for
the in-vivo imaging study, citrate capped AuNPs with an average size of 156.0 ± 57.4 nm
were synthesized as described in the previous chapter. The conjugation process for both
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types of AuNPs was the same. Briefly, a heterobifunctional thiol-PEG-acid (2000MW,
Nanocs, New York, NY) was added to the AuNPs at a weight ratio of 4:1 and the mixture
was incubated at 4°C for 48 hrs with gentle rocking to achieve PEGylation. PEGylated
AuNPs were collected after centrifuging at 10,000 rpm for 20 minutes at room temperature
and resuspended in 0.1M 2-(N-morpholino) ethanesulfonic acid buffer (MES, pH:5.5).
EDC/NHS chemistry was followed to conjugate the PEGylated AuNPs with the
anti-elastin antibody. Briefly, EDC (Oakwood Chemical, Estill, SC) and Sulfo-NHS
(Sigma Aldrich, St. Louis, MO) were added at a weight ratio of 2:1 and 4:1 to PEGylated
AuNPs respectively. The mixture was incubated at room temperature for 6 hours with
gentle vortexing. Resulting AuNPs were collected after centrifuging at 10,000 rpm for 20
minutes at room temperature and resuspended in 1mL of PBS (pH 7.8). 4µg anti-elastin
antibody (custom-made at Clemson University) per mg AuNPs was added, and the mixture
was incubated overnight at 4 °C under slow rocking. The excess antibodies were removed
by centrifuging the resulting solution at 10,000 rpm for 20 minutes. EL-AuNPs were
resuspended in saline to a concentration of 3mg/mL for ex-vivo imaging study injection
and 20mg/mL for the in-vivo imaging study.
Development of aneurysms with AngII in a mouse model
For the ex-vivo imaging study, fifteen male LDLr (-/-) mice (2 months of age, on a
C57BL/6 background) were obtained from the Jackson Laboratory (Bar Harbor, ME).
Eleven mice were used for aneurysm studies while four other mice were used as healthy
age-matched controls. Aneurysms were induced by systemic infusion of angiotensin II
(AngII, Bachem Americas, Torrance, CA) in combination with a diet with saturated fat
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(21% wt/wt) and cholesterol (0.2% wt/wt; catalog no. TD88137; Harlan Teklad) [92].
Briefly, mice were fed with a high-fat diet for one week before, and six weeks during AngII
infusion. Osmotic pumps (model 2004; Alzet, Cupertino, CA) filled with AngII were
implanted subcutaneously through an incision at the right back shoulder of the mice. 2%
to 3% isoflurane was inhaled by the mice as anesthesia throughout the surgical process.
The pumping rate for AngII was set to 1000ng/kg/min. Pumps were explanted four weeks
after the implantation and mice were allowed to recover for two weeks. Disease
progression was monitored with a high-frequency ultrasound machine, Fujifilm
VisualSonics Vevo 2100 (Fujifilm VisualSonics, Toronto, ON, Canada), by utilizing a
linear array probe (MS-550D, broadband frequency 22 MHz -55 MHz).
For the in-vivo imaging study, twenty male LDLr (-/-) mice (2 months of age, on a
C57BL/6 background) were obtained from the Jackson Laboratory (Bar Harbor, ME).
Seven mice were used for aneurysm studies among which one mouse was a healthy agematched control. Aneurysms were induced monitored in the same way as in the ex-vivo
imaging study. All animal use protocols for the study were approved by the Clemson
University Animal Research Committee.
Ultrasound analysis of AAAs
The ultrasound system, Fujifilm VisualSonics Vevo 2100 (Fujifilm VisualSonics,
Toronto, ON, Canada), was used for monitoring percent dilation and to assess the
circumferential strain throughout the cardiac cycle and PWV of the aneurysm. The animals
were placed in a supine position on the imaging table and were maintained under anesthesia
by inhaling 2% to 3% isoflurane during imaging. Heart rate and body temperature of the
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mice were carefully monitored during the imaging process. Suprarenal aortic inner
diameters were measured using the built-in ultrasound software on the basic-mode
ultrasound images.
Sagittal and transverse images for both healthy and aneurysmal aortas were
obtained in motion mode. Systolic and diastolic diameters were measured and recorded at
three different regions on each aneurysm or parent vessel using the built-in ultrasound
software. The diastolic-to-systolic circumferential Green-LaGrange strains were calculated
assuming axial symmetry using the two equations given below,
1 𝐷#$# (
𝐶𝑖𝑟𝑐𝑢𝑚𝑓𝑒𝑟𝑒𝑛𝑡𝑖𝑎𝑙 𝑆𝑡𝑟𝑎𝑖𝑛 (%) = XY
Z − 1[ ∗ 100
2 𝐷%&'
where 𝐷#$# represents the inner systolic aortic diameter and 𝐷%&' represents the inner
diastolic aortic diameter.
Ex-vivo Micro-CT imaging study
EL-AuNPs were given to the mice (n=15) as a contrast agent through a retro-orbital
injection at a dosage of 10 mg/kg animal weight under 2%-3% isoflurane anesthesia. Mice
were euthanized 24 hours after the injections, and intact aortas (from ascending aorta to
iliac bifurcation) were explanted. Surrounding connective tissue was cleaned before microCT scanning. Aortas were then immersed in corn oil and imaged (90kV, 250mAs, 300ms,
0.2mm Al filter) with a high-performance micro-CT system (Skyscan 1176, Bruker,
Billerica, MA). Reconstructions were carried out using the Skyscan Nrecon software based
on the Feldkamp algorithm. The reconstructed images of the aortas were visualized, and
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the dimensions of the aneurysms measured using DataViewer and CT-Vox software. 3D
maximum intensity projection (MIP) images were obtained to determine the distribution
of EL-AuNPs within the aortas while attenuation images were acquired to study the
intensity of the signals given by both EL-AuNPs and tissue. Signal intensity was further
quantified using CT-An software.
In-vivo Micro-CT imaging study
A baseline micro-CT scan (90kV, 250mAs, 200ms, 0.2mm Al filter) for each
mouse was performed with a high-performance micro-CT system (Skyscan 1176, Bruker,
Billerica, MA) to be used as control before the EL-AuNPs injection. EL-AuNPs were then
administrated retro-orbitally to the mice (n=14) as a contrast agent at a dosage of 10 mg/kg
animal weight under 2%-3% isoflurane anesthesia. The mice that received EL-AuNPs
injection were fasted for 24 hours to clear out the feces and at the meantime EL-AuNPs
were allowed to circulate for 24 hours to achieve targeting. Mice were scanned using the
same micro-CT system and the same imaging settings as were used in baseline scan under
1.5% isoflurane anesthesia. Reconstructions were carried out using the Skyscan Nrecon
software based on the Feldkamp algorithm. The reconstructed images of the aortas were
visualized using DataViewer and CT-Vox software. And signal intensity was further
quantified using CT-An software.
EL-AuNPs biodistribution analysis
Ten mice were used for determining the biodistribution of EL-AuNPs in-vivo. ELAuNPs were given to the mice (n=9) via retro-orbital injections at a dosage of 10 mg/kg
animal weight under 2%-3% isoflurane anesthesia. Mice were euthanized at day 1, day 5,
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and day 9 after the injections, and the entire livers, spleens, lungs and kidneys were
explanted. 1 mm thick of sample from each harvested organ was embedded in OCT and
sectioned for further darkfield imaging use. The rest of the samples were homogenized and
lysed in an acid (2%HCl +2% HNO3) overnight for gold extraction. The solution was then
collected, and ICP-MS was performed for quantifying the concentration of the gold
element in the samples.
Aortic burst failure testing
Burst pressure testing was performed on each suprarenal aortic segment within 24 hrs
after explant to study the rupture potential and location of the failure. Aortas were shipped in
EDTA-free-protease-inhibitor-cocktail on ice overnight to the University of South
Carolina. Branches were ligated using 12/0 nylon suture and the aneurysm, including 1-2 mm
distal and proximal to the necking region, were cannulated on shortened and roughed 26G
needle tips with 7/0 silk suture and mounted to our custom-designed multi-axial murine artery
mechanical testing device within an adventitial bath of PBS. The device enables temperature
control, hydration, inflation, and extension capabilities while recording images at 45° intervals
around the circumference of the tissue. All instruments are controlled via an integrated
LabVIEW code. Samples reported here were first extended to an axial stretch ratio of 1.2 and
then preconditioned through slow cyclic pressurization of luminal media using a syringe pump.
Then the syringe pump was set to maintain an inflation rate of 1-3 mmHg/s until bursting was
observed. PBS supplemented with phenol red was used as the luminal media to provide contrast
capabilities to identify burst locations. During inflation, the vessels were closely monitored for
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signs of failure, including dissection, and the pressure and location of failure were recorded. No
tissue that failed at or around the mounting suture or hardware were included in the analysis.
Aortic biaxial mechanical testing and data analysis1
The mechanical properties of aortic aneurysmal tissues and controls were tested at
the University of South Carolina (UofSC) within 24 hours of receiving tissues so that no
more than 48 hours passed between animal sacrifice and mechanical testing. Aortas were
mounted to a custom-designed biaxial testing rig. The details for this device and biaxial
testing procedures can be found in Lane et al. 2020a and 2020b [291, 292]. Briefly, this
test rig is equipped with a thin-beam loaded cell (LCL-113G; Omega Engineering),
pressure transducer (PX409; Omega Engineering), RS-232 infuse/withdraw syringe pump
(AL-1000; World Precision Instruments), motorized linear actuator (Z825B; Thorlabs),
and K-Cube motor controller (KDC101; Thorlabs). All components had PC USB interface
through a custom-written LabView code used to gather synchronous measurements while
controlling pumps and actuators. The testing chamber was filled with warm PBS solution
to maintain hydration throughout testing and PBS was flushed through the vessel lumen
and device tubing to remove bubbles. The unloaded outer diameter ( Do ) and length ( L )
were recorded using digital calipers. The artery then underwent five preconditioning cycles
consisting of pressurization from 10 to 160 mmHg and axial stretching to a deformed
length ( ! ) at, and 5% above and below, the pressurization force-invariant axial stretch
ratio, deemed the in vivo axial stretch.

1

Section prepared by John F. Eberth, PhD, Shahd Hasanain, BS and Liya Du, BS
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For data acquisition, the artery was extended to the three axial stretch ratios
described previously before undergoing pressurization cycles (0–120 mmHg) with
simultaneous force and outer diameter measurements at 10 mmHg pressure increments.
Data was recorded in triplicate and the average and standard deviations of these tests
reported. Primary continuous data collection consisted of pressure ( P ), deformed outer
diameter at the peak bulge location ( d o ), axial force ( f ), and axial stretch ratio ( lz ). Then
vessels were pressure fixed by replacing luminal PBS with 4% paraformaldehyde solution
and re-inflated to 100 mmHg in the axially extended state for 4 hours. In the deformed but
fixed state, micro-Computed Tomography Imaging (Quantum GX Micro-CT Imaging
System; PerkinElmer) was used to measure the deformed inner diameter. This step was
necessary due to the lack of transparency of these calcified and heterogeneous tissues.
Measurements consisted of an average of 4 locations along the circumference of the
aneurysm bulge and were processed using Fiji-ImageJ.
Assuming axial symmetry and incompressibility, the inner diameter is calculated
from,

d o2 V
di = 2
4 p!

(1)

where V is the volume measured using a combination of micro-CT and biaxial testing.
From the primary data collection described above, the mid-wall circumferential and
axial stretch ratios are calculated from

lq =

di + d o
!
, lz =
Di + Do
L
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(2)

where Di is the unloaded inner diameter.
The mean circumferential and axial stresses are then calculated from

sq = P

di
f
, sz =
2
d o - di
p ( d 0 4 - di2 4 )

(3)

and the lumen area compliance from

c=

p Ddi2
4 DP

,

(4)

where DP is the change from diastolic to systolic transmural pressures (80 to 120
mmHg) and Dd the change in inner diameter at these pressures.
In general, discrete data were analyzed at a common pressure and in vivo axial
stretch ratio unless otherwise noted.
Morphological analysis of the explanted suprarenal abdominal aorta
Morphological analysis was performed in the suprarenal area of the abdominal
aorta. For the ex-vivo study, outer aortic diameters were measured on the abdominal
ultrasound basic-mode-images at three different time points during a cardiac circle within
the parent vessel and the lesion. For the in-vivo study, inner suprarenal aortic diameters at
six different regions were measured using the built-in ultrasound software on the basicmode ultrasound images. Mean values were then calculated for each. The dilation was
calculated using the equation given below,
𝐷𝑖𝑙𝑎𝑡𝑖𝑜𝑛 (%) =

]) − 𝐷
]*
𝐷
× 100
])
𝐷
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]* represents the mean diameter of the healthy aorta and 𝐷
]) is the mean diameter
where 𝐷
of the pathological section.
Histological analysis of the aneurysms
Cryosections of both aneurysms and healthy aortas were used for histological
analysis. Aortas were fixed in buffered formalin, embedded in optimal cutting temperature
(OCT) compound (Sakura Finetek, Torrance, CA) after being washed in DI water and
sectioned per standard procedures. Five-micrometer sections were obtained and mounted
on positively charged glass slides. Slides were placed in 100% pre-chilled acetone (Fisher
Science Education, Nazerath, PA) for 10 minutes to further fix the tissue sections.
Subsequently, the slides were rinsed with tap water for 5 minutes to remove the OCT
compound for further staining. Slides were then stained with Verhoeff-van Gieson (VVG)
to visualize the elastin damage in different samples.
Darkfield microscopy and hyperspectral mapping
Cryosectioned histological samples (5µm) were examined with a CytoViva
enhanced darkfield microscope optics system (CytoViva, Inc., Auburn, AL). The system
(Olympus BX51) employs an immersion oil (Type A, nd> 1.515, Cargille Brand) ultradark-field condenser and a 40× air Plan-FL objective with an adjustable numerical aperture
from 1.2 to 1.4. Illumination was provided by a Fiber-lite DC 950 regulated illuminator.
Enhanced darkfield microscopy images were obtained using Exponent7 software with a
gain setting of 2.8 and an exposure time of 53 ms to visualize the EL-AuNPs. A
hyperspectral imager (mounted on a microscope and controlled by Environment for
Visualization software from Exelis Visual Information Solutions, Inc.) was used to extract
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spectral information for mapping the EL-AuNPs in the samples at an exposure time of
0.25ms with a full field of view (643 lines). Negative control samples (without AuNPs)
were imaged and analyzed to create a spectral library as a reference. Gold mapping was
achieved by applying a filtered spectral library by subtracting the negative control spectral
library.
Statistical analysis
All the results, including graphs in the figures, are given as mean± standard
deviation. Statistical analysis was performed using a one-way ANOVA and Tukey’s HSD
as a post-hoc test. Results were considered significantly different when p-values ≤0.05.
5.3 Results
Characterization of EL-AuNPs
EL-AuNPs used the ex-vivo study were prepared by conjugating the custom-made
antibody that recognizes degraded elastin with commercial gold nanoparticles. They were
characterized by a DLS system for size and surface charge before and after the conjugation
process. Before antibody conjugation, bare AuNPs had an average size of 150.00 ±
25.00nm and a zeta potential of -29.20 ± 3.91mV. EL-AuNPs had a final average size of
184.20 ± 18.09nm. The zeta potential of the NPs was measured as -5.06 ± 1.25mV. The
EL-AuNPs used in the in-vivo study were homemade and the characteristics were described
in the previous chapter. Briefly, the size of the AuNPs increased from 156.00 ± 57.40 nm
to 173.40 ± 53.08 nm and the zeta potential also increased from -17.6 ± 9.36 mV to -10.4
± 4.16 mV.
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Systemic AngII infusion-induced aneurysm mouse model
After the infusion of the AngII, severe aortic dilation (> 1.5-fold) as well as
moderate aortic dilation was observed at the suprarenal abdominal aorta in most of the mice
(Figure 5-2a). 2D transverse ex-vivo micro-CT images revealed an increase of aortic outer

Figure 5-2. Development of suprarenal aortic aneurysms with various properties, a.
Representative pictures showing the morphology of the whole explanted aortas. Various
levels of dilations (indicated by arrows) were found at the suprarenal abdominal aortic
regions in most of the AngII pump-implanted mice; b. Ex-vivo micro CT image showing
the cross-sections of aortas at the healthy region (c1) and the aneurysmal region (c2); c.
VVG staining shows different levels of elastin degradation amongst aneurysmal tissues
(4x, c2-c4, 40x, c6-c8) compared to the healthy aortic control with only intact elastin (4x,
c1, 40x, c5).
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diameters and thickening of the aortic wall in the lesions compared to the normal aorta
(Figure 5-2b). The enlargement of the suprarenal aortic diameters resulting from the
systemic infusion of AngII varied from 9.08%-193.25% of the normal size (Table 5-1).
VVG staining of the aneurysmal aorta demonstrated the degradation of elastin laminae
inside the aortic wall. Lesion development in mice corresponded with the extent of elastic
lamina degradation (Figure 5-2c). In fact, samples did not meet the 1.5-fold threshold but
still presented with elastin damage (Figure 5-3).
Table 5-1. Diameter and dilation percentages of suprarenal abdominal aortas
Diameter Measurements
Dilation Percentages Fold Increase

Sample

Healthy
(mm)

Aneurysmal
(mm)

MS#1

1.18±0.01

2.27±0.04

92.67%

1.93

MS#2

1.12±0.02

2.31±0.04

106.62%

2.07

MS#3

1.03±0.05

2.35±0.01

127.97%

2.28

MS#4

1.30±0.05

2.83±0.08

117.64%

2.18

MS#5

1.17±0.01

2.25±0.01

92.20%

1.92

MS#6

0.93±0.04

1.55±0.04

66.39%

1.66

MS#7

0.88±0.06

2.15±0.08

144.83%

2.45

MS#8

1.03±0.07

1.84±0.10

79.15%

1.79

MS#9

1.02±0.05

1.40±0.08

38.23%

1.38

MS#10

1.23±0.02

1.39±0.06

12.18%

1.12

MS#11

1.30±0.03

2.51±0.03

92.45%

1.92

MS#12

0.92±0.03

2.18±0.26

137.39%

2.37

MS#13

1.15±0.05

1.69±0.06

47.00%

1.47

MS#14

1.14±0.03

1.25±0.13

9.22%

1.09

MS#15

1.03±0.12

2.04±0.09

97.87%

1.98

MS#16

0.85±0.08

1.24±0.06

45.63%

1.46

MS#17

1.06±0.14

2.30±0.10

117.92%

2.18
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Figure 5-3. Elastin damage in aortic walls indicated by the red arrows for samples did not
meet the 1.5-fold threshold.
EL-AuNPs targeting to degraded elastin in the damaged aorta
3D reconstructed micro-CT models from both ex-vivo (Figure 5-4a) and in-vivo
scan (Figure 5-4b) presented stronger signals in the aneurysmal aortic segment than the
healthy aortic segment. This suggested that a much higher concentration of EL-AuNPs
accumulated at the aneurysmal area, which indicated their ability to target the aneurysms
within 24 hours while sparing the healthy regions of the aorta. Enhanced darkfield
microscopy (EDFM) in combination with VVG staining on the histological sections further
confirmed the targeting sites of EL-AuNPs within the aneurysmal tissues. EL-AuNPs were
found in darkfield microscopy images (Figure 5-4c) accumulating exclusively around the
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degraded elastin as identified by VVG staining while sparing healthy and intact elastin
fibers (Figure 5-4d). A stronger DFM signal was found in the section (Figure 5-4c1) which
showed more elastin damage (Figure 5-4d1) than the control section (Figure 5-4c2) that
contained only intact elastin fibers (Figure 5-4d2).

Figure 5-4. Localization of EL-AuNPs within aneurysmal tissues. a. An ex-vivo 3D model
that visualizes the morphology of an aneurysmal aorta (a1) and corresponding attenuation
mode that showed the distribution of EL-AuNPs (a2). b. An in-vivo 3D model showing
EL-AuNPs targeting in transverse, longitudinal, and sagittal sections; c. Darkfield
microscopy (DFM) of and d. corresponding histological analysis of elastin with VVG
staining. The signal given by EL-AuNPs was found at the positions where degraded elastin
was present, indicated by red arrows, while healthy and intact elastin fibers were devoid of
signals as indicated by yellow arrows.
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EL-AuNP accumulation indicates elastin damage level
Hyperspectral imaging (HSI), in conjunction with EDFM, provided spectral
information for the aneurysmal tissue and the attached EL-AuNPs. Specific signatures of
EL-AuNPs were mapped and separated from the noise given by the soft tissue according
to their different spectral features. Bright field microscopy indicated different levels of
elastin damage within different tissue samples by VVG staining (Figure 5-5a). EDFM and
hyperspectral mapping of the counterparts demonstrated that the amount of EL-AuNPs that
accumulated within the tissue samples varied with the elastin damage level (Figure 5-5b,
c, d). The decreasing integrity of elastic fibers in the aortic wall increased local EL-AuNP
accumulation. When extensive damage to elastin laminae was present in the bright field
image (Figure 5-5a2), hyperspectral mapping identified a large quantity of EL-AuNPs in
the tissue (Figure 5-5e2). Conversely, no EL-AuNP accumulation was mapped (Figure 55d1) in a control sample that showed no signs of elastin degradation (Figure 5-5a1).
Biodistribution of AAAs
HSI and EDFM were further used to visualize the distribution of EL-AuNPs in different
organs at different time points after the injection (Figure 5-6). One day after the injection,
EL-AuNPs were found in liver, spleen, lungs and kidneys in large quantities. Four days
later, there were still EL-AuNPs found in all four organs. The quantities of EL-AuNPs
slightly decreased in the liver, lungs and kidneys but increased in the spleen. On day 9 after
the injection, a small number of EL-AuNPs were still in the liver and spleens. However,
there was a significant decrease of the EL-AuNPs in all four organs. The images of lungs
and kidneys barely showed differences from the control that had no EL-AuNPs injection.
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Figure 5-5. Hyperspectral mapping of suprarenal aorta tissue targeted by EL-AuNPs, rows
from top to bottom correspond to suprarenal aortas with different levels of elastin damage
within the aortic walls, from high to low, respectively. a. Different elastin degradation
levels were found in the selected tissue samples; b. EDFM (40X) showed the existence of
high contrast EL-AuNPs in the tissues denoted by the white arrows; c. HSI (40X) and d.
Mapped images against their respective reference spectrum library generated with negative
controls.
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Figure 5-6. Hyperspectral mapping of liver, spleen, lungs, and kidneys visualizing the
biodistribution of EL-AuNPs at day 1, 5 and 9 after the injection.
The biodistributions of the EL-AuNPs at day 1, 5 and 9 after the injection have
been further quantified using ICP-MS. On day one, 1.70% of the given EL-AuNPs dose
accumulated in the liver while 1.10%, 0.55% and 0.07% of the EL-AuNPs were found in
spleen, lungs and kidneys, respectively. On day five, the EL-AuNPs in the liver was 0.59%
of the given dose. There were 1.39%, 0.53%, and 0.07% of the given EL-AuNPs remained
in the spleen, lungs, and kidneys, respectively. After 8 days of clearance, the number of the
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EL-AuNPs in the liver and spleen decreased to 0.32% and 0.03 % respectively. The amount
of the gold component in the lungs and kidneys were both below the detective limit.
Ultrasound analysis of AAAs
Ultrasound images of abdominal aortas were obtained before euthanasia. Healthy
controls exhibited a relatively uniform inner diameter (Figure 5-7a1) while dilation in the
AngII infused mice was most commonly observed at the suprarenal location (Figure 5-7a2a4). Circumferential strains for all samples ranged from 3.44 to 12.82%. Circumferential
strains of the healthy aortas were 16.08±2.40% (n=5) and were significantly decreased at
the aneurysmal aortic regions of the AngII-infused mice. For aneurysms with a similar
extent of dilation (MS#1, #5 and #11 with 92% dilation), the circumferential strains were
4.28±1.17%, 5.95±1.08%, and 9.60±1.05% respectively, suggesting the acute distensibility
of the aneurysmal aortic wall was not necessarily related to the extent of chronic dilation
(Figure 5-7b).
Correlation of ex-vivo CT signal and burst pressure of the aorta
The burst pressures for the samples harvested for ex-vivo study varied from 141.0
to 540.0 mmHg, while the burst pressure for healthy aortic controls was 566.5±30.4mmHg.
The 3D micro-CT models of the aortas showed higher signal intensity at the suprarenal
aortic regions of specimens having more server elastin damage and lower burst pressures,
indicating that the accumulation of our EL-AuNPs was inversely correlated to the level of
elastin damage and the load at failure (Figure 5-8a1-a3) while the age-matched control
samples did not show any signs of EL-AuNPs accumulation (Figure 5-8a4). In order to
establish a quantitative relationship between the signal and the ultimate burst pressure of
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Figure 5-7. In-vivo ultrasound and circumferential strains. a. Representative B-mode in
vivo ultrasound images of focalized aortic dilation indicated by red arrows; b.
Circumferential Green-LaGrange strains throughout the cardiac cycle for three aneurysms
with similar dilations (92%) but with different degrees of elastin damage. Ms#11 had minor
aortic elastin damage and Ms#1 had severe aortic elastin damage. * p<0.05, solid line in
each group represents the mean value.
the suprarenal aortas, the signals of the healthy aortic regions were used as negative
controls and were subtracted from the total. For the age-matched control groups, the signal
strength for all samples in the suprarenal region was 0. As the burst pressures of the
suprarenal aorta decreased, indicating a weakening of the aorta, higher signals for ELAuNPs were detected (Figure 5-8b). A power-law equation y = 20+08x-3.586 was
established with R2=0.9415, where x represents the burst pressure and y represents the
signal intensity, which demonstrated that the signal strengths given by EL-AuNPs had a
strong negative correlation to the burst pressures of the aneurysmal tissues (Figure 5-8b)
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whereas changes in aortic dilation (R2=0.1932) or circumferential strain (R2=0.3918) failed
to show strong correlations to burst pressures (Figure 5-8c, 5-8d).

Figure 5-8. Representative reconstructed aorta models in attenuation mode and correlation
between signal intensity, diameter increase, and burst pressure. a. 3D attenuation models
for aneurysmal and control aortas with different elastin damage levels showing different
suprarenal aortic signal intensity; b. A strong negative nonlinear correlation between signal
intensity and burst pressure was found while c. dilation vs. burst pressure and d. the CSs
vs. burst pressure was only weakly correlated with each other using the power-law.
EL-AuNP distribution and the initial burst site defined in ex-vivo CT scans
The initial sites where suprarenal aortas started to rupture under pressurization were
captured by a camera through visualization of the PBS supplemented with phenol red being
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expelled at rupture site (Figure 5-9a arrows). 3D micro-CT data obtained from ex-vivo
scans was displayed in the MIP mode, in which the lower-attenuation structures are not
well visualized [293], in order to study the distribution of EL-AuNPs within the aneurysmal
region (Figure 5-9b). Bright spots for EL-AuNPs in the reconstructed model could be
correlated to where the first rupture occurred, suggesting that the weakest spots had the
highest density of AuNP accumulation.

Figure 5-9. Representative burst pressure tests pictures and corresponding reconstructed
aorta models in MIP mode. a. Burst pressure test showing the location on the aneurysmal
wall where rupture is initiated under pressurization; b. For corresponding mouse aorta, the
EL-AuNP induced signals were non-uniformly distributed within the aneurysmal
segments. High-intensity spots correlate to the rupture sites.
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Correlation of in-vivo CT signal and biaxial mechanical properties of the aorta
Two geometrical parameters, outer aortic diameter and aortic wall thickness, and
two mechanical parameters, circumferential and axial stress, were measured and correlated
to the AuNPs to tissue ratio using OLS regression (Figure 5-9). There was no correlation
found between the outer aortic diameter and the AuNPs to tissue ratio while a slightly
negative correlation was found between the aortic wall thickness and AuNPs to tissue ratio
with R2=0.5602. Strong positive correlations with AuNPs to tissue ratio were found in both
circumferential stress (R2=0.9375) and axial stress (R2=0.7469).

Figure 5-9. Correlations between different parameters measured and calculated from the
biaxial mechanical testing and the AuNPs to tissue ratio.
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5.4 Discussion
In this aim, we tried to develop a potential targeted contrast agent for CT imaging
which will provide morphological information along with a better assessment of the rupture
risk of AAAs. Nanoparticles have been used for the development of enhanced molecular
imaging technologies targeting cancer cells [294]. AuNPs are commonly used due to their
outstanding properties such as noncytotoxicity, excellent biocompatibility, ease of surface
functionalization, strong light absorption, and scattering effects [294, 295]. Gehrmann, M.
K. et al. reported using 50nm cmHsp70.1-conjugated AuNPs for imaging Hsp70
membrane-positive mouse tumor cells in-vivo [296]. Here, we used spherical gold
nanoparticles with a final diameter of around 180 nm to target the AAAs. The increase in
gold particle size from ~150nm to ~180nm after the antibody conjugation process indicated
that we successfully conjugated the elastin antibody to the surface of the gold nanoparticles
for achieving targeted delivery.
Suprarenal aortic aneurysms were then successfully initiated by systemically
delivering AngII into LDLr (-/-) mice. AAAs were considered significant when the dilation
of the aorta exceeded 1.5 times (i.e., 50% dilation) its normal external diameter [297].
Based on this criterion, some of the aortic dilations we found in the mice were not
considered AAAs but at the initiating stage of AAAs. As reported by Trachet, B. et al., the
incidence rate of AAAs in AngII infused mice was 56% [298]. Pathological features such
as degradation of the elastic lamina and atherosclerosis were demonstrated by the
histological study results. These features are consistent with what has been reported in the
AngII infusion-induced AAA in the ApoE(-/-) mouse model [299], as well as in human
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AAAs [300]. And our results showed that the diameter increase, elastin degradation level,
and intraluminal atherosclerotic plaque formation in the suprarenal aortas vary among
animals. Such variability was advantageous in this study because it enabled a wider
spectrum fragmentation for correlation with AuNP accumulation.
To date, the targeting of AAAs for therapeutic and imaging purposes remains
significantly challenging because of the limited number of viable targets and a relatively
low hemodynamic residence time in the diseased aorta. Key pathological processes
occurring within AAAs such as inflammation, vascular smooth muscle cell apoptosis, and
even ECM remodeling have emerged as potential targets for nanoparticle-based
diagnostics [215]. Shirasu, T. et al. reported a passive AAA targeting system using
rapamycin nanoparticles. It was hypothesized in their study that the accumulation of
nanoparticles was a result of micro-defects caused by inflammatory cell infiltration and
ECM fragmentation [257]. For active targeting, macrophage targeting was reported for an
MRI imaging with ultra-small superparamagnetic iron oxide (USPIO) and fluorine 18labeled cross-linked iron oxide (18F-CLOF) in AngII-infused ApoE (-/-) mouse model
[220, 221, 223]. Klink, A. et al. [258] described the targeting of aortic adventitial ECM
remodeling-related collagen in AngII-infused and TGFb-neutralized C57BL/6 mice using
paramagnetic/fluorescent micellar nanoparticles functionalized with a collagen-binding
protein (CNA-35). All these previous targeting efforts focused on either inflammatory cells
or collagen. Levels of inflammation and collagen remodeling vary with time and therefore
cannot be used as a reliable surrogate for chronic aneurysmal rupture risk assessment.
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On the other hand, the metabolic turnover of elastin is slow, with a half-life
comparable to the human lifespan. Thus, unlike collagen fibers, the function of elastic
fibers is not thought to depend on constant remodeling and turnover [301]. The adult elastic
lamina does not remodel substantially within the timeline of aortic disease progression and
the degradation of in the aneurysmal wall is a consistent feature of AAAs making it an
ideal target for delivering nanoparticles. In this study, we successfully targeted gold
nanoparticles to the aneurysmal site in AngII-infused LDLr (-/-) mice by conjugating them
with antibodies that target only degraded-elastin as described previously [229]. Our results
suggested that the targeting of our EL-AuNPs was both elastin-specific and damagedependent as most of the EL-AuNPs were found attached to degraded elastin while sparing
the healthy unimpaired aorta. Furthermore, the quantity of EL-AuNPs accumulated in the
aneurysmal tissue was related to the extent of local elastin degradation which highlights
altered biomechanical properties of the aortic wall leading to further disease progression
and failure [45]. Thus, we tested if EL-AuNPs targeting could improve imaging and could
be used as a potential non-invasive AAA rupture risk stratification tool.
Non-invasive abdominal ultrasound is commonly used in the diagnosis and
monitoring of AAAs, mainly providing morphological information to evaluate disease
progression. Others reported that high-frequency ultrasound could be used to assess aortic
wall strain as part of biomechanical analysis in murine models [302, 303]. Our in-vivo
abdominal ultrasound results indicated a reduction of circumferential wall strain
throughout the cardiac cycle in the aneurysmal suprarenal aorta compared to the healthy
aorta and these findings are consistent with the results from previous studies. An increasing
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trend of EL-AuNP accumulation was found while the wall strain decreased. Our results
demonstrate that there could be a correlation between EL-AuNP accumulation and overall
biomechanics of the aneurysmal tissue.
Burst testing, a direct method of identifying rupture pressure and location,
supported the correlation between the signal given by targeted EL-AuNP and the rupture
potential of aneurysms [304]. We have used a well-established AngII model to assess
AAAs. Aneurysms in this model, however, do not spontaneously rupture, so all burst
pressure testing was performed on explanted aortas for correlation of rupture risk. Using a
power model, a strong negative correlation was found between EL-AuNPs in the ex-vivo
CT scans and the pressures at which a AAA will burst. Since the aortic diameter is the
primary clinical criteria used for surgical intervention, it was interesting to note that no
immediate pattern emerged correlating burst pressure to the extent of dilation in our AAAs.
Although many large AAAs failed at lower pressures, others withstood much higher
pressures. Incidentally, most AAAs in our study failed at or around the necking region and
a few failed at the site of the branches. Likewise, aneurysms with similar dilation were
shown to experience varying levels of circumferential strain throughout the cardiac cycle.
Thus, the signal intensity of EL-AuNPs measured by ex-vivo CT shows a more meaningful
relationship with the rupture risk of AAAs than does the increase in diameter or a decrease
in circumferential strain.
This finding was further confirmed in the in-vivo imaging study. Targeted in-vivo
imaging is more challenging because the AAAs usually locate deeply in the body covered
with connective tissues. Also, the unbonded EL-AuNPs in the blood pool can influence the
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targeted signal quantification. In order to minimize the influence of the non-specific signal
from the blood pool, we allowed the EL-AuNPs to circulate for 24 hours to achieve
sufficient targeting while most of the untargeted nanoparticles would be cleared out from
the blood. We found an increase of contrast at the suprarenal aortic area in the in-vivo CT
scan which again confirmed the targeting of the EL-AuNPs to the aneurysmal site.
Moreover, we found that the number of the AuNPs accumulated in the aneurysmal tissue
is not correlated to size of the aneurysm but was slightly negatively correlated to the
thickness of the aortic wall. AuNPs to tissue ratio was positively correlated to both
circumferential and axial stress suggesting the accumulation of AuNPs could be used as an
indicator of stresses in the aneurysmal tissue. Since the high stresses in the aneurysms make
them more tend to rupture, the AuNPs have the potential to assess the rupture risk of AAAs
from in-vivo CT imaging.
The variability of the animal model used in the current work provides a tremendous
strength in assessing our micro CT-based EL-AuNPs approach to AAA rupture potential.
Variations in EL-AuNP distribution were found not only among different suprarenal aortic
segments but also within the same aorta, suggesting variable degrees of elastin damage
within the aneurysm and the possible existence of a ‘weak point’ where the rupture of the
aneurysm initiates. Thus, our data suggest that an extent ECM degradation could be a more
meaningful way to look at which patients are more prone to rupture and need immediate
attention.
Moreover, the biodistribution of the EL-AuNPs in the major organs was studied to
assess their clearance rate. Contrast agents should be cleared out of the system within a
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reasonable time to ensure the safe application for the patients. Sonavane, G. et al. have
reported the biodistribution of AuNPs with different sizes in mice 24 hours after the
injection [305]. For 200nm EL-AuNPs, they found the highest concentration of gold in the
liver followed by spleen, lung, and kidneys. Similarly, according to our results, the ELAuNPs (~170nm) were mainly found in the livers and spleens, followed by kidneys and
lungs on all three time points after the injection. In general, the total number of EL-AuNPs
in the system decreased as the time goes by. And most of the EL-AuNPs were cleared out
of the system eight days after a working dose injection for imaging. The results indicated
that the EL-AuNPs were successfully cleared out of the system even in an animal model
that presented compromised liver functions [306]. Thus, our EL-AuNPs are promising to
be translated into a safe clinical use.
5.5 Conclusion
An AngII infusion LDLr (-/-) mouse model provided us with AAAs at different
stages and having different biological and biomechanical properties. Degradation of elastin
led to a decrease in aortic wall strain and a decrease in burst pressures in the aneurysmal
aorta. EL-AuNPs enabled visualization of the degraded elastin in AAA sites so that the
quantity of AuNPs could be used as a marker to predict the rupture risk and rupture sites
for AAAs. This approach is highly advantageous because small and pre-aneurysmal tissues
would likely demonstrate elastin damage prior to ultrasound diagnostics. Thus, such
degraded elastin-targeting nanoparticles have the diagnostic potential as a sensitive
noninvasive AAA targeting contrast agent for CT imaging.
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6. SPECIFIC AIM 3: TO INVESTIGATE WHETHER ELASTIN ANTIBODY
CONJUGATED PGG LOADED NANOPARTICLES CAN BE TARGETED TO AAAS
IN AN ANGII MOUSE MODEL AND WHETHER THEY STOP THE AAA
PROGRESSION AND RESTORE THE HEALTHY FUNCTION OF THE AORTIC
WALL BY REPAIRING ELASTIN
6.1 Introduction
AAA patients can be currently treated with surgical interventions or conservative
methods depending on the AAA status evaluated by its geometrical information and the
patient's condition. Although surgical repair can effectively help patients who have big or
ruptured AAA, the risk of the operation process and post-operation complications keep the
perioperative mortality high. Pharmacotherapy is an ideal choice for AAA patients who are
not recommended to be treated surgically. Even though to date, there is no
pharmacotherapy available on the market, potential pharmacotherapy for AAA that
focused on how to inhibit the degradation of ECM and maintain the integrity of the aortic
vascular wall has been wildly studied.
As described in chapter 2, many reported drugs are effective in preventing AAA
progression by inhibiting the MMP activity, stabilizing and regenerating the damaged
elastin lamina in the aneurysmal vascular wall in animal models. However, these drugs did
not show effects on stopping nor reversing the human AAA progression [307-310]. In order
to develop a pharmacotherapy that can effectively and safely work in AAA patients, it is
important to understand human AAA pathology. Various inflammatory mediators that can
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activate pro-inflammatory signaling pathways, such as TNF-α and MCP-1, are involved in
the pathogenesis of AAA by causing and maintaining the inflammatory response.
Proinflammatory signaling pathways, in turn, activate ECM degradation enzymes, such as
MMP-9 and MMP-2, and simultaneously reduce the expression of ECM synthetic
enzymes, such as LOX, thereby causing an overall loss of elastic fibers [180, 311]. It has
been established that elastin degradation is a primary cause of AAA progression [312]. The
regression of elastin fibers in the aortic wall and restoration of normal arterial architecture
would be preferable for treating AAA patients regardless of the aneurysm size.
PGG is a tannic acid derivative that has gained a lot of scientific attention recently
because of its inherent ability to stabilize elastin by establishing a strong cohesive bond
with the elastin in the ECM of the blood vessel. It can be used to provide an enhancement
in vascular biomechanical properties and increased enzymatic degradation resistance
[313]. Although tannic acid was also reported to have the same elastin binding ability as
PGG, PGG was found to be more stable and had less cytotoxicity; thus, it was more
favorable as an elastin-stabilizing agent [314].
Medial lamellar degradation in AAAs due to a combined effect of VSMC apoptosis,
increased inflammatory responses and oxidative stress, and disruption of tissue enzymatic
homeostasis can result in a reduction in elastin content and crosslinking [315]. Therapeutic
traits of PGG such as elastin stabilization, inhibition of MMPs, and antioxidant capacity
make it an attractive pharmacological option for AAA patients. In-vivo stabilization of
infrarenal aortic elastin by periadventitial PGG application or systemic PGG-NPs
administration in CaCl2-mediated rat AAA model has shown to preserve the integrity of

124

the elastic lamellae, thus, prevent early AAA formation [200, 313]. Moreover, immediately
after a localized elastase infusion in the porcine aorta, the intraluminal application of PGG
in the elastase treated aortic segment was also reported to inhibit early AAA formation
[316]. PGG-NPs that can successfully target to degraded ECM will achieve the controlled
release of PGG to the AAAs and be a potential pharmacotherapy to stop and reverse the
AAA progression.
It is important to test the functionality of PGG in stabilizing the degraded ECM in
an AngII infused mouse model. Comparing to the previously studied CaCl2-mediated rat
AAA model and elastase-mediated mouse AAA model, which were developed based on
localized surgical aortic damage, the aneurysms in AngII infused mouse model were
induced using a systemic method, which resembles human aneurysm formation. It will
offer a fresh perspective on the functionalities of PGG-NPs as a novel AAA treatment.
6.2 Materials and methods
Preparation of blank, DiR loaded and PGG loaded BSA NPs
Blank BSA NPs (BLN-NPs) were prepared to be used as a control for the study by
using a coacervation method described previously [19]. Briefly, 250 mg of BSA (Seracare,
Milford, MA) was dissolved in 4 mL of DI water. 3mg glutaraldehyde (EM grade 70%,
EMS, PA) was added into the BSA solution during stirring as a crosslinker. After an hour
of stirring under room temperature, the mixture was added dropwise to 24 mL of ethanol
under continuous sonication (Omni Ruptor 400 Ultrasonic Homogenizer, Omni
International Inc, Kennesaw, GA) on ice for 30 minutes. The obtained BLN-NPs were
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obtained by centrifugation at 6,000 rpm for 10 minutes and washed with water for three
times by resuspension.
1, 1-dioctadecyl-3, 3, 3, 3- tetramethylindotricarbocyanine iodide (DiR) dye
(PromoCell GmbH, Heidelberg, Germany) loaded BSA NPs (DiR-NPs) were obtained for
studying in-vivo targeting using the procedure described above with modifications. 250 mg
of BSA was dissolved in 4ml of DI water. 2.5 mg of DiR dye was dissolved in acetone first
and was then added to the BSA solution. 10.5 mg glutaraldehyde was added as a crosslinker
during stirring. After an hour of stirring under room temperature, the mixture was added
dropwise to 24 mL of ethanol under continuous sonication on ice for 30 minutes. The
obtained DiR-NPs were obtained by centrifugation at 4,000 rpm for 10 minutes and washed
with water for three times by resuspension.
PGG-loaded NPs (PGG-NPs) were prepared for the treatment study using the
modified version of the procedure described above. 250 mg of BSA was dissolved in 4 mL
of DI water. 125mg PGG was dissolved in 400 µl of dimethyl sulfoxide and added slowly
to the BSA solution under stirring. 3mg glutaraldehyde was then added as a crosslinker.
After an hour of stirring at room temperature, the mixture was added dropwise to 24 mL
of ethanol under continuous on ice for 30 minutes. PGG-NPs were obtained by
centrifugation at 6,000 rpm for 10 minutes and washed with water by resuspension.
Conjugation of NPs with degraded elastin antibodies
All NPs were conjugated with homemade degraded elastin antibodies before being
used in the animal study as described previously [19]. Briefly, 10 mg of NPs (blank, DiR
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loaded,

or

PGG

loaded)

were

PEGylated

with

2.5

mg

α-maleimide-ω-N-

hydroxysuccinimide ester poly (ethylene glycol) (mPEG-NHS, M.W. 2000, Nanocs, NY,
U.S.A.) at room temperature for one hour under gentle vortexing. 68 μg of Traut’s reagent
(G-Biosciences, Saint Louis, MO) was used for thiolation of 20 μg of a homemade elastin
antibody, and the mixture was incubated in PBS for an hour at room temperature under
gentle vortexing. Thiolated antibodies were added to the PEGylated NPs and incubated
overnight at 4 ºC on a slow rocker for conjugation.
In-vivo study in an AngII infusion induced mouse model
Forty-two male LDLr -/- mice (2 months of age, on a C57BL/6 background) were
obtained from the Jackson Laboratory (Bar Harbor, ME) for investigating the effects of the
NP treatment on the aneurysms. Aneurysms were induced by systemic infusion of AngII
(Bachem Americas, Torrance, CA) in combination with a diet with saturated fat (21%
wt/wt) and cholesterol (0.2% wt/wt; catalog no. TD88137; Harlan Teklad) throughout the
whole study. Osmotic pumps (model 2004; Alzet, Cupertino, CA) filled with AngII were
implanted subcutaneously to the mice. 2% to 3% isoflurane inhalation was used as
anesthesia during the surgery. The osmotic pump released AngII consistently for 4 weeks
at a rate of 1500ng/kg/min. Disease progression was monitored with Fujifilm VisualSonics
Vevo 2100 ultrasound machine (Fujifilm VisualSonics, Toronto, ON, Canada) by utilizing
a linear array probe (MS-550D, broadband frequency 22 MHz -55 MHz).
For the targeting study, 10mg/kg animal weight of anti-elastin antibody (EL)
conjugated DiR-NPs were injected intravenously to three mice after the 4-week infusion
of AngII. These mice were euthanized 24 hours later, and the aortas were harvested for

127

further analysis. For treatment study, twelve mice were treated with EL conjugated BLNNPs while another twelve mice received EL conjugated PGG-NPs, both at a dose of
10mg/kg animal weight, biweekly on week 4 and week 6 via the tail vein. Fifteen mice that
did not receive any kind of treatment were used as control. Three of the control mice were
euthanized at week 4; All other mice were euthanized at week 8 as shown in the timeline
graph (Figure 6-1). Blood was collected via a heart puncture and organs were harvested
after being perfused with saline for further analysis. All animal use protocols for the study
were approved by the Institutional Animal Care and Use Committee (IACUC) at Clemson
University.

Figure 6-1. Schematic representation of the study design.
Ultrasound analysis of AAAs
The ultrasound system, Fujifilm VisualSonics Vevo 2100 (Fujifilm VisualSonics,
Toronto, ON, Canada), was used for monitoring percent dilation and to assess the
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circumferential strain throughout the cardiac cycle and PWV of the aneurysm. The animals
were placed in a supine position on the imaging table and were maintained under anesthesia
by inhaling 2% to 3% isoflurane during imaging. Heart rate and body temperature of the
mice were carefully monitored during the imaging process. Suprarenal aortic inner
diameters were measured using the built-in ultrasound software on the basic-mode
ultrasound images. The dilation was calculated using the equation given below,
]) − 𝐷
]* )/𝐷
]) × 100
𝐷𝑖𝑙𝑎𝑡𝑖𝑜𝑛 (%) = (𝐷
]* represents the mean inner diameter of the suprarenal aorta before the surgery
where 𝐷
]) is the mean inner diameter after surgery at the time points mentioned above.
and 𝐷
Sagittal and transverse images for both healthy and aneurysmal aortas were
obtained in motion mode. Systolic and diastolic diameters were measured and recorded at
three different regions on each aneurysm or parent vessel using the built-in ultrasound
software. The diastolic-to-systolic circumferential Green-LaGrange strains and the
percentage change of the circumferential strains throughout the study were calculated
assuming axial symmetry using the two equations given below,
]#$# /𝐷
]%&' )2 − 1) × 100
𝐶𝑆 (%) = (1/2)((𝐷

(1)

𝐶𝑆 (%) = (𝐶𝑆) − 𝐶𝑆* )/𝐶𝑆) × 100

(2)

]#$# represents the inner systolic aortic diameter, 𝐷
]%&' represents the inner diastolic
where 𝐷
aortic diameter, 𝐶𝑆* represents the circumferential strain of the suprarenal aorta before the
surgery and 𝐶𝑆) is the circumferential strain after surgery at the time points mentioned
above.
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PW Doppler mode was used to measure the blood flow at the beginning and the
end of the suprarenal aortic lumen prior to each PWV acquisition. All PW Doppler
measurements were performed at a PRF of 20 kHz and a 45° incidence angle. Throughout
the acquisition, the ECG for each mouse was monitored and recorded. PWV at each time
point and the change of PWV throughout the study were then calculated with the two
equations below,
𝑃𝑊𝑉 = 𝑑/(𝑡( − 𝑡+ )
𝑃𝑊𝑉 𝐶ℎ𝑎𝑛𝑔𝑒 (%) = (𝑃𝑊𝑉) − 𝑃𝑊𝑉* )/𝑃𝑊𝑉) × 100

(1)
(2)

where d represents the distance between the beginning and end of the suprarenal aorta, 𝑡+
is the time when pressure wave arrives at the beginning point and 𝑡( is the time when
pressure wave arrives at the endpoint referenced to the R wave of the ECG, and 𝑃𝑊𝑉)
represents the PWV of the suprarenal aorta before the surgery and 𝑃𝑊𝑉* is the PWV after
surgery at the time points mentioned above.
Systemic interferon-gamma (IFN-γ) levels
Blood was drawn via a heart stick with a 1 mL syringe. After allowing 30 min for
clotting, the blood was centrifuged at 14,000 rpm for 10 min and the serum was collected.
Mouse serum was examined for IFN-γ using a commercial mouse ELISA kit (Invitrogen,
Carlsbad, CA) per manufactural protocol.
Histological analysis of the aneurysms
Frozen aortas were embedded in OCT compound (Sakura Finetek, Torrance, CA)
after being washed in DI water. The blocks were allowed to stay in -80ºC for overnight and
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then sectioned per standard procedures. Five-micrometer sections were mounted on
positively charged glass slides. Slides were placed in 100% pre-cooled acetone (Fisher
Science Education, Nazerath, PA) for 10 minutes to fix the sections. Subsequently, the
slides were rinsed with tap water for 5 minutes to remove the OCT compound and stained
with hematoxylin and eosin (H&E) for tissue morphology and VVG for elastic fibers.
Some fresh samples were imaged directly after removing the OCT compound and imaged
with a fluorescent microscope to visualize the DiR-NPs targeting within the tissue.
In-situ zymography
In-situ zymography was performed on 5µm cryosections to evaluate MMP activity
in the suprarenal aortic tissue samples. All the cryosections were rinsed with tap water for
5 minutes to remove the OCT. Each section was treated with 200µL of the mixture of
0.2mg/mL DQ-Gelatin (Invitrogen, Eugene, OR) in developing buffer and then incubated
at 37°C for two hours. After being washed in DI water for 5 minutes, all sections were
stained with DAPI (Life Technologies, Carlsbad, CA) for 5 mins and an EVOSTM XL cell
imaging system (Invitrogen, Bothell, WA) was used to capture images of the samples.
Immunohistochemistry (IHC) for macrophages
All the cryosections were rinsed with PBS 3 times for 5 minutes per time to remove
the OCT compound. The sections were firstly treated with 3% hydrogen peroxide under
room temperature for 10 minutes to block the endogenous peroxidase activity. Then, the
unspecific binding sites on the sections were blocked with background buster (Innovex
Biosciences, Richmond, CA) under room temperature for 30 minutes. The sections were
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incubated with the primary antibodies (anti-CD68 and anti-CD80) at 4°C overnight. An
avidin-biotin complex method (Vector, Burlingame, CA) was used to detect and amplify
the target signal and the staining was completed using a DAB kit (Vector, Burlingame,
CA). Slides were counterstained with hematoxylin.
Flow cytometry
The spleens and thymus of the mice from BLN-NPs, PGG-NPs, and control groups
were collected, minced, and meshed on 70 μm filters. Immunofluorescence staining was
performed as described in previous studies [201, 317]. Briefly, cells were incubated with
Fc block solution (purified anti-mouse CD16/CD32, clone 2.4G2, BD Biosciences) for 15
minutes at room temperature to prevent non-specific binding. For cell surface markers,
cells were incubated with the fluorescently conjugated antibody with CD68, APC antiCD68 (clone FA-11) (BioLegend, San Diego, CA) in the dark for 30 minutes at 4ºC. For
intracellular cytokine TGFβ-1 staining, cells were permeabilized with fix/permeabilization
buffer (eBiosciences, San Diego, CA) for 15 minutes before antibody PE anti-TGFβ1
(clone TW7-2089) (BioLegend, San Diego, CA) staining. After the extensive washing of
cells in FACS buffer, the cytometric acquisition was performed using the Attune NxT flow
cytometer (Thermo Fisher Scientific, Waltham, MA). Data analysis was performed using
FlowJo (TreeStar, Ashland, OR) software. For gating, lymphocytes were identified using
FSC and SSC gating, and signals were selected based on SSC-A/H and FSC-A/H
characteristics. Then CD68+ or TGFb1+ cells were selected on the base of their expression
level. Data are the representative of triplicate of repetition twice.
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Quantitative polymerase chain reaction (qPCR)
Suprarenal aortas were homogenized and lysed in TRIzolTM (Invitrogen, Carlsbad,
CA) for mRNA extraction. mRNAs were isolated per manufacturer’s protocol. The quality
of the mRNA extracted was confirmed with the A260/A280 ratio as measured by a BioTek
Synergy 2 plate reader (BioTek, Winooski, VT). Primers were designed for obtaining
cDNA copies of MMP-2, TIMP-1, TIMP-2, LOX, elastin (ELN), and housekeeping genes
actin-beta (ACTB) and peptidylprolyl isomerase A (PPIA) (sequences are shown in Table
6-1) and obtained from Integrated DNA TechnologiesTM (Coralville, IA). cDNA was
obtained via reverse transcriptase (RT)-PCR using an OneStep RT-PCR kit (Qiagen,
Valencia, CA) as per manufacturer’s protocol. The qPCR was performed in the following
sequence using a Rotor gene qPCR machine (Qiagen, Valencia, CA): 15 secondes at 94ºC,
30 seconds at 60ºC, and 30 seconds at 72ºC for 40 circles. Gene expression in each sample
was normalized to the expression of the housekeeping genes and compared to the control
group using the 2-(ΔΔT) cycle threshold (Ct) analysis as follow:
∆∆Ct = (Ct ,-./01 /030 − Ct 4050.0360 /030 )7890.:;031-<
− (Ct ,-./01 /030 − Ct 4050.0360 /030 )=>31.><
Aortic biaxial mechanical testing and data analysis2
The mechanical properties of aortic aneurysmal tissues and controls were tested at
the University of South Carolina (UofSC) as described in Chapter 5. No more than 48 hours
passed between animal sacrifice and mechanical testing. Aortas were mounted to a custom-

2

Section prepared by John F. Eberth, PhD and Shahd Hasanain, BS
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Table 6-1. Primers designed for qPCR
Mouse MMP2_FWD

AACGGTCGGGAATACAGCAG

Mouse MMP2_REV

GTAAACAAGGCTTCATGGGGG

Mouse TIMP1_FWD

GGCATCTGGCATCCTCTTGT

Mouse TIMP1_REV

TTAGCATCCAGGTCCGAGTTG

Mouse TIMP2_FWD

TATCTACACGGCCCCCTCTT

Mouse TIMP2_REV

TCCCAGGGCACAATGAAGTC

Mouse ELN_FWD

CCACCTCTTTGTGTTTCGCTG

Mouse ELN_REV

ACCCAAAGAGCACACCAACAAT

Mouse LOX_FWD

ACGGCTTGTGTAACTGCAAAC

Mouse LOX_REV

TCTGGGAAAGCGCACAGAG

MMP-2

TIMP-1

TIMP-2

ELN

LOX

designed biaxial testing rig. The details for this device and biaxial testing procedures can
be found in Lane et al. 2020a and 2020b [291, 292]. Briefly, this test rig is equipped with
a thin-beam loaded cell (LCL-113G; Omega Engineering), pressure transducer (PX409;
Omega Engineering), RS-232 infuse/withdraw syringe pump (AL-1000; World Precision
Instruments), motorized linear actuator (Z825B; Thorlabs), and K-Cube motor controller
(KDC101; Thorlabs). All components had PC USB interface through a custom-written
LabView code used to gather synchronous measurements while controlling pumps and
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actuators. The testing chamber was filled with warm PBS solution to maintain hydration
throughout testing and PBS was flushed through the vessel lumen and device tubing to
remove bubbles. The unloaded outer diameter ( Do ) and length ( L ) were recorded using
digital calipers. The artery then underwent five preconditioning cycles consisting of
pressurization from 10 to 160 mmHg and axial stretching to a deformed length ( ! ) at, and
5% above and below, the pressurization force-invariant axial stretch ratio, deemed the invivo axial stretch.
For data acquisition, the artery was extended to the three axial stretch ratios
described previously before undergoing pressurization cycles (0–120 mmHg) with
simultaneous force and outer diameter measurements at 10 mmHg pressure increments.
Data was recorded in triplicate and the average and standard deviations of these tests
reported. Primary continuous data collection consisted of pressure ( P ), deformed outer
diameter at the peak bulge location ( d o ), axial force ( f ), and axial stretch ratio ( lz ). Then
vessels were pressure fixed by replacing luminal PBS with 4% paraformaldehyde solution
and re-inflated to 100 mmHg in the axially extended state for 4 hours. In the deformed but
fixed state, micro-Computed Tomography Imaging (Quantum GX Micro-CT Imaging
System; PerkinElmer) was used to measure the deformed inner diameter. This step was
necessary due to the lack of transparency of these calcified and heterogeneous tissues.
Measurements consisted of an average of 4 locations along the circumference of the
aneurysm bulge and were processed using Fiji-ImageJ.
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Assuming axial symmetry and incompressibility, the inner diameter is calculated
from,

di = 2

d o2 V
4 p!

(5)

where V is the volume measured using a combination of micro-CT and biaxial testing.
From the primary data collection described above, the mid-wall circumferential and
axial stretch ratios are calculated from

lq =

di + d o
!
, lz =
Di + Do
L

(6)

where Di is the unloaded inner diameter.
The mean circumferential and axial stresses are then calculated from

sq = P

di
f
, sz =
2
d o - di
p ( d 0 4 - di2 4 )

(7)

and the lumen area compliance from

c=

p Ddi2
4 DP

,

where DP is the change from diastolic to systolic transmural pressures (80 to 120
mmHg) and Dd the change in inner diameter at these pressures.
In general, discrete data were analyzed at a common pressure and in vivo axial
stretch ratio unless otherwise noted.
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(8)

Statistical analysis
The data are reported as the mean ± standard deviation. Data from the same group
at different time points were analyzed by paired T-test. Data from different groups were
analyzed by one-way ANOVA followed by Tukey’s HSD as a post-hoc test.
6.3 Results
AngII infusion induced mouse model and in-vivo targeting study
After four weeks of AngII infusion, aneurysms with different sizes were found at
the suprarenal region of the mice. According to the ultrasound diameter measurements on
week four, some aortic dilations were less than 50%, which didn’t meet the diagnostic
standard for AAAs (part of the data presented). To bestow the study more clinical
significance, we focused on mice with dilation of more than 50% at the suprarenal aorta
for further study.
For studying the in-vivo targeting of the nanoparticle carrier, DiR-NPs were
delivered systemically via tail vail and allowed to circulate for 24 hours. The aortas of the
mice were explanted and imaged ex-vivo using the IVIS Lumina imaging system
(PerkinElmer, Branford, CT) to visualize the DiR-NPs signal (Figure 6-2). According to
the IVIS images (Figure 6-2 a2 and a3), the suprarenal region of the mice aortas where the
aneurysms were found (Figure 6-2 a1) showed high fluorescent signal exclusively,
indicating the accumulation of the DiR-NPs in the aneurysmal tissue. Further histological
analysis showed that the DiR-NPs appeared at the sites where degraded elastin was
displayed in the VVG staining (Figure 6-2 b and c). These results confirmed that our
nanoparticle carrier could successfully reach and accumulate in the aneurysmal tissue by
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targeting the degraded elastin in the ECM. These nanocarriers could be used for targeted
drug delivery to stabilize the ECM and stop the progression of the aneurysm.

Figure 6-2. DiR-NPs targeting in AngII mice model. a. Overall targeting in the aorta; b.
VVG staining indicating sites of degraded elastin; c. Fluorescent imaging of the counterpart
visualizing DiR-NPs distribution within the tissue.
The influence of PGG treatment in aortic dilation percentage
All the mice that were used in the treatment study showed similar percentages of
dilation when the AngII infusion was finished. According to the average inner diameters
of aneurysms at week four measured and calculated from in-vivo abdominal ultrasound, all
three groups (n=5) had a more than 100% diametric increase during the AngII infusion.
After four more weeks (2 injections) of treatment, only in the PGG-NPs group, it has been
found that the size of the aneurysms became smaller. The dilation percentages for
aneurysms in the BLN-NPs group and the control group kept increasing even without the
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Figure 6-3. In-vivo ultrasound and percentage of dilation change in all three groups. a.
Representative B-mode in-vivo ultrasound images of abdominal aortas before pump
implantation, at 4 weeks when the infusion of the Ang II was finished, and 8 weeks when
the treatment was finished; b. Gross view of the aortas from BLN-NPs (b1), PGG-NPs
(b2), and control group (b3) at the endpoint.
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AngII infusion (Figure 6-3a). The gross views of the explanted aortas also presented
smaller outer aortic diameters of the suprarenal area in the PGG-NPs group comparing to
the BLN-NPs and the control group (Figure 6-3b).
Precisely, after the treatment, the PGG-NPs group showed a decrease (p=0.07) in
aortic dilation percentage from 139.16±49.14% at week four to 97.75±49.77% at week
eight. However, for the BLN-NPs group, the aortic diameter kept increasing to a significant
level (p<0.01) from 104.10±34.14% at week four to 182.44±46.55% at week eight. And
the aortic diameter significantly increased (p=0.03) from 109.38±27.13% at week four to
188.11±84.92% at week eight for the control group. (Figure 6-4).

Figure 6-4. Dilation percentage (> 50% at week 4) of BLN-NPs group, PGG-NPs group,
and control group before the treatment at week 2 and 4, and during the treatment at week
5, 6, 7 and 8, green arrows indicated the timepoints when the injection happened.
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The same trend has also been observed in the suprarenal aortas with a dilation
percentage smaller than 50% (Figure 6-5). By the end of the AngII infusion, these mice
only presented moderate enlargement of the suprarenal aorta. After the treatment, the PGGNPs group still showed a significant decrease (p=0.02) in aortic dilation percentage from
22.09±5.24% at week four to 7.82±8.26% at week eight. As for the control group, the aortic
diameter kept increasing from 21.01±18.71% at week four to 43.95±17.94% at week eight.

Figure 6-5. Dilation percentage (< 50% at week 4) of PGG-NPs group and control group
before the treatment at week 2 and 4, and during the treatment at week 5, 6, 7, and 8. Green
arrows indicated the timepoints when the injection happened.
The influence of PGG treatment in CSs and PWVs
All the mice used for the study had a decrease of the systolic diameter to diastolic
diameter ratio at the end of the AngII infusion. During four weeks of the PGG-NPs
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treatment, the mechanical behavior of the aortic walls during a cardiac cycle started
returning to normal while in the BLN-NPs and the control group, the ratios kept decreasing

Figure 6-6. Change in circumferential strains for PGG-NPs, BLN-NPs, and control groups.
a. Representative M-mode in-vivo ultrasound images of abdominal aortas before pump
implantation, at 4 weeks when the infusion of the Ang II was finished, and at 8 weeks when
the treatment was finished, showing the mechanical behavior change in a cardiac cycle; b.
(%) change of corresponding circumferential Green-LaGrange strains throughout the
cardiac cycle at week 2 and 4, and during the treatment at week 5, 6, 7, and 8. Green arrows
indicated the timepoints when the injection happened.
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(Figure 6-6a). CSs were further calculated to evaluate the change in the distensibility of
the aneurysmal aortic wall (Figure 6-6b). All aneurysmal aortas showed a reduction in the
strain values after the formation of the aneurysms.
By the end of the AngII infusion, the CSs of PGG-NPs, BLN-NPs, and control
groups have decreased by 58.25±8.25%, 53.30±2.36%, and 56.85±4.73%, respectively.
And after 4 weeks of NPs treatment, the aortas treated with PGG-NPs started to regain their
distensibility, showing only a 24.50±10.34% CS decrease comparing to the healthy aortas.
However, the CSs for both BLN-NPs treated group and control group decreased even more
to 70.42±4.73% and 78.14±4.77% respectively at the endpoint of the treatment.
PWVs were also calculated to evaluate the progression of the AAAs (Figure 6-7).
Before the surgery, the PGG-NPs group, BLN-NPs group, and control group have PWVs
of 2.28±0.27 mm/ms, 2.21±0.17 mm/ms, and 2.38±0.28 mm/ms respectively. All
aneurysmal aortas showed a reduction in the PWV after the formation of the aneurysms.
The PWVs for the PGG-NPs, BLN-NPs, and control group dropped to 1.35±0.33 mm/ms,
1.56±0.11 mm/ms, and 1.49±0.19 mm/ms, respectively, after the AngII infusion. With four
weeks of treatment, the PWV of the PGG-NPs group increased back to 2.43±0.13 mm/ms
while the PWV was 0.97±0.12 mm/ms for BLN-NPs group and 1.09±0.32 mm/ms for the
control group.
The changes in CSs and the PWVs were also monitored for the suprarenal aortas
that had a dilation percentage of less than 50% at different time points. Both of the
parameters changed in the same pattern as bigger aneurysms reported above (Figure 6-8).
The CSs on average dropped by 28.07% after the AngII infusion in the PGG treated group
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Figure 6-7. Change in pulse wave velocities for PGG-NPs, BLN-NPs, and control group
at week 2 and 4, and during the treatment at week 5, 6, 7, and 8. Green arrows indicated
the timepoints when the injection happened.
and by 8.32% in the control group. After four weeks of treatment, the average drop of CSs
in the PGG treated group was only 6.89% comparing to 50.83% in the control group
(Figure 6-8a). Moreover, the PWVs of the PGG group firstly decreased from 2.82±0.22
mm/ms to 1.32±0.31 mm/ms as the AAAs progress, and then increased to 2.34±0.22
mm/ms after PGG-NPs treatment. On the other hand, the PWVs of the control group firstly
decreased from 2.12±0.23 mm/ms to 1.43±0.24 mm/ms as the AAAs progress, and then
kept decreasing to 1.24±0.13 mm/ms without any treatment (Figure 6-8b).
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Figure 6-8. Change in a. circumferential strains and b. pulse wave velocities for suprarenal
aortas that have <50% dilation in PGG-NPs and control group at week 2 and 4, and during
the treatment at week 5, 6, 7, and 8. Green arrows indicated the timepoints when the
injection happened.
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Histological analysis
H&E and VVG staining of the suprarenal aortic sections from all three groups and
aneurysms harvested at week 4 right after the AngII infusion provided information about
the tissue morphology, cellular infiltration, and elastin degradation. The staining for the
sections from the 4-week group exhibited the original status of the aneurysms before the

Figure 6-9. Histological images of tissue sections with H&E and VVG staining for 4-week,
control, BLN-NPs, and PGG-NPs group at 4X and 40X.
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treatment. An increase in aortic diameter was observed after the aneurysm formation.
Massive inflammatory cells infiltrated the adventitial and medial layer of the aortas and
severe elastin degradation in the aortic medial was also remarked. Comparing to the 4week aneurysm and the sections from BLN-NPs and control group, the morphology of the
tissues from PGG-NPs group were the closest to healthy with a relatively normal size and
minimal infiltration of inflammatory cells (Figure 6-9a and 6-9b). Moreover, the VVG
staining showed the most intact elastin laminae in the PGG-NPs group, while in the other
three groups, there was severe degradation of elastin and formation of intraluminal plaques
(Figure 6-9c and 6-9d).
Assessment of systemic inflammation
Serum IFN-γ levels were measured to evaluate the systemic inflammation. The
control group had the highest amount of IFN-γ (49.94 ± 14.30 pg/ml) in the serum,
followed by the BLN-NPs group (33.34 ±13.16 pg/ml). The PGG-NPs treated group has
the lowest serum IFN- γ concentration (13.55 ± 8.09 pg/ml). The difference in IFN-γ
concentration between the BLN-NPs and the control group was not significantly different
at the 0.05 level. However, IFN-γ concentration in the PGG-NPs group was significantly
lower than the control group (p<0.01) and BLN-NPs group (p=0.04) (Figure 6-10).
Flow cytometry showed a significant decrease of CD68 positive cells in the spleens
(p<0.058) and a modest decrease in the thymuses from PGG-NPs treated mice comparing
to the control group (Figure 6-11a). Similarly, the TGFβ-1 level significantly decreased
after the treatment with PGG-NPs compared with the control group (p<0.05) in spleens
(Figure 6-11b).
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Figure 6-10. Serum IFN- γ concentrations of control, BLN-NPs, and PGG-NPs group.

Figure 6-11. Flow cytometry dot plots and scatter plots for CD68+ cells and TGFβ1+
expression in spleens and thymuses from the control group and PGG-NPs treated group.
*p<0.05.
Assessment of local inflammation
IHC staining for CD68 and CD80 in suprarenal aortic sections from PGG-NPs,
BLN-NPs, control, and 4-week group identified the infiltration of macrophages in the
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aneurysmal tissue. The BLN-NPs, control and the 4-week group showed an intense panmacrophage (CD68) staining (Figure 6-12 a1-a3). The PGG-NPs group was stained
positive for CD68, but the staining only appeared in limited areas in the tissue and was less
intense compared to the other three groups (Figure 6-12 a4). The BLN-NPs group, control
group, and the 4 weeks group also showed intense M1 macrophage (CD80) staining (Figure
6-12 b1-b3) while the PGG-NPs group barely showed any staining (Figure 6-12 b4).

Figure 6-12. IHC results for CD68 (a1-a4), staining for the macrophage infiltration, and
CD80 (b1-b4), staining for the M1 macrophages, in the suprarenal aortic tissue from the 4week group, control group, BLN-NPs group, and PGG-NPs group.
In-situ zymography of the suprarenal aortic sections from PGG-NPs, BLN-NPs,
control, and 4-week group visualized the MMP activities. The PGG-NPs group showed
significant suppression of signal from MMP activities (Figure 6-13d) comparing to 4-week,
control, and the BLN-NPs group (Figure 6-13 a, b, and c).
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Figure 6-13. In-situ zymography showing MMPs activity in aneurysms harvested from the
a. 4-week group, b. control group, c. BLN-NPs group, and d. PGG-NPs group.
qPCR analysis of the mRNA from the cells in the aneurysmal tissue showed that
the BLN-NPs treatment did not seem to significantly affect all tested gene expressions. The
MMP-2 expression in the PGG-NPs group was significantly lower compared to the control
group (p=0.04) (1/5 of the control group expression) and modestly lower than the BLNNPs group (1/4 of the BLN-NPs group expression) (Figure 6-14 a). TIMP-1 and TIMP-2
expression were both upregulated in the PGG-NPs group. PGG-NPs group showed a 2.2fold upregulation of TIMP-1 and a significantly higher expression of TIMP-2 (2.8-fold
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upregulation) comparing to the control group (p=0.07), and a 2-fold upregulation of TIMP1 and 1.6-fold upregulation of TIMP-2 comparing to BLN-NPs group (Figure 6-14 b, c).

Figure 6-14. qPCR results of mRNA extracted from aneurysms harvested from the control
group, BLN-NPs group, and PGG-NPs group for MMP-2, TIMP-1, and TIMP-2
expression. **p<0.05, *p<0.1.
The effect of PGG treatment on elastin related genes
qPCR analysis of the mRNA of ELN and LOX from the cells in the aneurysmal
tissue showed a slightly increased ELN expression by 1.8-fold and 1.5-fold higher LOX
expression in the PGG treated group. The BLN-NPs treatment again did not seem to change
both ELN and LOX gene expressions comparing to the control group (Figure 6-15).
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Figure 6-15. qPCR analysis of ELN and LOX for the control group, BLN-NPs group, and
PGG-NPs group.
Biaxial mechanical testing
A leftward shift in the pressure-diameter curves indicated decreased dilation in the
PGG treated group across the entire pressure range with a more prominent inflection point
normally observed in elastic arteries of small animals (Figure 6-16 a). Accordingly, both
unloaded and physiologically loaded outer diameters significantly decreased with elastase
PGG-NP treatment. The direct observation of the force vs. pressure relationship showed
an increasing value of force for PGG-NP group compared to the control group (Fig. 6-16
b). A significantly higher force was recorded for physiological pressures at these axial
stretch ratios for the PGG-NPs group compared to the control group. A decrease in stiffness
was observed in the circumferential direction in the PGG-NP group as indicated by the
slope of the stretch-stress responses (Figure 6-16 c). A much lower circumferential stress
in the control group was required to achieve the same circumferential as the PGG-NP
treated group. Moreover, an increase in lumen area compliance was present in the PGGNPs groups compared to the control group (Figure 6-16 d).
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Figure 6-16. Biaxial test results for PGG-NPs and control group.
6.4 Discussion
Targeted drug delivery to AAAs possesses certain inherent challenges like
hemodynamic conditions in the aorta and the complexity of pathophysiological markers
expressed in the tissue. Much of the remodeling happens in the ECM of the aneurysmal
tissue thus making it vital to design a vehicle that can reach and be retained in the ECM to
maximize its effect. Being one of the most common animal models of AAA, we chose to
work with the AngII model to stimulate spontaneous AAA formation in mice [289]. The
formation of AAAs in this model resembles human disease in aspects that include male
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gender preponderance, the setting of mild hypertension, and the presence of hyperlipidemia
[290]. Moreover, the formation of intraluminal thromboses (ILT), which has been
commonly seen in this model as well as in human AAAs, would limit the access to the
aortic wall from the lumen for targeting drug delivery.
Owing to our group’s documented publications that elastin degradation presents as
a hallmark signal in AAAs, a novel targeting technique has been developed [318]. We have
loaded BSA nanoparticles with DiR dye in order to quench autofluorescence from ECM
proteins to test the targeting ability of these nanocarriers to degrading elastin in-vivo [319].
Concurring with the data shown by Nosoudi et al. [169], and Karamched et al. [242], we
demonstrate the targeted delivery of nanoparticles to the aneurysmal site. More
importantly, our histological results showed that the DiR-NPs accumulated at the medial
layer of the aorta where the elastin was degrading. It indicated that the targeting of the NPs
was achieved actively under the guidance of the conjugated antibodies regardless of the
ILT. This finding was supported by our previous study suggesting the NPs targeted through
the vasa vasorum rather than from the aortic lumen [169].
The change of aneurysmal aortic diameter is one of the most intuitional parameters
that could be used to decide the efficacy of a AAA pharmacotherapy. We measured the
inner diameter of the aneurysms at different timepoints throughout the study as a part of
the evaluation for the status of aneurysms. Not all mice presented a more than 1.5-fold
aortic enlargement, a clinical criterion for diagnosing AAAs, by the end of the AngII
infusion. Then, we looked at two important biomechanical properties of aorta i.e., CS and
PWV to further assess the development of the aneurysms. CS decreased significantly in
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AngII infused mice developing aneurysms. It indicated that the aneurysmal aortic walls
responded less to blood pressure variation after the aneurysm formation. Our observations
coincide with other documented results, for example, by Favreau et al. [303], Trachet et al.
[320], and Phillips et al. [321].
In contrast to the findings of increased PWVs [322-324], we noticed a significant
decrease after 28 days of Ang-II infusion. This follows our hypothesis that increased local
aortic diameter at the site of the aneurysm increases the time taken by the pulse to travel
along the aneurysm. Moreover, the decrease of PWVs as a result of larger aortic diameters
overweighed the increase of PWVs caused by the increase of aortic wall stiffness. Nandlall
et al. also reported a decrease in PWV after AAA formation in an ApoE/TIMP-1 -/- murine
model [325].
After 4 weeks of treatment, we observed a significant decrease in the size of PGGNPs treated aneurysms. However, the aneurysm sizes in the BLN-NPs and untreated group
kept increasing. The PGG-NPs treated aneurysms also restored part of their CSs and
showed a significant increase in PWVs while the CSs and PWVs kept decreasing in the
control groups. In coherence with the findings in a CaCl2 induced rat model [169], we
believe that the targeted delivery of PGG could restore the mechanical properties of the
aneurysmal tissue and regress the aneurysms. This has been further confirmed by the
observations from biaxial mechanical tests. The results from the biaxial mechanical tests
indicated that PGG-NP treatment AAAs had better elasticity compared to the control group
and presented higher strength against pressurization. Overall, our research demonstrated
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the potential for the PGG-NP treatment to help aneurysmal tissue to regain better
mechanical properties and decrease the rupture risk of the AAAs.
Then we looked into the mechanism of how PGG functioned both systemically and
locally to halt and reverse the AAA progression. Inflammation in the aortic wall is a main
trigger of AAA onset. Chronic inflammatory cell infiltration in the adventitial and medial
aortic layers and the upregulation of the pro-inflammatory cytokine would result in the
VSMCs apoptosis and ECM degradation, primarily elastic lamina degradation by
proteolytic enzymes such as MMPs and cathepsins [35, 77, 78]. The progression of the
local aortic inflammatory response requires the enhanced recruitment of inflammatory cells
from the system [326]. Mellak et al. reported that the monocytes from the spleen could be
mobilized by the presence of AngII and contribute to the development of AAA and the
occurrence of rupture [327]. According to our flow cytometry results, a significant decrease
in CD68 positive cells in the spleen was observed in PGG-NPs treated group compared
with the control group. This indicated that PGG could reduce the available monocyte
subsets in the system, thus, decrease the aortic macrophage accumulation and attenuate the
inflammatory response in the local aneurysmal tissue.
The formation of AAAs also usually results in an altered systemic level of cytokines
such as IFN-γ and TGFβ1. The expression of IFN-γ has been reported to be consistently
upregulated in the circulation and tissues of patients with AAA [328], and has been shown
to induce productions of MMP-9 in macrophages and MMP-2 in SMCs to promote AAA
progression [329]. IFN-γ producing CD8 positive T cells were found to promote the
development of aneurysm by increasing MMP producing macrophages [330]. It has been
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reported that the inhibition of IFN-γ in the elastase AAA mouse model could abrogate the
formation of aneurysms [329, 330]. We observed a significantly higher level of IFN-γ in
the serum of the BLN-NPs treated group and the control group compared to the PGG-NPs
treated group, indicating the systemic IFN-γ suppressing role of PGG-NPs in the AngII
mouse model.
We further looked at how PGG treatment influenced the TGFβ1 level systemically.
An overexpressed local level of TGFβ1 has been proved to be beneficial for stopping the
progression of AAAs and stabilizing the already-formed aortic aneurysms [82, 331]. Here,
interestingly, we found that the TGFβ1 cytokines level significantly decreased in the
spleens. This could be evidence to support that the PGG-NPs reduced the systemic
inflammatory responses in the AngII mouse model, but further studies are required to
describe the role of the spleen TGF β1 level in the formation and progression of AAAs.
Overall, our results suggested that PGG-NPs treatment could suppress the production of
systemic inflammatory markers.
At the aneurysmal site, PGG can be thought to have two functions, one is to
stabilize the ECM by inhibiting MMPs locally and two, to increase elastin fiber deposition.
It is known that MMP-2 is one of the key players in AAA’s pathophysiology. MMP-2
expression levels have been known to increase in AAA conditions in humans [332].
Activated macrophages are responsible for producing MMP-2, whose levels are not
counter-balanced by the activity of their inhibitors (TIMPs) [333]. TIMPs play a crucial
role in reducing aortic aneurysm formation. Results from Eskandari et al. [334] and
Ikonomidis et al. [335] stressed the importance of TIMP-1 in protecting ECM against
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aneurysm formation. The role of TIMP-2 is, however, controversial in the pathology of
AAAs. Although TIMP-2 inhibits some MMPs it can also act as an MMP-2 activator. So,
it can both promote and attenuate aneurysm formation. Xiong et al.[336] have reported that
the absence of TIMP-2 led to protection against aneurysm formation probably by
hampering MMP-2 production. However, Aoki et al. showed the protective effect of TIMP2 in AAA formation by reducing the MMP-2 activity [337]. Putting all these facts aside,
the imbalance of MMP and TIMP activity is primarily responsible for the degradation of
collagen and elastin [85], which are the integral parts of the ECM.
Parasaram et al.[338] have reported that PGG could inhibit MMP activity in-vitro
and even under acellular conditions (PGG added to development buffer during zymography
rather than in cell culture medium). They have also shown that TIMP-1 levels were
increased in rat pulmonary fibroblasts treated with PGG in-vitro. In our study, we showed
that PGG inhibited MMP activity in the aneurysmal tissue by performing in-situ
zymography on the aneurysmal sections. PGG-NPs treated aortas showed diminished
MMP activity compared to the control and BLN-NP group. Moreover, we observed that
PGG-NPs treatment significantly reduced the MMP-2 expression while upregulated the
TIMP expression in the aneurysmal tissue compared with the control group. PGG-NP
treatment was suggested to help achieve a protease/anti-protease balance in the aneurysmal
tissue.
Sinha et al. [18] and Parasaram et al. [338] have further shown that PGG also helped
in increasing elastin deposition in cell cultures, possibly by holding the tropoelastin
molecules together. This helps LOX to finish crosslinking them before being “washed out”.
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While the amount of tropoelastin produced by cells remained fairly similar in control and
PGG treated cells, PGG treated cells have more elastic fibers laid down in the ECM. Our
results of VVG staining indicated the replenishment of elastin fibers that were lost during
the aneurysm development in the PGG-NP treated group. Restoration of elastin fibers at
the aneurysmal site explained the changes observed in the biomechanical properties of
aorta in this group. However, the expressions of ELN and LOX were not significantly
enhanced in the PGG-NPs treated aneurysmal tissue. This could be a result of 1) the loaded
PGG has been fully released from the nanocarrier after two weeks so the local genetic
expressions returned to normal as shown in our previous cell culture study [338], and 2)
the fact that most elastin fibers have already been repaired at the point of sample harvesting.
By stabilizing the elastin fibers in the ECM, PGG-NP treatment further ameliorated
the inflammation in the AAAs. Some products of ECM degradation, such as elastin
fragments (EFs) or elastin degradation products (EDPs), at the site of injury are
chemotactic to macrophages [339]. Thus, suppression of elastin degradation may have
further led to a suppression of macrophage activity in the area and significant suppression
of MMP activity in the PGG-NP group. We have shown using IHC that the levels of CD68
stained macrophages decreased significantly with PGG treatment. Furthermore, CD80
staining reveals a complete absence of pro-inflammatory (M1) macrophages at the
aneurysmal site. With the obtained results, one can arrive at the conclusion that PGG works
by both inhibiting MMPs and restoring elastin in the aorta, which stops the recruitment of
macrophages, thereby restoring a “normal” microenvironment at the aneurysmal site.
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6.5 Conclusion
In this specific aim, we investigated the AAA treatment efficacy of PGG-NPs in
the AngII infusion induced mice model. The PGG-NPs treated mice showed restoration of
normalcy in the aorta with developed aneurysms in terms of aortic diameter, tissue
morphology, elastin fibers in the ECM, inflammation scenario, and the mechanical
properties. Targeted delivery of these PGG-NPs demonstrated a very promising therapeutic
strategy for the reversal of already established AAAs.
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7. CONCLUSION AND FUTURE RECOMMENDATIONS
7.1 Conclusions
AAA diagnosis and treatment have always been challenging owing to the
complexity of the lesion location and AAA pathophysiology. Misdiagnosing of AAAs that
tend to rupture can put the patients in a life-threatening situation. Even if the AAAs were
successfully diagnosed with the current clinical diagnostic strategies, the mortality of the
patients who received treatment remains high. In this research, we focused on targeting the
degradation of elastin in the aneurysmal tissue, an essential protein that maintains the aortic
elasticity and the degradation products of which mediates the local inflammation, in an
attempt to develop a safe and efficient diagnostic tool as well as pharmacotherapy.
The first part of this research aimed to develop a targeted imaging contrast agent
using AuNPs to provide details about aortic mechanical properties that could help generate
a more accurate diagnosis. In this part of the research, we synthesized negatively charged
150nm AuNPs and modified their surfaces with antibodies that could target the degraded
elastin. We have shown that these EL-AuNPs are not cytotoxic and also could be mostly
clear out of the system within ten days. Moreover, we showed that optimized EL-AuNPs
could enhance the CT imaging contrast of the tissue with elastin damage exclusively. And
the contrast enhancements of signal in the CT-scans are positively correlated to the elastin
damage level in the in-vitro arterial models. We further tested these EL-AuNPs in the AngII
infusion induced mouse AAA model and showed targeting of the EL-AuNPs to the
aneurysmal tissue in both in-vivo and ex-vivo CT scans. Correlations between the
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accumulation of EL-AuNPs in the aneurysms and the mechanical properties (burst pressure
and biaxial tests) have been built to render the EL-AuNPs potential to be used as a tool to
assess the rupture risk of the AAAs.
The second part of the research focused on studying the therapeutic effects of PGG
loaded BSA nanoparticles on AAAs in the same AngII model. Two injections of PGG-NPs
within four weeks have shown to be effective in reducing the inflammatory response both
locally and systemically. By stopping the inflammation in the aneurysmal tissue, PGG-NPs
helped preserve the ECM and thus slowed down the AAA progression. Besides the antiinflammatory effect, the treatment of PGG-NPs restored the elastin fibers in the aortic
media, which improved the mechanical properties of the aneurysmal tissue and reduced
their risks of rupture. Therefore, targeted delivery of PGG-NPs could be a promising
pharmacotherapy for the AAA patients who are not recommended to undergo surgical
interventions.
7.2 Recommendation for future work
•

In this dissertation, we investigated the possibility of using EL-AuNPs as a
targeted contrast agent to provide information about the micro defects in the
aneurysmal tissue. We chose bursting tests and biaxial tests to assess the
mechanical properties of the AAAs in order to find their correlation with
the EL-AuNPs accumulated int the tissue. However, very limited
parameters were tested in this study, and the accumulation of EL-AuNPs
was correlated to each one of them independently. Considering the
complication of the actual in-vivo environment, it is desired to develop a
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scoring system that combines all the mechanical data into one total score,
which will later be correlated to the EL-AuNPs. It will increase the overall
accuracy of using EL-AuNPs accumulation to represent the AAA rupture
potential.
•

In our ex-vivo study, we observed the accumulation of EL-AuNPs in the
weak spot within the aneurysmal sac. The areas that showed the highest
signal intensity in the AAAs were found to rupture the first in the bursting
tests. This indicated that we could use the EL-AuNPs to visualize the
potential rupture sites in the AAAs. However, it was very challenging to
apply this idea to the in-vivo study due to the limited quality of the CT
imaging and the large amount of connective tissue around the AAAs. It
would be essential to increase the imaging quality and visualize the weak
spot of the AAAs in the in-vivo CT scans. The detailed EL-AuNPs maps
that show the weak spot in the aneurysmal wall could be beneficial in
assisting the clinical AAA repairing.

•

It would be of interest to optimize the AuNP dose used in visualizing the
AAAs in-vivo. In this dissertation, we only used one dose, 10mg/kg animal
weight for both in-vivo and ex-vivo imaging studies. In the cell culture
studies, we have shown very low toxicity of AuNPs at a dose that equaled
to 100mg/kg animal dose in animal studies. An increased dose may increase
the sensitivity of detecting the micro defects in the AAAs while remaining
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non-toxic to the animals that receive the injection. Also, the optimization of
the AuNPs dose can increase the CT imaging quality and accuracy.

• AuNPs could also be used as an imaging contrast agent for other elastin
damage related diseases such as thoracic aortic aneurysms and chronic
obstructive pulmonary disease. We have already shown in this research that
the EL-AuNPs can achieve targeting in the aorta and can be distributed to
the lungs.
•

In this research, many aspects of how PGG-NPs helped stop and reverse the
AAA progression has been studied. We revealed the anti-inflammatory and
ECM regenerating role of the PGG-NPs. It would be interesting to study
how PGG interacts with the aneurysmal tissue on the molecular level. It
would provide us more insights into the AAA pathophysiology. This could
also help us to optimize the dose of PGG-NPs injected to achieve the best
treatment efficacy.

•

Our in-vivo data showed that the treatment of PGG could restore the local
elastin in the aneurysmal tissue. However, it didn’t resolve the ILT that was
commonly observed in this animal model as well as in the human AAAs. It
would be useful to develop a combined treatment using PGG and drugs that
could either resolve or stabilize the ILTs. On the one hand, the antiinflammatory effect of PGG could help to slow down the formation of ILTs;
on the other hand, the complementary drugs could resolve or stabilize the
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existed ILT and prevent the formation of deadly embolus. It would help
restore the normal functionality of the aneurysmal abdominal aorta.
•

In this dissertation, we developed a diagnostic tool that could be used to
assess AAA rupture potential as well as pharmacotherapy that has shown
effectiveness in curing AAAs. It would be interesting to combine the use of
AuNPs and PGG-NPs into one NP system to achieve theranostic purposes.
By loading the BSA nanocarriers with both AuNPs and PGG, this novel
nanoparticle system can not only be used as a contrast agent for visualizing
the AAAs but also locally release PGG in a controlled manner that cures
the disease.

•

All the in-vivo studies we have performed in this study were performed in
an AngII infusion induced mouse model. The targeting of NPs would be
challenging in large animals. The dose of injection, the biodistribution and
toxicity after injection can be totally different in larger animals as well as
human. In order to translate all our findings into clinical use, it is important
to perform further studies in larger animal models such as elastase induced
porcine model.

•

Here, in this research, the antibodies were designed to target the elastin
degradation in rodents. In order to successfully target the AAAs in human
for clinical use, the antibodies used for modifying the NPs should be
customized to target the human elastin fragments. And the conjugation
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conditions should be further optimized for the new antibodies to achieve
better imaging or treating efficacy.
•

We have developed a nanocarrier that could be used to deliver drugs locally
to the AAAs. We could use this nanocarrier to load other drugs that have
shown to reduce the inflammatory response in the cell culture studies or in
animal studies but failed in clinical trials when they were delivered
systemically, such as doxycycline, statins and coumaperine derivatives.
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